Descriptor: "MESH : Adolescent" / Topic: mesh: adult - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"MESH : Adolescent"' showing total 199 results

Start Over Descriptor "MESH : Adolescent" Topic mesh: adult

199 results on '"MESH : Adolescent"'

1. Factors related to the relative survival of patients with diffuse large B-cell lymphoma in a population-based study in France: does socio-economic status have a role?

Author: Alain Monnereau, Sébastien Orazio, Olivier Dejardin, Sandra Le Guyader-Peyrou, Marc Maynadié, Xavier Troussard, Registre des hémopathies malignes de la Gironde, Institut Bergonié - CRLCC Bordeaux, Cancer environnement ( EPICENE ), Bordeaux population health ( BPH ), Université de Bordeaux ( UB ) -Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Bordeaux ( UB ) -Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Cancers et préventions, Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Registre des hémopathies malignes de Côte d'Or, Registre des hémopathies malignes de Basse-Normandie, CHU Caen, Laboratoire d'hématologie biologique [Caen], Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Cancer environnement (EPICENE ), Bordeaux population health (BPH), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Registre des hémopathies malignes de Basse-Normandie [CHU Caen], Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Laboratoire d'Hématologie Biologique [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), université de Bourgogne, LNC, and Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, 0301 basic medicine, Pediatrics, Multivariate analysis, MESH: Registries, MESH : Aged, MESH: Comorbidity, Comorbidity, MESH : Lymphoma, Large B-Cell, Diffuse, MESH: Aged, 80 and over, 0302 clinical medicine, International Prognostic Index, MESH : Child, MESH: Child, MESH : Population Surveillance, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, MESH : Female, Registries, Young adult, Child, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Relative survival, MESH: Patient Outcome Assessment, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Articles, Hematology, Middle Aged, MESH : Adult, Prognosis, MESH : Patient Outcome Assessment, 3. Good health, MESH: Young Adult, Population Surveillance, MESH: Survival Analysis, 030220 oncology & carcinogenesis, MESH : Comorbidity, Marital status, Female, France, Lymphoma, Large B-Cell, Diffuse, Non-Hodgkin Leukemia, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Factor Analysis, Statistical, MESH : Young Adult, MESH : Factor Analysis, Statistical, MESH: Prognosis, MESH: Population Surveillance, MESH: Social Class, Young Adult, 03 medical and health sciences, MESH : Adolescent, Internal medicine, MESH : Social Class, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Survival analysis, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, medicine.disease, Survival Analysis, MESH: Male, Patient Outcome Assessment, MESH: France, 030104 developmental biology, Social Class, MESH: Lymphoma, Large B-Cell, Diffuse, MESH : Survival Analysis, Factor Analysis, Statistical, business, MESH: Female, Diffuse large B-cell lymphoma, MESH : Registries
Abstract: IF 7.702; International audience; The survival of patients with diffuse large B-cell lymphoma has increased during the last decade as a result of addition of anti-CD20 to anthracycline-based chemotherapy. Although the trend is encouraging, there are persistent differences in survival within and between the USA and European countries suggesting that non-biological factors play a role. Our aim was to investigate the influence of such factors on relative survival of patients with diffuse large B-cell lymphoma. We conducted a retrospective, multicenter, registry-based study in France on 1165 incident cases of diffuse large B-cell lymphoma between 2002 and 2008. Relative survival analyses were performed and missing data were controlled with the multiple imputation method. In a multivariate analysis, adjusted for age, sex and International Prognostic Index, we confirmed that time period was associated with a better 5-year relative survival. The registry area, the medical specialty of the care department (onco-hematology versus other), the time to travel to the nearest teaching hospital, the place of treatment (teaching versus not-teaching hospital -borderline significance), a comorbidity burden and marital status were independently associated with the 5-year relative survival. Adjusted for first-course treatment, inclusion in a clinical trial and treatment discussion in a multidisciplinary meeting were strongly associated with a better survival outcome. In contrast, socio-economic status (determined using the European Deprivation Index) was not associated with outcome. Despite therapeutic advances, various non-biological factors affected the relative survival of patients with diffuse large B-cell lymphoma. The notion of lymphoma-specific expertise seems to be essential to achieve optimal care management and reopens the debate regarding centralization of these patients' care in hematology/oncology departments.
Published: 2016

2. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients

Author: Raphaël Chiron, Laurent Debarbieux, Frédérique Carrié, Nicolas Molinari, Isabelle Sermet, Isabelle Vachier, Jean-Paul Pirnay, Emilie Saussereau, Nicolas Dufour, Benoit Godbert, Daniel De Vos, Debarbieux, Laurent, Cellule Pasteur UPMC, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP), Biologie Moléculaire du Gène chez les Extrêmophiles (BMGE), Institut Pasteur [Paris] (IP), Département des Maladies Respiratoires [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve, Service de Pneumologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre de recherche Croissance et signalisation (UMR_S 845), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Cellule Pasteur, Université Paris Diderot - Paris 7 (UPD7)-PRES Sorbonne Paris Cité, Laboratory for Molecular and Cellular Technology, Queen Astrid Military Hospital [Brussels], PHAGESPOIRS, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie (MISTEA), Institut National de la Recherche Agronomique (INRA)-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), This work was supported by Vaincre la Mucoviscidose, the French Cystic Fibrosis Foundation [RC20120600714/1/1/141], and Programme Transversal de Recherches [417] from Institut Pasteur and Assistance Publique Hôpitaux de Paris., Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris], Institut Pasteur [Paris], Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut National de la Recherche Agronomique (INRA), PRES Sorbonne Paris Cité-Université Paris Diderot - Paris 7 (UPD7), Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro)-Institut National de la Recherche Agronomique (INRA), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut Pasteur [Paris], Biologie Moléculaire du Gène chez les Extrêmophiles ( BMGE ), Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Arnaud de Villeneuve, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Centre de recherche Croissance et signalisation ( UMR_S 845 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Diderot - Paris 7 ( UPD7 ) -PRES Sorbonne Paris Cité, Mathématiques, Informatique et STatistique pour l'Environnement et l'Agronomie ( MISTEA ), and Institut National de la Recherche Agronomique ( INRA ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro )
Subjects: Male, Time Factors, Cystic Fibrosis, medicine.medical_treatment, Antibiotics, pulmonary infection, [ SDV.MP.BAC ] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, medicine.disease_cause, MESH: Bacterial Load, Cystic fibrosis, MESH : Cross-Sectional Studies, MESH: Sputum, MESH : Female, MESH: Microbial Viability, MESH: Middle Aged, biology, MESH: Pseudomonas Infections, General Medicine, MESH : Adult, MESH : Pseudomonas aeruginosa, Middle Aged, MESH : Pseudomonas Infections, 3. Good health, Biological Therapy, Chronic infection, medicine.anatomical_structure, Infectious Diseases, MESH: Young Adult, Pseudomonas aeruginosa, MESH: Pseudomonas aeruginosa, Female, MESH : Bacterial Load, medicine.symptom, Pseudomonas Phages, MESH : Time Factors, Adult, Microbiology (medical), phage therapy, Phage therapy, Adolescent, MESH: Cystic Fibrosis, medicine.drug_class, MESH : Male, MESH : Young Adult, MESH: Pseudomonas Phages, Microbiology, Young Adult, MESH: Cross-Sectional Studies, MESH : Adolescent, MESH : Cystic Fibrosis, medicine, Humans, MESH : Middle Aged, Pseudomonas Infections, MESH: Adolescent, Microbial Viability, MESH: Humans, MESH : Humans, MESH: Time Factors, MESH : Microbial Viability, Sputum, MESH: Adult, medicine.disease, biology.organism_classification, [SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, Bacterial Load, MESH: Male, Cross-Sectional Studies, MESH : Pseudomonas Phages, MESH : Sputum, [SDV.MP.BAC] Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology, MESH: Biological Therapy, MESH: Female, MESH : Biological Therapy, Bacteria, Respiratory tract
Abstract: International audience; Bacteriophages have been shown to be effective for treating acute infections of the respiratory tract caused by antibiotic-resistant bacteria in animal models, but no evidence has yet been presented of their activity against pathogens in complex biological samples from chronically infected patients. We assessed the efficacy of a cocktail of ten bacteriophages infecting Pseudomonas aeruginosa following its addition to 58 sputum samples from cystic fibrosis (CF) patients collected at three different hospitals. Ten samples that did not contain P. aeruginosa were not analysed further. In the remaining 48 samples, the addition of bacteriophages led to a significant decrease in the levels of P. aeruginosa strains, as shown by comparison with controls, taking two variables (time and bacteriophages) into account (p = 0.024). In 45.8% of these samples, this decrease was accompanied by an increase in the number of bacteriophages. We also tested each of the ten bacteriophages individually against 20 colonies from each of these 48 samples and detected bacteriophage-susceptible bacteria in 64.6% of the samples. An analysis of the clinical data revealed no correlation between patient age, sex, duration of P. aeruginosa colonization, antibiotic treatment, FEV1 (forced expiratory volume in the first second) and the efficacy of bacteriophages. The demonstration that bacteriophages infect their bacterial hosts in the sputum environment, regardless of the clinical characteristics of the patients, represents a major step towards the development of bacteriophage therapy to treat chronic lung infections.
Published: 2014
Full Text: View/download PDF

3. The global burden of hip and knee osteoarthritis: estimates from the Global Burden of Disease 2010 study

Author: Sandra Nolte, Laura L Laslett, Anthony D. Woolf, Emma Smith, Theo Vos, Damian G Hoy, Ilana N. Ackerman, Marita Cross, Richard H. Osborne, Marlene Fransen, Flavia M. Cicuttini, Lisa Bridgett, Rachelle Buchbinder, Graeme Jones, Lyn March, Sean R.M. Williams, Francis Guillemin, Christopher Hill, Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, School of Population Health, University of Queensland, Charité - Universitätsmedizin Berlin / Charite - University Medicine Berlin, Institute of Public Health [Berlin, Germany], School of Health and Social Development [Deakin University], Deakin University [Burwood], The Royal Melbourne Hospital, Melbourne EpiCentre, Faculty of Health Sciences [University of Sydney], The University of Sydney, School of Medicine [Western Sydney University], Western Sydney University (UWS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), The Queen Elizabeth Hospital, Adelaide, The Health Observatory [University of Adelaide], University of Adelaide, Menzies Research Institute Tasmania, University of Tasmania, Hobart, Tasmania, Australia, University of Tasmania (UTAS), Department of Epidemiology and Preventive Medicine, Monash University, Victoria, Australia, Monash University [Clayton], Institute for Health Metrics and Evaluation [University of Washington], University of Washington [Seattle], Cabrini Institute, Monash University [Melbourne], Royal Cornwall Hospital, Royal North Shore Hospital ( RNSH ) -The University of Sydney [Sydney], Charite-Universitatsmedizin Berlin [Berlin], Hôpital universitaire de la Charité de Berlin, Melbourne Medical School-The Royal Melbourne Hospital, The University of Sydney [Sydney], Western Sydney University ( UWS ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université de Lorraine ( UL ) -Université Paris Descartes - Paris 5 ( UPD5 ), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Western Sydney University, and University of Tasmania [Hobart, Australia] (UTAS)
Subjects: Male, MESH : Prevalence, Epidemiology, MESH : Age Distribution, MESH : Aged, MESH: Global Health, Osteoarthritis, MESH : Child, Preschool, Global Health, MESH: Regression Analysis, Severity of Illness Index, Osteoarthritis, Hip, MESH: Aged, 80 and over, MESH : Child, Cost of Illness, MESH : Regression Analysis, MESH: Child, MESH: Osteoarthritis, Knee, Prevalence, Immunology and Allergy, MESH : Cost of Illness, MESH : Female, MESH: Incidence, Young adult, Child, MESH : Sex Distribution, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Incidence, Incidence (epidemiology), MESH: Sex Distribution, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, MESH: Cost of Illness, Middle Aged, Osteoarthritis, Knee, MESH: Infant, MESH : Incidence, 3. Good health, MESH: Quality-Adjusted Life Years, MESH: Young Adult, Child, Preschool, Regression Analysis, MESH : Severity of Illness Index, Female, Quality-Adjusted Life Years, MESH : Osteoarthritis, Hip, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Male, Immunology, Population, MESH : Young Adult, General Biochemistry, Genetics and Molecular Biology, Knee Osteoarthritis, Young Adult, Age Distribution, Rheumatology, MESH : Adolescent, MESH: Severity of Illness Index, Severity of illness, medicine, Humans, MESH : Middle Aged, MESH : Osteoarthritis, Knee, Sex Distribution, MESH : Aged, 80 and over, education, MESH: Age Distribution, MESH: Prevalence, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Child, Preschool, Infant, MESH: Adult, MESH : Quality-Adjusted Life Years, medicine.disease, Obesity, MESH: Male, Quality-adjusted life year, Physical therapy, MESH : Global Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Osteoarthritis, Hip, business, MESH: Female
Abstract: International audience; OBJECTIVE:To estimate the global burden of hip and knee osteoarthritis (OA) as part of the Global Burden of Disease 2010 study and to explore how the burden of hip and knee OA compares with other conditions.METHODS:Systematic reviews were conducted to source age-specific and sex-specific epidemiological data for hip and knee OA prevalence, incidence and mortality risk. The prevalence and incidence of symptomatic, radiographic and self-reported hip or knee OA were included. Three levels of severity were defined to derive disability weights (DWs) and severity distribution (proportion with mild, moderate and severe OA). The prevalence by country and region was multiplied by the severity distribution and the appropriate disability weight to calculate years of life lived with disability (YLDs). As there are no deaths directly attributed to OA, YLDs equate disability-adjusted life years (DALYs).RESULTS:Globally, of the 291 conditions, hip and knee OA was ranked as the 11th highest contributor to global disability and 38th highest in DALYs. The global age-standardised prevalence of knee OA was 3.8% (95% uncertainty interval (UI) 3.6% to 4.1%) and hip OA was 0.85% (95% UI 0.74% to 1.02%), with no discernible change from 1990 to 2010. Prevalence was higher in females than males. YLDs for hip and knee OA increased from 10.5 million in 1990 (0.42% of total DALYs) to 17.1 million in 2010 (0.69% of total DALYs).CONCLUSIONS:Hip and knee OA is one of the leading causes of global disability. Methodological issues within this study make it highly likely that the real burden of OA has been underestimated. With the aging and increasing obesity of the world's population, health professions need to prepare for a large increase in the demand for health services to treat hip and knee OA.
Published: 2014

4. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010

Author: Lakshmi Vijayakumar, H. Ross Anderson, David Singh, Doruk Ozgediz, Ted R. Miller, David Chou, Sumeet S. Chugh, Patricia J. Erwin, Samath D Dharmaratne, Steven E. Lipshultz, Roderick J. Hay, Pon Hsiu Yeh, Luigi Naldi, Valery L. Feigin, Patricia Espindola, Laurie M. Anderson, Beth E. Ebel, Ziad A. Memish, Victor Aboyans, Fiona M. Blyth, Derrick A Bennett, Richard H. Osborne, Mohammad H. Forouzanfar, Maria Segui-Gomez, Ella Sanman, Myles Connor, Esteban Porrini, Don C. Des Jarlais, John R. Condon, Gretchen L. Birbeck, Luc E. Coffeng, Tim Driscoll, David Bartels, Bishnu Pahari, G. Remuzzi, F.G.R. Fowkes, Kyle J Foreman, Joshua A. Salomon, Suzanne Barker-Collo, Mengru Wang, Leslie T. Cooper, Diego Gonzalez-Medina, Ali A. Mokdad, Andrea Panozo Rivero, George A. Mensah, Diana Haring, Julie O. Denenberg, Murugesan Raju, Ralph L. Sacco, Robin Marks, Ian Bolliger, Jeffrey A. Towbin, Rita Krishnamurthi, Dharani Ranganathan, David Phillips, Benjamin C Cowie, Paul S. F. Yip, Charles Mock, Bruno Hoen, Robert G. Weintraub, Frederick P. Rivara, Kaustubh Dabhadkar, Jonathan R. Carapetis, K. Ellicott Colson, Wenzhi Wang, Diego De Leo, Lisa M. Knowlton, Guy B. Marks, Michael S Lipnick, Rashmi Jasrasaria, Flavio Gaspari, Richard F. Gillum, John J. McGrath, Jacqueline Mabweijano, Rogelio Perez Padilla, Marlene Fransen, Allyne Delossantos, Theo Vos, Rafael Lozano, Damian G Hoy, Thomas Roberts, Anthony D. Woolf, Zhi Jie Zheng, Karen Sliwa, Andrew E. Moran, Boris Bikbov, Jessica Singleton, Spencer L. James, Mohsen Naghavi, Kim Mulholland, Saad B. Omer, Yara A. Halasa, Sherine E. Gabriel, Leslie Mallinger, Peter Burney, Imad M. Tleyjeh, Majid Ezzati, Jennifer A. Taylor, Thomas Truelsen, Akira Matsumori, Emelia J. Benjamin, Mary M. McDermott, Kiumarss Nasseri, James Harrison, Honglei Chen, Emmanuela Gakidou, M. Nathan Nair, Jerry Abraham, Karen Courville De Vaccaro, Kenji Shibuya, Rakesh Aggarwal, Stephanie Y. Ahn, Steven D. Colan, Christopher J L Murray, Aref A. Bin Abdulhak, Michael Burch, Tony R. Merriman, Nabila Dahodwala, Sudha Jayaraman, Catherine Michaud, Louisa Degenhardt, C. Arden Pope, Monica Cortinovis, Richard Matzopoulos, Norberto Perico, Matthew A. Corriere, Kelsey Pierce, Charles Atkinson, Tim Adair, Abraham D. Flaxman, Michael F. Macintyre, Gregory R. Wagner, Paul Norman, Herbert C. Duber, Kathryn H. Jacobsen, Peter J. Hotez, Andre Keren, Felipe Rodriguez De Leòn, Samantha M. Colquhoun, Michael H. Criqui, Kavi Bhalla, Soufiane Boufous, Narayanaswamy Venketasubramanian, Alan D. Lopez, Larry M. Baddour, Ana Olga Mocumbi, David B. Rein, Jürgen Rehm, Stephen S Lim, Farshad Pourmalek, Nicole E. Johns, Ganesan Karthikeyan, Martin A. Weinstock, Lyn March, Donald S. Shepard, K.M. Venkat Narayan, Michael Freeman, Chiara Bucello, Nicholas J Kassebaum, Adofo Koranteng, Eduardo A. Undurraga, Kerrianne Watt, Mohammad A. AlMazroa, Marita Cross, Fernando Perez-Ruiz, Rasmus Havmoeller, Uchechukwu Sampson, Emma Smith, Bongani M. Mayosi, Summer Lockett Ohno, Michelle L. Bell, John H. McAnulty, E. Ray Dorsey, Lesley Rushton, Matthew J. Miller, Azadeh Zabetian, James D. Wilkinson, David C. Schwebel, Olive Kobusingye, Katrina F Ortblad, Martin O'Donnell, Jon Paul Khoo, William G. Couser, Miriam Alvarado, Richard C. Franklin, Lisa C. Rosenfeld, Andrew C Steer, Bernadette Thomas, Jeyaraj D Pandian, Sarah Wulf, Kathryn G. Andrews, Neuroépidémiologie Tropicale ( NET ), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Respiratory Epidemiology and Public Health, Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Cisco Systems, CISCO Systems, Inc, Department of dermatology, Milano University-Azienda Ospedaleria Ospedali Riuniti di Bergamo, centre for photomolecular science, Imperial College London, Department of neurology, Miller School of Medicine-University of Miami [Coral Gables], Département Cité des métiers - Cité de la santé - Universcience ( CDM/CDS ), Cité des Sciences et de l'Industrie, Public Health, Cell biology, Cardiothoracic Surgery, Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Imperial College London-Royal Brompton Hospital-National Heart and Lung Institute [UK], Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, University of Miami [Coral Gables]-University of Miami Leonard M. Miller School of Medicine (UMMSM), and Département Cité des métiers - Cité de la santé - Universcience (CDM/CDS)
Subjects: Male, Pediatrics, MESH : Mortality, MESH : Aged, Poison control, Disease, MESH : Child, Preschool, 030204 cardiovascular system & hematology, Global Health, MESH: Cause of Death, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Child, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Cause of Death, MESH: Child, MESH : Female, 030212 general & internal medicine, Child, Cause of death, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, Mortality rate, MESH: Infant, Newborn, Age Factors, 1. No poverty, MESH : Infant, General Medicine, Middle Aged, MESH : Adult, MESH: Infant, 3. Good health, MESH : World Health, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Young Adult, Child, Preschool, Female, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Sex Factors, Population, MESH : Young Adult, MESH : Infant, Newborn, Young Adult, 03 medical and health sciences, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, MESH : Adolescent, Injury prevention, medicine, Humans, MESH : Middle Aged, Mortality, MESH : Aged, 80 and over, education, Aged, MESH : Cause of Death, MESH: Adolescent, MESH: Age Factors, MESH: Humans, MESH: Mortality, business.industry, MESH: Child, Preschool, MESH : Humans, Infant, Newborn, Infant, MESH: Adult, Verbal autopsy, MESH: Male, Years of potential life lost, MESH : Age Factors, business, MESH: Female, MESH: World Health, Demography
Abstract: International audience; BACKGROUND: Reliable and timely information on the leading causes of death in populations, and how these are changing, is a crucial input into health policy debates. In the Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010), we aimed to estimate annual deaths for the world and 21 regions between 1980 and 2010 for 235 causes, with uncertainty intervals (UIs), separately by age and sex. METHODS: We attempted to identify all available data on causes of death for 187 countries from 1980 to 2010 from vital registration, verbal autopsy, mortality surveillance, censuses, surveys, hospitals, police records, and mortuaries. We assessed data quality for completeness, diagnostic accuracy, missing data, stochastic variations, and probable causes of death. We applied six different modelling strategies to estimate cause-specific mortality trends depending on the strength of the data. For 133 causes and three special aggregates we used the Cause of Death Ensemble model (CODEm) approach, which uses four families of statistical models testing a large set of different models using different permutations of covariates. Model ensembles were developed from these component models. We assessed model performance with rigorous out-of-sample testing of prediction error and the validity of 95% UIs. For 13 causes with low observed numbers of deaths, we developed negative binomial models with plausible covariates. For 27 causes for which death is rare, we modelled the higher level cause in the cause hierarchy of the GBD 2010 and then allocated deaths across component causes proportionately, estimated from all available data in the database. For selected causes (African trypanosomiasis, congenital syphilis, whooping cough, measles, typhoid and parathyroid, leishmaniasis, acute hepatitis E, and HIV/AIDS), we used natural history models based on information on incidence, prevalence, and case-fatality. We separately estimated cause fractions by aetiology for diarrhoea, lower respiratory infections, and meningitis, as well as disaggregations by subcause for chronic kidney disease, maternal disorders, cirrhosis, and liver cancer. For deaths due to collective violence and natural disasters, we used mortality shock regressions. For every cause, we estimated 95% UIs that captured both parameter estimation uncertainty and uncertainty due to model specification where CODEm was used. We constrained cause-specific fractions within every age-sex group to sum to total mortality based on draws from the uncertainty distributions. FINDINGS: In 2010, there were 52*8 million deaths globally. At the most aggregate level, communicable, maternal, neonatal, and nutritional causes were 24*9% of deaths worldwide in 2010, down from 15*9 million (34*1%) of 46*5 million in 1990. This decrease was largely due to decreases in mortality from diarrhoeal disease (from 2*5 to 1*4 million), lower respiratory infections (from 3*4 to 2*8 million), neonatal disorders (from 3*1 to 2*2 million), measles (from 0*63 to 0*13 million), and tetanus (from 0*27 to 0*06 million). Deaths from HIV/AIDS increased from 0*30 million in 1990 to 1*5 million in 2010, reaching a peak of 1*7 million in 2006. Malaria mortality also rose by an estimated 19*9% since 1990 to 1*17 million deaths in 2010. Tuberculosis killed 1*2 million people in 2010. Deaths from non-communicable diseases rose by just under 8 million between 1990 and 2010, accounting for two of every three deaths (34*5 million) worldwide by 2010. 8 million people died from cancer in 2010, 38% more than two decades ago; of these, 1*5 million (19%) were from trachea, bronchus, and lung cancer. Ischaemic heart disease and stroke collectively killed 12*9 million people in 2010, or one in four deaths worldwide, compared with one in five in 1990; 1*3 million deaths were due to diabetes, twice as many as in 1990. The fraction of global deaths due to injuries (5*1 million deaths) was marginally higher in 2010 (9*6%) compared with two decades earlier (8*8%). This was driven by a 46% rise in deaths worldwide due to road traffic accidents (1*3 million in 2010) and a rise in deaths from falls. Ischaemic heart disease, stroke, chronic obstructive pulmonary disease (COPD), lower respiratory infections, lung cancer, and HIV/AIDS were the leading causes of death in 2010. Ischaemic heart disease, lower respiratory infections, stroke, diarrhoeal disease, malaria, and HIV/AIDS were the leading causes of years of life lost due to premature mortality (YLLs) in 2010, similar to what was estimated for 1990, except for HIV/AIDS and preterm birth complications. YLLs from lower respiratory infections and diarrhoea decreased by 45-54% since 1990; ischaemic heart disease and stroke YLLs increased by 17-28%. Regional variations in leading causes of death were substantial. Communicable, maternal, neonatal, and nutritional causes still accounted for 76% of premature mortality in sub-Saharan Africa in 2010. Age standardised death rates from some key disorders rose (HIV/AIDS, Alzheimer's disease, diabetes mellitus, and chronic kidney disease in particular), but for most diseases, death rates fell in the past two decades; including major vascular diseases, COPD, most forms of cancer, liver cirrhosis, and maternal disorders. For other conditions, notably malaria, prostate cancer, and injuries, little change was noted. INTERPRETATION: Population growth, increased average age of the world's population, and largely decreasing age-specific, sex-specific, and cause-specific death rates combine to drive a broad shift from communicable, maternal, neonatal, and nutritional causes towards non-communicable diseases. Nevertheless, communicable, maternal, neonatal, and nutritional causes remain the dominant causes of YLLs in sub-Saharan Africa. Overlaid on this general pattern of the epidemiological transition, marked regional variation exists in many causes, such as interpersonal violence, suicide, liver cancer, diabetes, cirrhosis, Chagas disease, African trypanosomiasis, melanoma, and others. Regional heterogeneity highlights the importance of sound epidemiological assessments of the causes of death on a regular basis. FUNDING: Bill & Melinda Gates Foundation.
Published: 2012

5. Patterns of physical activity and sedentary behaviour in the general population in France: cluster analysis with personal and socioeconomic correlates

Author: Joël Coste, Abdou Y. Omorou, Hélène Escalon, Anne Vuillemin, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Institut National de Prévention et d'Education pour la Santé (INPES), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), and Institut National de Prévention et d'Education pour la Santé ( INPES )
Subjects: Male, Pediatrics, MESH : Aged, Poison control, physical activity, Transportation, MESH: Logistic Models, Logistic regression, 0302 clinical medicine, MESH : Child, MESH : Exercise, Surveys and Questionnaires, MESH: Child, MESH : Socioeconomic Factors, Cluster Analysis, MESH : Female, 030212 general & internal medicine, clusters, MESH : Leisure Activities, Child, 2. Zero hunger, MESH: Aged, education.field_of_study, MESH: Middle Aged, 1. No poverty, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Adult, Middle Aged, 3. Good health, Homogeneous, MESH: Young Adult, Female, France, MESH : Surveys and Questionnaires, MESH: Sedentary Lifestyle, Adult, medicine.medical_specialty, MESH: Socioeconomic Factors, Adolescent, MESH : Male, Population, Physical activity, MESH : Young Adult, World health, socioeconomic status, 03 medical and health sciences, Young Adult, Leisure Activities, MESH : Adolescent, sedentary behaviour, medicine, MESH : Transportation, MESH : Cluster Analysis, Humans, MESH : Middle Aged, Occupations, MESH: Surveys and Questionnaires, education, MESH : France, Socioeconomic status, Exercise, MESH: Leisure Activities, Socioeconomic differences, Aged, MESH: Adolescent, MESH: Humans, MESH: Occupations, business.industry, MESH: Transportation, MESH : Humans, Public Health, Environmental and Occupational Health, MESH : Occupations, correlates, MESH: Adult, 030229 sport sciences, MESH: Cluster Analysis, MESH: Male, MESH: France, Logistic Models, Socioeconomic Factors, MESH: Exercise, MESH : Sedentary Lifestyle, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Sedentary Behavior, business, MESH: Female, Demography, MESH : Logistic Models
Abstract: International audience; BACKGROUND:Few studies have focused on relating physical activity (PA) and sedentary behaviour (SB) to identify homogeneous groups. This study aimed to identify patterns of PA and SB in France general population and their correlates.METHODS:A sample of 3294 (mean age 44 ± 17 years) from the general population in France was included. PA and SB were assessed by the World Health Organization Global Physical Activity Questionnaire. Cluster analysis was used to identify PA and SB patterns, with polytomous logistic regression to identify their correlates.RESULTS:Five clusters were identified: (i) 'low total PA, active-transportation and low SB' (41%), (ii) 'low total PA and moderate SB' (22%), (iii) 'low total PA, leisure-time PA and high SB' (15%), (iv) 'high total PA, moderate occupational PA and moderate SB' (17%) and (v) 'high total PA, vigorous occupational PA and low SB' (5%). Occupational PA substantially contributed to total PA which depended on socioeconomic status (SES): low total PA and high SB in higher SES and high total PA and low SB in lower SES.CONCLUSIONS:Based on PA and SB, French adults were clustered into groups with socioeconomic differences emphasizing that adapted interventions may be more beneficial for health.
Published: 2016

6. Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study

Author: Valérie Jooste, Zoé Uhry, Anne-Marie Bouvier, Jean Faivre, Sophie Grabar, N. Duport, Sylvain Manfredi, Aurélien Belot, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), FRANCIM, Réseau des registres français du cancer, Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques [Lyon], Hospices Civils de Lyon (HCL), Service des Maladies de l'Appareil Digestif [CHU Rennes], CHU Pontchaillou [Rennes], Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National du Cancer (INCA), Santé publique France, Pontchaillou. Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire [Rennes], Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Centre Hospitalier Universitaire de Rennes, and Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: Male, Epidemiology, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Anus Neoplasms, MESH: Research Papers: Gastrointestinal Cancer, 0302 clinical medicine, MESH : Child, MESH: Child, Medicine, MESH: Incidence, MESH : Carcinoma, Squamous Cell, Child, education.field_of_study, MESH: Middle Aged, Obstetrics, MESH : Infant, MESH: Carcinoma, Squamous Cell, MESH: Follow-Up Studies, Anal canal, Anus Neoplasms, Prognosis, Research Papers, MESH: Infant, MESH : Incidence, 3. Good health, Survival Rate, Oncology, MESH: Young Adult, Child, Preschool, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, 030211 gastroenterology & hepatology, medicine.medical_specialty, MESH : Research Papers: Gastrointestinal Cancer, Mitomycin, MESH : Young Adult, United-States, MESH: Prognosis, 03 medical and health sciences, MESH : Adolescent, Humans, Anal cancer, MESH : Middle Aged, MESH : Anus Neoplasms, education, Aged, Gynecology, MESH: Adolescent, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, Infant, MESH : Follow-Up Studies, MESH: Adult, Epidermoid Carcinoma, medicine.disease, Cervical-cancer, incidence, Randomized-trial, MESH: Female, Cancer Research, MESH: Registries, MESH : Child, Preschool, Risk Factors, MESH: Risk Factors, MESH : Female, Registries, Cervical cancer, MESH: Aged, MESH : Prognosis, Incidence (epidemiology), Smoking, MESH: Infant, Newborn, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, medicine.anatomical_structure, Female, France, Adult, Human-Papillomavirus, Risk, Adolescent, MESH: Survival Rate, anal cancer, MESH : Male, Population, Human Papilloma Virus Vaccine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer Incidence, MESH : Infant, Newborn, survival, Young Adult, cancer registry, MESH : France, Survival rate, Radiotherapy, business.industry, Infant, Newborn, Cancer, MESH: Male, MESH: France, business, MESH : Registries, Follow-Up Studies
Abstract: IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 person-years among men and from 0.7 to 1.3/100 000 person-years among women from 1982 to 2012. Among women, the increase peaked after 2005, with an annual percentage change of +3.4% between 2005 and 2012, as compared with +2.6% among men. The net survival was 56% (95% confidence interval, 49-64) at 5 years and 48% (33-70) at 10 years among men. It was higher among women, at 65% (61-69) and 56% (50-63) at 5 and 10 years, respectively. The prognosis improved between 1989-1997 and 1998-2004. This improvement was slightly greater for men than for women, thus progressively reducing the gap between sexes. The incidence of squamous-cell anal canal cancer increased slightly among both sexes, but the increase was more marked among women than among men. The potential benefit of prophylactic female human papilloma virus vaccination against cervical cancer in France should be further evaluated.
Published: 2016

7. Estimating the Burden of Leptospirosis among Febrile Subjects Aged below 20 Years in Kampong Cham Communities, Cambodia, 2007-2009

Author: Seiha Heng, Arnaud Tarantola, Rekol Huy, Touch Sok, Sopheak Hem, Florian Vogt, Sowath Ly, Mathieu Picardeau, Sovann Ly, Nima Asgari, Irene Votsi, Philippe Buchy, Simon Cauchemez, Bertrand Guillard, Institut Pasteur du Cambodge, Réseau International des Instituts Pasteur (RIIP), Modélisation mathématique des maladies infectieuses, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), London School of Hygiene and Tropical Medicine (LSHTM), World Health Organization [Phnom Penh] (WHO), Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Centre Collaborateur FAO/OMS pour l'épidémiologie de la leptospirose, Institut Pasteur [Paris], Centre National de Référence de la Leptospirose - National Reference Center Leptospirosis (CNR), Ministry of Health [Phnom Penh], National Center of Parasitology (CNM), National Malaria Center [Phnom Penh], This study was supported by the World Health Organization and the European Union and Pediatric Vaccine Dengue Initiative project (PDVI) from the International Vaccine Institute (IVI). Aside from coauthor NA who helped discuss the study results and edit the article, the funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Institut Pasteur du Cambodge-Réseau International des Instituts Pasteur ( RIIP ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), London School of Hygiene and Tropical Medicine ( LSHTM ), World Health Organization [Phnom Penh] ( WHO ), World Health Organization, Centre National de Référence des Leptospires-Biologie des Spirochètes ( CNR-CC FAO/OMS ), Communicable Disease Department [Phnom Penh] ( CDC MOH ), Ministry of Health, National Center for Malaria Control, Parasitology and Entomology, Ministry of Health of Cambodgia, and This study was supported by the World Health Organization and the European Union and Pediatric Vaccine Dengue Initiative project (PDVI) from the International Vaccine Institute (IVI).
Subjects: MESH : Cambodia/epidemiology, Male, Rural Population, Pathology and Laboratory Medicine, Biochemistry, 0302 clinical medicine, MESH : Immunoglobulin M/blood, MESH : Child, MESH: Rural Population, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Child, Chikungunya, Enzyme-Linked Immunoassays, lcsh:Science, Child, MESH : Dengue/epidemiology, Leptospira, education.field_of_study, MESH : Antibodies, Bacterial/blood, MESH : Infant, MESH: Leptospirosis, Leptospirosis, MESH: Infant, MESH: Immunoglobulin M, 3. Good health, Bacterial Pathogens, Veterinary Diseases, Medical Microbiology, Child, Preschool, medicine.medical_specialty, 030106 microbiology, Immunology, MESH: Social Planning, Microbiology, 03 medical and health sciences, Signs and Symptoms, MESH : Adolescent, MESH : Leptospirosis/blood, Humans, education, Immunoassays, Microbial Pathogens, MESH: Adolescent, MESH: Humans, Bacteria, Public health, MESH : Humans, lcsh:R, MESH: Child, Preschool, Organisms, Infant, Biology and Life Sciences, Proteins, MESH: Adult, Japanese encephalitis, medicine.disease, Tropical Diseases, lcsh:Q, Veterinary Science, MESH: Female, Demography, 0301 basic medicine, Bacterial Diseases, Physiology, lcsh:Medicine, Fevers, MESH: Dengue, MESH : Child, Preschool, medicine.disease_cause, Serology, Dengue fever, Dengue, Geographical Locations, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, Zoonoses, Immune Physiology, MESH: Antibodies, Bacterial, Medicine and Health Sciences, MESH : Female, Multidisciplinary, Immune System Proteins, biology, MESH: Infant, Newborn, MESH : Adult, Antibodies, Bacterial, Infectious Diseases, Female, Social Planning, Pathogens, Cambodia, Research Article, Neglected Tropical Diseases, Adult, MESH : Dengue/blood, Asia, Adolescent, MESH : Male, 030231 tropical medicine, Population, MESH : Infant, Newborn, Research and Analysis Methods, Antibodies, MESH : Social Planning, Diagnostic Medicine, medicine, MESH : Leptospirosis/epidemiology, business.industry, MESH: Cambodia, Infant, Newborn, biology.organism_classification, MESH: Male, MESH : Rural Population, Immunoglobulin M, People and Places, Immunologic Techniques, business
Abstract: International audience; BACKGROUND:Leptospirosis is an emerging but neglected public health challenge in the Asia/Pacific Region with an annual incidence estimated at 10-100 per 100,000 population. No accurate data, however, are available for at-risk rural Cambodian communities.METHOD:We conducted anonymous, unlinked testing for IgM antibodies to Leptospira spp. on paired sera of Cambodian patients
Published: 2016

8. Bronchoalveolar Lavage in Hypersensitivity Pneumonitis: A Series of 139 Patients

Author: Caillaud, Denis M, Vergnon, Jean M, Madroszyk, Anne, Melloni, Boris M, Murris, Marlene, Dalphin, Jean-Charles, Renseigné, Non, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement ( LCE ), and Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC )
Subjects: Male, Pathology, Lymphocyte, MESH : Aged, Bronchoalveolar Lavage, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH : Farmer's Lung, MESH: Aged, 80 and over, Immunology and Allergy, Eosinophilia, MESH : Female, Aged, 80 and over, MESH: Aged, MESH : Bronchoalveolar Lavage Fluid, MESH: Middle Aged, MESH: Bronchoalveolar Lavage, medicine.diagnostic_test, General Medicine, Middle Aged, MESH : Adult, respiratory system, medicine.anatomical_structure, MESH: Young Adult, Female, medicine.symptom, Bronchoalveolar Lavage Fluid, MESH : Bronchoalveolar Lavage, Hypersensitivity pneumonitis, Alveolitis, Extrinsic Allergic, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Alveolitis, Extrinsic Allergic, Immunology, CD4-CD8 Ratio, MESH : Young Adult, MESH: Alveolitis, Extrinsic Allergic, Young Adult, Antigen, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, MESH: Adolescent, MESH: Farmer's Lung, Pharmacology, MESH: Humans, Lung, MESH: Bronchoalveolar Lavage Fluid, business.industry, MESH : Humans, MESH: Adult, medicine.disease, MESH: Male, Neutrophilia, respiratory tract diseases, Bronchoalveolar lavage, MESH : CD4-CD8 Ratio, Farmer's Lung, MESH: CD4-CD8 Ratio, business, MESH: Female, [ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, CD8
Abstract: International audience; Hypersensitivity pneumonitis (HP) is characterized by a lymphocytic alveolitis, classically delineated by an increase of CD8+ lymphocytes, with an inversion of the CD4+/CD8+ ratio. The aim of this study is both to describe the yield and cell bronchoalveolar lavage (BAL) profile and to revisit the assumption of low BAL CD4/CD8 ratio in the diagnosis of HP. A multicentric study was conducted on 139 patients who fulfilled the standardized diagnostic criteria of HP, mainly affected by farmer's lung. Mean total cell count in BAL fluid was 594 ± 401.10(3) cells /ml. Prominent absolute lymphocytic alveolitis, moderate neutrophilia, and mild eosinophilia and mastocytosis were found. Mean CD4/CD8 ratio was 3.8 ± 6.1 (median 2.1). Thirty four percent of the patients showed lymphocytic CD8 alveolitis (ratio < 1). The CD4/CD8 ratio was not different between forms, etiologies of HP, and time elapsed since last antigen exposure, but was higher in women (p=0.02). BAL in HP shows high total cell and lymphocyte counts, moderate neutrophilia, and mild eosinophilia and mastocytosis. An absence of low CD4/CD8 ratio should not at all exclude diagnosis.
Published: 2012

9. Oncogenic Alterations in Papillary Thyroid Cancers of Young Patients

Author: G. Sassolas, Z. Hafdi Nejjari, A. Ferraro, M. S. Gandhi, C. Kwon Jung, E. Borbone, M. Decaussin Petrucci, B. Rousset, F. Borson Chazot, N. Berger, FUSCO, ALFREDO, registre rhone-alpin du cancer de la thyroide, Hospices Civils de Lyon (HCL), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-registre rhone-alpins du cancer de la thyroide, Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), departement de pathologie, Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ) -registre rhone-alpins du cancer de la thyroide, Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), G., Sassola, Z., Hafdi Nejjari, A., Ferraro, M. S., Gandhi, C., Kwon Jung, E., Borbone, M., Decaussin Petrucci, B., Rousset, F., Borson Chazot, N., Berger, and Fusco, Alfredo
Subjects: Male, Oncology, Pathology, Oncogene Proteins, Fusion, endocrine system diseases, MESH: Carcinoma, Papillary, Endocrinology, Diabetes and Metabolism, Disease, MESH : Oncogene Proteins, Fusion, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Endocrinology, MESH : Child, MESH: Child, MESH : Female, Young adult, Child, Lymph node, education.field_of_study, MESH : Prognosis, MESH : Genes, ras, Thyroid, Age Factors, Protein-Tyrosine Kinases, MESH : Adult, Prognosis, 3. Good health, medicine.anatomical_structure, Thyroid Cancer, Papillary, MESH: Thyroid Neoplasms, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, Mitogen-Activated Protein Kinases, MESH : Mutation, Adult, Proto-Oncogene Proteins B-raf, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH : Male, Population, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, 030209 endocrinology & metabolism, MESH: Protein-Tyrosine Kinases, MESH: Prognosis, MESH : Carcinoma, Papillary, Thyroid carcinoma, Young Adult, 03 medical and health sciences, Median follow-up, MESH : Adolescent, Internal medicine, MESH : Protein-Tyrosine Kinases, medicine, Humans, Thyroid Neoplasms, education, MESH : Proto-Oncogene Proteins B-raf, MESH: Adolescent, MESH: Age Factors, MESH: Proto-Oncogene Proteins B-raf, MESH: Humans, business.industry, Carcinoma, MESH : Humans, MESH : Mitogen-Activated Protein Kinases, MESH: Adult, MESH: Mitogen-Activated Protein Kinases, Carcinoma, Papillary, MESH : Thyroid Neoplasms, MESH: Male, MESH: Genes, ras, Genes, ras, Mutation, MESH : Age Factors, business, MESH: Female, V600E, MESH: Oncogene Proteins, Fusion
Abstract: International audience; BACKGROUND: Papillary thyroid carcinoma (PTC) in young people usually has an aggressive initial presentation, though a good general prognosis despite recurrences in 10%-20% of patients. A number of genetic alterations that activate the mitogen-activated protein kinase (MAPK) pathway have been found in PTC. Some of these alterations have been identified as prognostic factors of PTC in adults. The objective of the current study was to comprehensively characterize all known oncogenic alterations of the MAPK pathway in young people. METHODS: One hundred three PTCs removed from 9 children, 19 adolescents, and 75 young adults were submitted to molecular analyses. RESULTS: Altogether, 57 alterations were found in 56 PTCs (55%) corresponding to V600E BRAF in 20.3%, RAS mutations in 12.6%, RET/PTC 1 in 11.6%, RET/PTC 3 in 8.7%, and rearrangement of NTRK in 1.9%. The prevalence of all alterations increased with age (22.2% in children; 52.6% in adolescents, 51.4% in adults 20-25 years, and 55.1% in adults 25-35 years). Prevalence increased from 39.2% earlier to 61.3% after 20 years mainly due to BRAF mutations. Classic-type PTC was associated with a larger prevalence of alterations, predominantly BRAF and RET/PTC, whereas the follicular variant was chiefly associated with RAS. RET/PTC (1 and 3) was significantly associated with extrathyroid extension (ET) and lymph node metastasis (es) (LNM). This association was found in the adult group. There were no associations of BRAF or RAS mutations with ET or LNM. A 3-year median follow up was available for 90 patients. RET/PTC 1 and 3 was associated with short-term disease dissemination (cervical lymph node recurrences and distant metastases) in young adults (p=0.001). Persistent illness was more prevalent in patients with (15%) than in patients without (7%) genetic alterations. CONCLUSION: PTCs in young patients display a low prevalence of the already identified oncogenic alterations. The increasing prevalence with age is mainly due to V600E BRAF mutation. There is no relation between tumor aggressiveness and BRAF mutation. There is a relation between the presence of RET/PTC (1 and 3) and the histological and clinical short-term aggressiveness of PTC in the population of young adults. Such a relation is not found in children and adolescents.
Published: 2012

10. Epidemiological trends in invasive aspergillosis in France: the SAIF network (2005–2007)

Author: Stéphane Bretagne, B. Lebeau, F. de Monbrison, Olivier Lortholary, Karine Sitbon, Françoise Dromer, Jean-Pierre Gangneux, Bruno Coignard, Y. Le Strat, Centre d'infectiologie Necker-Pasteur [CHU Necker], Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Service de Parasitologie-Mycologie [Rennes], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Laboratoire de parasitologie-mycologie, CHU Grenoble, Laboratoire de Parasitologie-Mycologie, Centre Hospitalo-Universitaire de Lyon, Département des maladies infectieuses, Institut de Veille Sanitaire (INVS), Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Biologie moléculaire et immunologie parasitaires et fongiques (BIPAR), École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Veille Sanitaire, Laboratoire de santé animale, sites de Maisons-Alfort et de Dozulé, Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Agence nationale de sécurité sanitaire de l'alimentation, de l'environnement et du travail (ANSES)-Institut National de la Recherche Agronomique (INRA)-École nationale vétérinaire d'Alfort (ENVA)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris] (IP), Université de Rennes (UR), Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], École nationale vétérinaire - Alfort (ENVA)-Institut National de la Recherche Agronomique (INRA)-Laboratoire de santé animale, sites de Maisons-Alfort et de Normandie, CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Signalisation et Réponses aux Agents Infectieux et Chimiques ( SeRAIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Biologie moléculaire et immunologie parasitaires et fongiques ( BIPAR ), Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ) -AFSSA-Ecole Nationale Vétérinaire d'Alfort-Institut National de la Recherche Agronomique ( INRA ), CHU Necker - Enfants Malades [AP-HP], Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-IFR140, and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)
Subjects: Male, Epidemiology, MESH : Prospective Studies, MESH : Aged, Aspergillosis, Mannans, 0302 clinical medicine, MESH: Immunocompromised Host, Prospective Studies, MESH: Incidence, Aged, 80 and over, Invasive Pulmonary Aspergillosis, 0303 health sciences, MESH: Middle Aged, Incidence, General Medicine, MESH : Incidence, 3. Good health, Aspergillus, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Young Adult, Drug Therapy, Combination, Microbiology (medical), MESH: Invasive Pulmonary Aspergillosis, medicine.medical_specialty, MESH : Young Adult, 03 medical and health sciences, Galactomannan, Pharmacotherapy, MESH: Mannans, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, MESH: Adolescent, MESH: Humans, MESH : Seasons, 030306 microbiology, MESH : Humans, MESH: Adult, MESH: Antifungal Agents, medicine.disease, chemistry, galactomannan, Immunology, MESH: Female, Antifungal Agents, chemistry.chemical_compound, MESH: Aged, 80 and over, Risk Factors, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Risk Factors, MESH : Female, 030212 general & internal medicine, Prospective cohort study, MESH: Aged, Incidence (epidemiology), MESH : Aspergillus, MESH : Immunocompromised Host, Middle Aged, MESH : Adult, MESH: Hospitals, MESH : Risk Factors, Hospitals, MESH : Hospitals, Infectious Diseases, MESH: Aspergillus, outcome, Female, France, Seasons, medicine.drug, Adult, Adolescent, MESH : Male, MESH : Antifungal Agents, Immunocompromised Host, Young Adult, Internal medicine, voriconazole, medicine, MESH : France, Voriconazole, invasive aspergillosis, business.industry, MESH : Drug Therapy, Combination, Galactose, MESH: Male, MESH: Prospective Studies, MESH: France, Transplantation, MESH: Drug Therapy, Combination, MESH : Invasive Pulmonary Aspergillosis, Caspofungin, business, MESH : Mannans, MESH: Seasons
Abstract: International audience; A prospective (2005-2007) hospital-based multicentre surveillance of EORTC/MSG-proven or probable invasive aspergillosis (IA) cases whatever the underlying diseases was implemented in 12 French academic hospitals. Admissions per hospital and transplantation procedures were obtained. Cox regression models were used to determine risk factors associated with the 12-week overall mortality. With 424 case-patients included, the median incidence/hospital was 0.271/10(3) admissions (range 0.072-0.910) without significant alteration of incidence and seasonality over time. Among the 393 adults (62% men, 56 years (16-84 years)), 15% had proven IA, 78% haematological conditions, and 92.9% had lung involvement. Acute leukaemia (34.6%) and allogeneic stem cell transplantation (21.4%) were major host factors, together with chronic lymphoproliferative disorders (21.6%), which emerged as a new high-risk group. The other risk host factors consisted of solid organ transplantation (8.7%), solid tumours (4.3%), systemic inflammatory diseases (4.6%) and chronic respiratory diseases (2.3%). Serum galactomannan tests were more often positive (≥69%) for acute leukaemia and allogeneic stem cell transplantation than for the others (
Published: 2011

11. Increased Levels of Circulating Endothelial-Derived Microparticles and Small-Size Platelet-Derived Microparticles in Psoriasis

Author: Philippe Humbert, Chrystelle Vidal, Sabeha Biichle, Estelle Seilles, Fabien Pelletier, Francine Garnache-Ottou, Fanny Angelot, François Aubin, Philippe Saas, Département de dermatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Clinical Investigation Centre, Centre d'Investigation Clinique de Besançon (Inserm CIC 1431), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Plateforme de Biomonitoring, Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Centre d'Investigation Clinique de Besançon ( CICB ), Etablissement Français du Sang Bourgogne Franche-Comté-Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Franche-Comté ( UFC ), Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, MESH: Platelet Membrane Glycoprotein IIb, MESH : Psoriasis, MESH : Aged, MESH : Cell-Derived Microparticles, 030204 cardiovascular system & hematology, Biochemistry, MESH : Platelet Membrane Glycoprotein IIb, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Cell-Derived Microparticles, MESH: Cell-Derived Microparticles, Medicine, MESH : Female, MESH: Endothelial Cells, Platelet, ComputingMilieux_MISCELLANEOUS, MESH: Blood Platelets, MESH: Aged, MESH: Psoriasis, 0303 health sciences, MESH: Middle Aged, Middle Aged, MESH : Adult, humanities, 3. Good health, Platelet Endothelial Cell Adhesion Molecule-1, MESH : Antigens, CD31, Female, Adult, Blood Platelets, Platelet Membrane Glycoprotein IIb, Adolescent, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Dermatology, 03 medical and health sciences, Text mining, MESH : Adolescent, Psoriasis, Humans, MESH : Middle Aged, Molecular Biology, Aged, 030304 developmental biology, MESH: Adolescent, MESH: Humans, MESH : Endothelial Cells, business.industry, MESH : Humans, Endothelial Cells, MESH : Blood Platelets, MESH: Adult, MESH: Antigens, CD31, Cell Biology, medicine.disease, MESH: Male, Immunology, business, MESH: Female
Abstract: International audience
Published: 2011

12. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)

Author: Pierre Bordigoni, Danielle Canioni, Michèle Milili, Nathalie Lambert, Claire Galambrun, Marie Ouachée-Chardin, Filomeen Haerynck, Françoise Le Deist, Despina Moshous, Christelle Lenoir, Stephanie Rigaud, Lionel Galicier, Fabien Touzot, Capucine Picard, Mohamed Hamidou, Hirokazu Kanegane, Ester Mejstrikova, Helen Chapel, Eduardo López-Granados, Stéphane Blanche, Alain Dabadie, Jana Pachlopnik Schmid, Pierre-Simon Rohrlich, Fabian Hauck, Geneviève de Saint Basile, Claudin Schiff, Jean-Louis Stephan, Alain Fischer, Isabelle Pellier, Nizar Mahlaoui, Sylvain Latour, Alain Fourmaintraux, Vincent Barlogis, IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'anatomie pathologique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Graduate School of Medicine, University of Toyama, Department of pediatrics, University of Oxford [Oxford], Teaching Hospital Motol and 2nd Medical School, Charles University, Department of Pediatric Hematology and Oncology, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Groupe Hospitalier Sud Réunion (GHSR), Centre Hospitalier Universitaire [Rennes], Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Department of Paediatric Pulmonology, Ghent University Hospital, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Département de pédiatrie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, CHU Saint-Etienne, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'étude des Déficits Immunitaires, Assistance Publique-Hôpitaux de Paris, Service d'Immunologie et d'Hématologie Pédiatrique, Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), University of Oxford, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Collège de France - Chaire Médecine expérimentale (A. Fischer), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), IFR Necker-Enfants Malades ( IRNEM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Groupe Hospitalier Sud Réunion ( GHSR ), Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Génétique Humaine des Maladies Infectieuses ( Inserm U980 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), and Assistance publique - Hôpitaux de Paris (AP-HP)
Subjects: Male, MESH : Retrospective Studies, MESH: X-Linked Inhibitor of Apoptosis Protein, MESH : Aged, MESH : Child, Preschool, Biochemistry, Cohort Studies, Immunoenzyme Techniques, Hypogammaglobulinemia, MESH: Lymphoproliferative Disorders, 0302 clinical medicine, MESH : Child, MESH: Child, hemic and lymphatic diseases, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, XIAP Deficiency, Signaling Lymphocytic Activation Molecule Associated Protein, X-Linked Lymphoproliferative Syndrome, Child, MESH: Cohort Studies, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH : Lymphoproliferative Disorders, Intracellular Signaling Peptides and Proteins, MESH : Infant, Hematology, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH: Infant, 3. Good health, Survival Rate, MESH : Phenotype, Phenotype, MESH: Young Adult, Child, Preschool, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH : Mutation, Adult, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH: Survival Rate, MESH : Male, Immunology, MESH : Young Adult, MESH : Cohort Studies, X-Linked Inhibitor of Apoptosis Protein, Biology, MESH: Phenotype, Virus, Young Adult, 03 medical and health sciences, MESH : Intracellular Signaling Peptides and Proteins, MESH : Immunoenzyme Techniques, MESH : Adolescent, MESH: Intracellular Signaling Peptides and Proteins, medicine, Humans, MESH : Middle Aged, MESH: Immunoenzyme Techniques, Aged, Retrospective Studies, 030304 developmental biology, MESH: Adolescent, Hemophagocytic lymphohistiocytosis, Cytopenia, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Infant, X-linked lymphoproliferative disease, MESH: Adult, MESH: Retrospective Studies, Cell Biology, medicine.disease, Lymphoproliferative Disorders, MESH: Male, MESH : X-Linked Inhibitor of Apoptosis Protein, Mutation, Histopathology, MESH: Female, 030215 immunology
Abstract: X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions.
Published: 2011

13. Adaptive Differentiation ofPlasmodium falciparumPopulations Inferred from Single‐Nucleotide Polymorphisms (SNPs) Conferring Drug Resistance and from Neutral SNPs

Author: Rabia Mazmouz, Agnès Aubouy, Emmanuelle Renard, Sabah A. Omar, Jérôme Clain, Sarah Falcão, Emeline Broussier, Abdoulaye Djimde, Vély Jean-François, Jean-François Lepère, Jacques Le Bras, Dorina G. Bustos, Oumou Maïga-Ascofaré, Milijaona Randrianarivelojosia, Mère et enfant face aux infections tropicales (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD) - Université Paris Descartes - Paris 5 (UPD5), Malaria Research and Training Center, Department of Epidemiology of Parasitic Diseases, Faculty of Medicine, Pharmacy, and Odontostomatology, Université de Bamako, Centre de consultations de Bandraboua, Research Institute for Tropical Medicine, Institut Pasteur de Madagascar, Institut Pasteur de Madagascar - Réseau International des Instituts Pasteur (RIIP), Kenya Medical Research Institute, Unité de Recherche 010, IRD, Service National de Lutte Antipaludique, Financial support: French Ministry of Health (grant to the Centre National de Réference du Paludisme), Institut de Médecine et d'Epidémiologie Appliquée/Fondation Léon Mba (grant 5988CLN90PFGO), French Ministry of Foreign Affairs for the France-Philippine Technical Cooperation Project on Malaria (grant), Bio-MalPar Network of Excellence., Mère et enfant en milieu tropical : pathogènes, système de santé et transition épidémiologique (MERIT - UMR_D 216), Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5), Réseau International des Instituts Pasteur (RIIP), and Kenya Medical Research Institute (KEMRI)
Subjects: Male, MESH: Philippines, MESH: Geography, Philippines, [SDV]Life Sciences [q-bio], Genes, Protozoan, Adaptation, Biological, Drug Resistance, MESH : Aged, Drug resistance, MESH: Africa, MESH : Child, Preschool, MESH : Malaria, Falciparum, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Child, Polymorphism (computer science), MESH: Child, MESH : Haiti, MESH : Philippines, MESH : Plasmodium falciparum, Immunology and Allergy, MESH : Female, MESH : Adaptation, Biological, Malaria, Falciparum, Child, MESH : DNA, Protozoan, MESH: Plasmodium falciparum, Aged, 80 and over, MESH: Aged, Genetics, 0303 health sciences, MESH: Middle Aged, Geography, biology, MESH: Polymorphism, Single Nucleotide, MESH: Malaria, Falciparum, MESH: Infant, Newborn, MESH : Polymorphism, Single Nucleotide, MESH : Geography, MESH : Infant, Middle Aged, MESH : Adult, MESH: Infant, 3. Good health, [SDV] Life Sciences [q-bio], MESH: Haiti, Infectious Diseases, MESH: Genes, Protozoan, MESH: Young Adult, Child, Preschool, MESH : Genes, Protozoan, MESH: Drug Resistance, Female, Adult, Adolescent, MESH : Africa, MESH : Male, Plasmodium falciparum, 030231 tropical medicine, MESH : Young Adult, MESH: DNA, Protozoan, Context (language use), Single-nucleotide polymorphism, MESH : Infant, Newborn, Polymorphism, Single Nucleotide, Young Adult, 03 medical and health sciences, MESH : Adolescent, parasitic diseases, Humans, MESH : Middle Aged, Allele, MESH : Aged, 80 and over, Gene, Allele frequency, Aged, 030304 developmental biology, MESH: Adolescent, MESH : Drug Resistance, MESH: Humans, MESH: Adaptation, Biological, MESH: Child, Preschool, MESH : Humans, Infant, Newborn, Infant, MESH: Adult, DNA, Protozoan, biology.organism_classification, Haiti, MESH: Male, Africa, MESH: Female
Abstract: International audience; BACKGROUND: Theoretical and experimental data support the geographic differentiation strategy as a valuable tool for detecting loci under selection. In the context of Plasmodium falciparum malaria, few populations have been studied, with limited genomic coverage. METHODS: We examined geographic differentiation in P. falciparum populations on the basis of 12 single-nucleotide polymorphisms (SNPs) in 4 genes encoding drug resistance determinants, 5 SNPs in 2 genes encoding antigens, and a set of 17 putatively neutral SNPs dispersed on 13 chromosomes. We sampled 326 parasite isolates representing 7 P. falciparum populations from regions with varied levels of malaria transmission (Gabon, Kenya, Madagascar, Mali, Mayotte, Haiti, and the Philippines). RESULTS: Frequencies of drug resistance alleles varied considerably among populations (mean F(ST), 0.52). In contrast, allele frequencies varied significantly less for antigenic and neutral SNPs (mean F(ST), 0.16 and 0.24, respectively). This contrasting pattern was more pronounced when only the African populations were considered. Signature of selection was detected for most of the resistant SNPs but not for the antigenic SNPs. CONCLUSION: These data further validate the utility of geographic differentiation for identifying loci under strong positive selection, such as drug resistance loci. This study also provides frequencies of molecular makers of resistance in some overlooked populations.
Published: 2010

14. Antithymocyte globulins and chronic graft-vs-host disease after myeloablative allogeneic stem cell transplantation from HLA-matched unrelated donors: a report from the Sociéte Française de Greffe de Moelle et de Thérapie Cellulaire

Author: Colette Raffoux, Mohamad Mohty, R. Tabrizi, J.Y. Cahn, Ibrahim Yakoub-Agha, J. H. Bourhis, Yosr Hicheri, Norbert Ifrah, Mauricette Michallet, Agnès Buzyn, Nathalie Dhedin, Myriam Labopin, Marie-Lorraine Balere, Didier Blaise, Gérard Socié, Helene Esperou, Noel Milpied, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Centre hospitalier universitaire de Nantes (CHU Nantes), Université Bordeaux Segalen - Bordeaux 2, Service des maladies du sang, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Groupe Hospitalier Sud, Centre Léon Bérard [Lyon], Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), Institut Gustave Roussy (IGR), Service greffe de moelle osseuse, Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers, Centre hospitalier universitaire de Nantes ( CHU Nantes ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Institut Gustave Roussy ( IGR ), and Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]
Subjects: Male, MESH: Tissue Donors, Cancer Research, MESH : Retrospective Studies, MESH : Aged, MESH: Rabbits, Graft vs Host Disease, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH : HLA Antigens, MESH: Antilymphocyte Serum, HLA Antigens, MESH : Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Female, MESH: Animals, Cumulative incidence, MESH: Incidence, MESH: HLA Antigens, MESH : Tissue Donors, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, Hematology, Histocompatibility Testing, Incidence, Incidence (epidemiology), MESH : Graft vs Host Disease, MESH : Histocompatibility Testing, MESH : Adult, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Incidence, Tissue Donors, 3. Good health, Leukemia, Myeloid, Acute, Leukemia, Treatment Outcome, surgical procedures, operative, Oncology, 030220 oncology & carcinogenesis, Female, Rabbits, MESH: Stem Cell Transplantation, MESH: Leukemia, Myeloid, Acute, MESH: Myelodysplastic Syndromes, Adult, endocrine system, medicine.medical_specialty, Adolescent, MESH : Transplantation, Homologous, MESH : Male, MESH : Leukemia, Myeloid, Acute, MESH : Antilymphocyte Serum, MESH: Graft vs Host Disease, MESH : Myelodysplastic Syndromes, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, MESH: Histocompatibility Testing, MESH : Stem Cell Transplantation, 03 medical and health sciences, MESH : Adolescent, Internal medicine, MESH: Transplantation, Homologous, medicine, Animals, Humans, Transplantation, Homologous, MESH : Middle Aged, MESH : Rabbits, Aged, Antilymphocyte Serum, Retrospective Studies, MESH: Adolescent, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH: Humans, business.industry, Myelodysplastic syndromes, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Male, Histocompatibility, Transplantation, Graft-versus-host disease, Myelodysplastic Syndromes, Immunology, MESH : Animals, business, MESH: Female, Stem Cell Transplantation, 030215 immunology
Abstract: International audience; This retrospective report assessed the impact of rabbit antithymocyte globulins (ATG), incorporated within a standard myeloablative conditioning regimen prior to allogeneic stem cell transplantation (allo-SCT) using human leukocyte antigen-matched unrelated donors (HLA-MUD), on the incidence of acute and chronic graft-vs-host disease (GVHD). In this series of leukemia patients, 120 patients (70%) did not receive ATG ('no-ATG' group), whereas 51 patients received ATG ('ATG' group). With a median follow-up of 30.3 months, the cumulative incidence of grade 3-4 acute GVHD was 36% in the no-ATG group and 20% in the ATG group (P = 0.11). The cumulative incidence of extensive chronic GVHD was significantly lower in the ATG group as compared to the no-ATG group (4 vs 32%, respectively; P = 0.0017). In multivariate analysis, the absence of use of ATG was the strongest parameter associated with an increased risk of extensive chronic GVHD (relative risk) = 7.14, 95% CI: 1.7-33.3, P = 0.008). At 2 years, the probability of nonrelapse mortality, relapse, overall and leukemia-free survivals was not significantly different between the no-ATG and ATG groups. We conclude that the addition of ATG to GVHD prophylaxis resulted in decreased incidence of extensive chronic GVHD without an increase in relapse or nonrelapse mortality, and without compromising survival after myeloablative allo-SCT from HLA-MUD.
Published: 2010

15. TP53 codon 72 polymorphism and cervical cancer

Author: R.J. Pegoraro, Annarosa Del Mistro, M. Pillai, Dhananjaya Saranath, Angel Suarez-Rincon, Joseph Menczer, Adam N. Rosenthal, Giovanni Rezza, Åslaug Helland, Theodoros Agorastos, Virginia M. Schmitt, Maria Blettner, Mark H. Stoler, Jae Weon Kim, Stefanie J. Klug, Ming-Tsang Wu, Sylvia M. F. Brenna, Margaret M. Madeleine, Andrea L. Haws, Peter J.F. Snijders, Wannapa Settheetham-Ishida, Meike Ressing, Martín Carlos Abba, Aleksandra Dybikowska, Marco Ciotti, Tsuyoshi Yamashita, Masatsugu Ueda, Gulielmina Ranzani, Magnus von Knebel Doeberitz, Zivile Gudleviciene, Sun H. Jee, Alan Hildesheim, Hextan Y.S. Ngan, Ate G.J. van der Zee, Krisztina Szarka, Sharmila Sengupta, Ulf Gyllensten, Anna R. Giuliano, Yoshimitsu Niwa, Hiroshi Shirasawa, Ruth Tachezy, Susanta Roychoudhury, Olivier Humbey, Akira Nishikawa, C. Simon Herrington, Ingeborg Zehbe, Jochem Koenig, B. R. Das, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Targeted Gynaecologic Oncology (TARGON), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Pathology, and CCA - Oncogenesis
Subjects: Arginine, MESH : Polymorphism, Genetic, MESH: Genes, p53, MESH : Aged, Physiology, Uterine Cervical Neoplasms, MESH: Papillomavirus Infections, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Genotype, MESH : Female, Cervical cancer, Genetics, MESH: Aged, MESH : Papillomavirus Infections, 0303 health sciences, MESH: Middle Aged, HPV infection, MESH: Genetic Predisposition to Disease, Middle Aged, MESH : Adult, WILD-TYPE P53, Hardy–Weinberg principle, 3. Good health, MESH: Uterine Cervical Neoplasms, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Meta-analysis, Female, Adult, Adolescent, MESH : Uterine Cervical Neoplasms, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Genes, p53, 03 medical and health sciences, Young Adult, SQUAMOUS INTRAEPITHELIAL LESIONS, MESH : Adolescent, INDIAN WOMEN, MESH: Polymorphism, Genetic, medicine, Humans, Genetic Predisposition to Disease, MESH : Middle Aged, Allele, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, Polymorphism, Genetic, HUMAN-PAPILLOMAVIRUS TYPE-16, business.industry, P53 ARG72PRO POLYMORPHISM, HEALTHY WOMEN, Papillomavirus Infections, MESH : Humans, MESH: Adult, Odds ratio, medicine.disease, Genes, p53, GENOTYPES, HARDY-WEINBERG EQUILIBRIUM, RISK-FACTORS, MESH : Genetic Predisposition to Disease, business, MESH: Female, HPV INFECTION
Abstract: Background Cervical cancer is caused primarily by human papillomaviruses (HPV). The polymorphism rs1042522 at codon 72 of the TP53 tumour-suppressor gene has been investigated as a genetic cofactor. More than 80 studies were done between 1998 and 2006, after it was initially reported that women who are homozygous for the arginine allele had a risk for cervical cancer seven times higher than women who were heterozygous for the allele. However, results have been inconsistent. Here we analyse pooled data from 49 studies to determine whether there is an association between TP53 codon 72 polymorphism and cervical cancer.Methods Individual data on 7946 cases and 7888 controls from 49 different studies worldwide were reanalysed. Odds ratios (OR) were estimated using logistic regression, stratifying by study and ethnic origin. Subgroup analyses were done for infection with HPV, ethnic origin, Hardy-Weinberg equilibrium, study quality, and the material used to determine TP53 genotype.Findings The pooled estimates (OR) for invasive cervical cancer were 1.22 (95% CI 1.08-1-39) for arginine homozygotes compared with heterozygotes, and 1.13 (0.94-1.35) for arginine homozygotes versus proline homozygotes. Subgroup analyses showed significant excess risks only in studies where controls were not in Hardy-Weinberg equilibrium (1.71 [1.21-2.42] for arginine homozygotes compared with heterozygotes), in non-epidemiological studies (1.35 [1.15-1.58] for arginine homozygotes compared with heterozygotes), and in studies where TP53 genotype was determined from tumour tissue (1.39 [1.13-1.73] for arginine homozygotes compared with heterozygotes). Null results were noted in studies with sound epidemiological design and conduct (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes), and studies in which TP53 genotype was determined from white blood cells (1.06 [0.87-1.29] for arginine homozygotes compared with heterozygotes).Interpretation Subgroup analyses indicated that excess risks were most likely not due to clinical or biological factors, but to errors in study methods. No association was found between cervical cancer and TP53 codon 72 polymorphism when the analysis was restricted to methodologically sound studies.Funding German Research Foundation (DFG).
Published: 2009

16. Multiple tumours in survival estimates

Author: Stefano Guzzinati, Florence Molinié, Rafael Marcos-Gragera, Eva Ardanaz, Tiziana Cassetti, Angel Izquierdo Font, Milena Sant, Stanislaw Gozdz, Rafael Peris-Bonet, Pascale Grosclaude, Emmanuel Desandes, Michel Coleman, Laura Ciccolallo, Lucia Mangone, Freddie Bray, Hermann Brenner, Giovanna Tagliabue, Mariano Santaquilani, Enrico Grande, Maria Zwierko, Jan Willem Coebergh, Emanuele Crocetti, Giulia Zigon, Roberta De Angelis, Stefano Ferretti, Andrea Tavilla, Gemma Gatta, Silvia Francisci, Paolo Contiero, Rosario Tumino, Laufey Tryggvadottir, Franco Berrino, Hans Storm, Paolo Baili, David Brewster, National Centre for Epidemiology, Surveillance and Health Promotion, Istituto Superiore di Sanita [Rome], Evaluative Epidemiology Unit, Fondazione IRCCS, Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Neurology, and Public Health
Subjects: Male, Oncology, Cancer Research, Survival, MESH : Age Distribution, MESH : Aged, MESH : Neoplasms, Multiple Primary, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Neoplasms, Multiple Primary, MESH: Aged, 80 and over, 0302 clinical medicine, Multiple Primary, Prostate, Neoplasms, Epidemiology, 80 and over, Cancer registries, MESH: Neoplasms, Multiple Primary, MESH : Female, 030212 general & internal medicine, Young adult, 10. No inequality, MESH : Sex Distribution, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, Relative survival, Medicine (all), MESH: Sex Distribution, Multiple tumours, Neoplasm, Adolescent, Adult, Age Distribution, Aged, Europe, Female, Humans, Middle Aged, Sex Distribution, Survival Analysis, Young Adult, Percentage point, MESH : Adult, 3. Good health, Multiple tumours - survival estimates, medicine.anatomical_structure, MESH: Young Adult, MESH: Survival Analysis, 030220 oncology & carcinogenesis, medicine.medical_specialty, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, MESH : Middle Aged, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH: Male, Surgery, Cancer registry, MESH: Europe, MESH : Survival Analysis, business, MESH: Female
Abstract: In international comparisons of cancer registry based survival it is common practice to restrict the analysis to first primary tumours and exclude multiple cancers. The probability of correctly detecting subsequent cancers depends on the registry's running time, which results in different proportions of excluded patients and may lead to biased comparisons. We evaluated the impact on the age-standardised relative survival estimates of also including multiple primary tumours. Data from 2,919,023 malignant cancers from 69 European cancer registries participating in the EUROCARE-4 collaborative study were used. A total of 183,683 multiple primary tumours were found, with an overall proportion of 6.3% over all the considered cancers, ranging from 0.4% (Naples, Italy) to 12.9% (Iceland). The proportion of multiple tumours varied greatly by type of tumour, being higher for those with high incidence and long survival (breast, prostate and colon-rectum). Five-year relative survival was lower when including patients with multiple cancers. For all cancers combined the average difference was -0.4 percentage points in women and -0.7 percentage points in men, and was greater for older registries. Inclusion of multiple tumours led to lower survival in 44 out of 45 cancer sites analysed, with the greatest differences found for larynx (-1.9%), oropharynx (-1.5%), and penis (-1.3%). Including multiple primary tumours in survival estimates for international comparison is advisable because it reduces the bias due to different observation periods, age, registration quality and completeness of registration. The general effect of inclusion is to reduce survival estimates by a variable amount depending on the proportion of multiple primaries and cancer site. (C) 2008 Elsevier Ltd. All rights reserved.
Published: 2009

17. The advantage of women in cancer survival: An analysis of EUROCARE-4 data

Author: Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health
Subjects: Oncology, Male, Pathology, Cancer Research, cancer survival - women, MESH : Age Distribution, MESH : Aged, MESH: Risk Assessment, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Residence Characteristics, Neoplasms, 80 and over, Gender differences, Sex hormones, MESH: Neoplasms, MESH : Female, MESH: Residence Characteristics, Young adult, Age of Onset, MESH : Risk Assessment, MESH : Sex Distribution, MESH: Diagnosis-Related Groups, MESH: Aged, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, Relative survival, Thyroid, MESH: Sex Distribution, Middle Aged, MESH : Adult, 3. Good health, MESH : Age of Onset, Europe, MESH : Diagnosis-Related Groups, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH : Residence Characteristics, Female, EUROCARE, Adult, medicine.medical_specialty, Adolescent, MESH: Age of Onset, MESH : Male, MESH : Sex Factors, Population, MESH : Europe, MESH : Young Adult, Rectum, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, Risk Assessment, 03 medical and health sciences, Young Adult, Age Distribution, Sex Factors, MESH: Sex Factors, SDG 3 - Good Health and Well-being, Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Sex Distribution, education, MESH : Aged, 80 and over, MESH: Age Distribution, Survival analysis, Diagnosis-Related Groups, 030304 developmental biology, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, Cancer survival, Survival Analysis, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: Europe, Age of onset, MESH : Survival Analysis, business, MESH: Female
Abstract: We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.
Published: 2009

18. Incidence and survival of gastric non-Hodgkin's lymphoma: A population-based study from the Association of the French Cancer Registries (FRANCIM)

Author: Danzon, Arlette, Belot, Aurélien, Maynadié, Marc, Remontet, Laurent, Dupont, Anne Claire Gossart, Carbonnel, Franck, Renseigné, Non, FRANCIM, Réseau des registres français du cancer, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de Biostatistique, Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Registre des hémopathies malignes de Côte d'Or, Service de biostatistique, Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Agents pathogènes et inflammation - UFC (EA 4266) ( API ), and Université de Franche-Comté ( UFC )
Subjects: Male, Multivariate analysis, MESH: Registries, MESH : Age Distribution, MESH : Aged, 0302 clinical medicine, MESH: Lymphoma, Non-Hodgkin, Risk Factors, MESH: Risk Factors, Epidemiology, MESH : Stomach Neoplasms, MESH : Neoplasm Staging, MESH : Female, Registries, MESH: Incidence, 030212 general & internal medicine, Age of Onset, MESH : Sex Distribution, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Relative survival, Incidence, Lymphoma, Non-Hodgkin, Incidence (epidemiology), MESH: Sex Distribution, Not Otherwise Specified, MESH: Stomach Neoplasms, MESH: Neoplasm Staging, Hematology, General Medicine, Middle Aged, MESH : Adult, Prognosis, MESH : Risk Factors, MESH : Incidence, MESH : Age of Onset, 3. Good health, Oncology, MESH: Young Adult, MESH: Survival Analysis, 030220 oncology & carcinogenesis, Female, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, France, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Age of Onset, MESH : Young Adult, MESH: Multivariate Analysis, MESH: Prognosis, Young Adult, 03 medical and health sciences, Age Distribution, Stomach Neoplasms, MESH : Adolescent, Internal medicine, medicine, Humans, MESH : Middle Aged, MESH : Lymphoma, Non-Hodgkin, Radiology, Nuclear Medicine and imaging, Sex Distribution, MESH : France, MESH: Age Distribution, Survival analysis, Aged, Neoplasm Staging, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH : Multivariate Analysis, Cancer, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, medicine.disease, Survival Analysis, MESH: Male, MESH: France, Multivariate Analysis, Immunology, MESH : Survival Analysis, Age of onset, business, MESH: Female, MESH : Registries
Abstract: International audience; BACKGROUND: Most epidemiological studies on gastric lymphomas (GL) were carried out before changes in therapy were introduced. The aim of the study was to measure the incidence of GL and to estimate survival. MATERIAL AND METHODS: Data were provided by the Association of the French Cancer Registries database. Age-standardized incidence rates were calculated for 786 incident cases diagnosed between 1978 and 2002. Crude and relative survival were calculated for 361 cases diagnosed between 1989 and 1997. Effects specific to sex, age at diagnosis, year of diagnosis, and grade of malignancy were estimated in multivariate analysis. RESULTS: Incidence was stable during the study period. However, high-grade GL frequency increased whereas low-grade and not otherwise specified (NOS) GL frequencies were respectively stable and decreased. At 5 years, relative survival was 63% in men and 60% in women. Patients aged 75 or older had a five-year relative survival of 33%. Age at diagnosis was the only significant prognostic factor in multivariate analysis. Time trend improvement in prognosis was observed. DISCUSSION: Results in elderly patients show that therapeutic regimens should be specifically designed and assessed for them. The prognosis improvement trend is probably related to the implementation of changes in management of patients and has to be confirmed by more recent data.
Published: 2009

19. Prognostic Factors for Leukemic Induction Failure in Children With Acute Lymphoblastic Leukemia and Outcome After Salvage Therapy: The FRALLE 93 Study

Author: Claudine Schmitt, Marie-Françoise Auclerc, Jean-Michel Cayuela, Gérard Michel, André Baruchel, Guy Leverger, Marianne Debré, Yves Perel, Brigitte Pautard, Thierry Leblanc, Gérard Socié, Raphaël Porcher, Caroline Oudot, Christophe Piguet, Virginie Gandemer, Vincent Levy, Claire Berger, Christiane Vermylen, Service de Pédiatrie médicale - Spécialités médicales [CHU Limoges], CHU Limoges, Service d'hématologie pédiatrique, Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'Investigations Cliniques 9504, Université Paris Diderot - Paris 7 (UPD7)-Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département de Biostatistique et Informatique Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Sain-Louis, Service d'onco-hématologie pédiatrique, hôpital Sud, Service de Pédiatrie Oncologie, Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Département d'hématologie pédiatrique, Université Catholique de Louvain = Catholic University of Louvain (UCL), CHU Amiens-Picardie, Service d'Hématologie et Oncologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Unité d'hématologie et de transplantation, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université Paris Diderot - Paris 7 ( UPD7 ) -CHU Saint Louis [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Sain-Louis, Hôpital Sud, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Université Catholique de Louvain ( UCL ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Service d'hématologie-immunologie-oncologie pédiatrique, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], and De Villemeur, Hervé
Subjects: Male, [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Oncology, MESH: Remission Induction, Cancer Research, MESH : Antineoplastic Combined Chemotherapy Protocols, MESH: Treatment Failure, Lymphoblastic Leukemia, MESH : Prospective Studies, Salvage therapy, MESH : Analysis of Variance, MESH: Logistic Models, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH : Child, Risk Factors, MESH: Risk Factors, MESH: Child, Antineoplastic Combined Chemotherapy Protocols, MESH : Precursor Cell Lymphoblastic Leukemia-Lymphoma, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, MESH : Female, Prospective Studies, Treatment Failure, Child, Prospective cohort study, 0303 health sciences, MESH : Prognosis, Remission Induction, MESH : Infant, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Adult, Prognosis, MESH : Risk Factors, MESH: Infant, MESH: Salvage Therapy, 3. Good health, MESH: Antineoplastic Combined Chemotherapy Protocols, Child, Preschool, 030220 oncology & carcinogenesis, Female, France, Adult, medicine.medical_specialty, Adolescent, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Risk category, 03 medical and health sciences, MESH : Treatment Failure, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH : Adolescent, MESH: Analysis of Variance, Internal medicine, Acute lymphocytic leukemia, medicine, Humans, MESH : France, 030304 developmental biology, Salvage Therapy, MESH: Adolescent, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Analysis of Variance, MESH : Remission Induction, MESH: Humans, business.industry, MESH : Humans, MESH: Child, Preschool, Infant, Cancer, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, MESH: France, Clinical trial, Logistic Models, Multicenter study, MESH : Salvage Therapy, business, MESH: Female, MESH : Logistic Models
Abstract: Purpose To identify prognostic factors and to evaluate the outcome of children with acute lymphoblastic leukemia (ALL) failure after induction therapy. Patients and Methods Between June 1993 and December 1999, 1,395 leukemic children were included in the French Acute Lymphoblastic Leukemia 93 study. Results Fifty-three patients (3.8%) had a leukemic induction failure (LIF) after three- or four-drug induction therapy. In univariate analysis, high WBC count (P = .001), mediastinal mass (P = .017), T-cell phenotype (T-ALL; P = .001), t(9;22) translocation (P = .001), and a slow early response (at day 8 and/or on day 21, P = .001) were predictive of LIF. The following three prognostic groups for LIF were identified by multivariate analysis: a low-risk group with B-cell progenitor (BCP) ALL without t(9;22) (odds ratio [OR] = 1), an intermediate-risk group with T-ALL and a mediastinal mass (OR = 7.4, P < .0001), and a high-risk group with BCP-ALL and t(9;22) or T-ALL without a mediastinal mass (OR = 28.4, P < .0001). Complete remission (CR) was subsequently obtained in 43 patients (81%). The 5-year overall survival (OS) rate of the 53 patients was 30% ± 6%. The 5-year OS rate among allogeneic graft recipients, autologous graft recipients, and after chemotherapy were 30.4% ± 9.6% (50% ± 26% after genoidentical transplantation), 50% ± 17.7%, and 41.7% ± 14.2%, respectively (P = .18). Fourteen patients (26%) were still in first CR after a median of 83 months (range, 53 to 117 months). Conclusion Three risk categories for LIF in children with ALL were identified. Approximately one third of patients with LIF can be successfully treated with salvage therapy overall. Subsequent CR after LIF is mandatory for cure.
Published: 2008

20. Comparison of AMPLICOR® and Hybrid Capture II® assays for high risk HPV detection in normal and abnormal liquid-based cytology: Use of INNO-LiPA Genotyping assay to screen the discordant results

Author: A. Petitjean, L. Z. Mo, Jean-Luc Prétet, Bernadette Kantelip, Christiane Mougin, Sylvain Monnier-Benoit, Didier Riethmuller, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Inno lipa, MESH: Reagent Kits, Diagnostic, Bethesda system, MESH : Aged, Uterine Cervical Neoplasms, MESH : Genotype, Cervix Uteri, MESH : Cervical Intraepithelial Neoplasia, MESH: Papillomavirus Infections, Polymerase Chain Reaction, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Nucleic Acid Hybridization, MESH: Genotype, 0302 clinical medicine, MESH: Papillomaviridae, Cytology, MESH : Female, MESH : Reagent Kits, Diagnostic, Papillomaviridae, MESH : Polymerase Chain Reaction, MESH : Papillomavirus Infections, MESH: Aged, 0303 health sciences, MESH: Middle Aged, medicine.diagnostic_test, Hybrid capture, Nucleic Acid Hybridization, virus diseases, MESH: Cervix Uteri, Middle Aged, MESH : Adult, MESH : Nucleic Acid Hybridization, female genital diseases and pregnancy complications, 3. Good health, MESH: Uterine Cervical Neoplasms, Infectious Diseases, 030220 oncology & carcinogenesis, Liquid-based cytology, MESH : Vaginal Smears, Female, MESH : Sensitivity and Specificity, Nucleic Acid Amplification Techniques, Adult, Adolescent, Genotype, MESH: Vaginal Smears, MESH : Uterine Cervical Neoplasms, [SDV.CAN]Life Sciences [q-bio]/Cancer, Biology, Sensitivity and Specificity, MESH: Nucleic Acid Amplification Techniques, 03 medical and health sciences, MESH : Adolescent, Virology, medicine, Humans, MESH : Middle Aged, Human papillomavirus, MESH : Papillomaviridae, Genotyping, Aged, 030304 developmental biology, Vaginal Smears, MESH: Adolescent, MESH: Humans, Papillomavirus Infections, MESH : Humans, MESH: Adult, MESH: Polymerase Chain Reaction, MESH : Nucleic Acid Amplification Techniques, Uterine Cervical Dysplasia, MESH: Sensitivity and Specificity, High risk hpv, MESH : Cervix Uteri, Reagent Kits, Diagnostic, MESH: Cervical Intraepithelial Neoplasia, MESH: Female
Abstract: International audience; The study was aimed to evaluate the feasibility of detecting human papillomavirus (HPV) in women with normal or abnormal cervical smears using the Roche Amplicor MWP HPV Test. We compared by AMPLICOR Test and Hybrid Capture II (HCII) Test, the prevalence of HR-HPV in 470 cervical samples including 55 samples with WNL cytology, 208 ASC-US, 193 LGSIL and 14 HGSIL. Samples with discordant results were retested with INNO-LiPA Genotyping HPV Test v2. The HR-HPV positivity in WNL cytology samples was similar (21.8%) by AMPLICOR and HCII. In ASC-US, the HPV positivity was 42.3% by both tests. In LGSIL, HPV positivity was 66.3% and 66.8% by AMPLICOR and HCII, respectively. In HGSIL, 92.8% of samples were positive by AMPLICOR and 85.7% by HCII. The agreement of both tests was 96.2% with a Kappa value of 0.92. Eighteen cases were discordant: 9 HCII positive/AMPLICOR negative and 9 HCII negative/AMPLICOR positive. The INNO-LiPA test revealed HPV positivity in every case. Interestingly, all HCII+/AMPLICOR- samples were found to harbour HPV53. As for the HCII-/AMPLICOR+ samples, 8 demonstrated a multiple infection with HR 16- and/or 18- and/or 56-phylogenetically related HPV types. Moreover, two of these samples were co-infected with HPV6 and two other with HPV54. By using consensus HR-HPV as our reference HPV positivity, the sensitivity (96.6%) and specificity (100%) of AMPLICOR was similar to that of HCII Test. The AMPLICOR HPV Test is sensitive, specific, feasible and appropriate for routine HPV detection.
Published: 2008

21. Accuracy of Ultrasonography in Diagnosis of Testicular Rupture After Blunt Scrotal Trauma

Author: Damien Cellarier, Carlos Del Coro, Hugues Bittard, François Kleinclauss, G. Guichard, Eric Chabannes, Jamal El Ammari, Stéphane Bernardini, Pierre Yves Loock, Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Departement of Surgery, Hospital Auxilio Mutuo, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Saas, Philippe, Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC)
Subjects: Male, MESH: Orchiectomy, MESH: Rupture, MESH : Retrospective Studies, MESH : Hematocele, MESH : Aged, 030232 urology & nephrology, Hematocele, Wounds, Nonpenetrating, 030218 nuclear medicine & medical imaging, Avulsion, MESH: Aged, 80 and over, 0302 clinical medicine, Testis, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Wounds, Nonpenetrating, MESH : Orchiectomy, Ultrasonography, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Testis, Ultrasound, Testicular rupture, Middle Aged, MESH : Adult, MESH: Wounds, Nonpenetrating, Testicular trauma, 3. Good health, medicine.anatomical_structure, Scrotum, [SDV.IMM]Life Sciences [q-bio]/Immunology, MESH : Sensitivity and Specificity, medicine.symptom, Adult, endocrine system, medicine.medical_specialty, [SDV.IMM] Life Sciences [q-bio]/Immunology, Adolescent, MESH : Male, Urology, MESH : Scrotum, Sensitivity and Specificity, MESH : Rupture, Lesion, MESH: Hematocele, 03 medical and health sciences, Tunica albuginea (ovaries), MESH : Adolescent, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Retrospective Studies, Rupture, MESH : Testis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Scrotum, MESH: Sensitivity and Specificity, MESH: Male, Surgery, business, Orchiectomy
Abstract: International audience; OBJECTIVES: The aim of this study is to determine the accuracy of ultrasonography for the diagnosis of testis rupture after scrotal trauma and its sensitivity and specificity for testis rupture, tunica albuginea breach, testicular hematoma, testis avulsion, epididymis injuries, and hematocele. METHODS: Between 1996 and 2006, 33 patients underwent surgical exploration for blunt scrotal trauma. All these patients had an emergency scrotal ultrasonography with the use of a 7.5 or 10 MHz linear transducer. Ultrasonographic findings were compared with surgical findings to calculate sensitivity and specificity of ultrasonography for each type of lesion. RESULTS: Of 33 patients, 16 presented a testis rupture. Testis rupture was in all cases suspected ultrasonographically by the loss of contour of the testis and heterogeneous parenchyma. Tunica albuginea breach was visualized in only 8 patients. Sensitivity and specificity of ultrasound for testis rupture were 100% and 65%, respectively. Moreover, ultrasonography allowed diagnosis of hematocele (sensitivity: 87% and specificity: 89%), testicular hematoma (sensitivity: 71%, specificity: 77%), and testis avulsion (sensitivity: 100%, specificity: 97%). Ultrasonography results for epididymis injuries were poor. On 7 patients, 3 epididymis lesions were misdiagnosed by ultrasound examination. CONCLUSIONS: Ultrasonography can distinguish various scrotal injuries. Testicular rupture is probably the most severe injury that needs early surgical treatment to improve testis salvage rate. In our work, ultrasonography is highly sensitive in the diagnosis of testis rupture and can provide information on the scrotal contents integrity that can help the physician to determine the optimal treatment.
Published: 2008

22. Selective predisposition to bacterial infections in IRAK-4–deficient children: IRAK-4–dependent TLRs are otherwise redundant in protective immunity

Author: Sami Al-Hajjar, Carlos Rodríguez-Gallego, John I. Gallin, Toshiro Hara, Maya Chrabieh, Andrew C. Issekutz, Huey Hsuan Chang, Horst von Bernuth, Joanne Smart, Helen Chapel, Eric Vivier, László Maródi, David P. Speert, Mimi L.K. Tang, Jean-Laurent Casanova, Capucine Picard, Xiaoxia Li, Steven M. Holland, Shen-Ying Zhang, Franck J. Barrat, Stephan Ehl, Abdulaziz Al-Ghonaium, Ben Zion Garty, Chaim M. Roifman, Xavier Bossuyt, Douglas R. McDonald, Anne Puel, Hidetoshi Takada, Ofer Levy, Damien Sanlaville, Laurent Abel, Frederic Geissmann, Richard L. Miller, Cheng-Lung Ku, Kun Yang, Noorbibi K. Day-Good, Coleen K. Cunningham, Génétique Humaine des Maladies Infectieuses (Inserm U980), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Interactions cellulaires neuroendocriniennes (ICN), Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique (CNRS), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de Chirurgie, Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION ), Génétique Humaine des Maladies Infectieuses ( Inserm U980 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), Interactions cellulaires neuroendocriniennes ( ICN ), Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique ( CNRS ), Centre d'Immunologie de Marseille - Luminy ( CIML ), Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance Publique - Hôpitaux de Marseille (APHM)-Hospices Civiles de Marseille-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), and University of Groningen
Subjects: Male, Myeloid, Lipopolysaccharide, MESH : Cytokines, medicine.medical_treatment, MESH : Leukocytes, MESH : Child, Preschool, chemistry.chemical_compound, 0302 clinical medicine, MESH : Child, MESH: Child, Leukocytes, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, Immunology and Allergy, Myeloid Cells, MESH : Female, Child, Cells, Cultured, MESH: Cytokines, 0303 health sciences, Toll-like receptor, MESH : Gene Expression Regulation, Interleukin, Cell Differentiation, PNEUMOCOCCAL MENINGITIS, MESH : Infant, Bacterial Infections, Articles, MYELOID DIFFERENTIATION FACTOR-88, MESH : Adult, MESH: Infant, MESH: Gene Expression Regulation, C-REACTIVE PROTEIN, Pedigree, 3. Good health, MESH : Bacterial Infections, Interleukin-1 Receptor-Associated Kinases, medicine.anatomical_structure, Cytokine, Child, Preschool, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH : Mutation, MESH : Cell Differentiation, IRAK4 KINASE-ACTIVITY, MESH: Toll-Like Receptors, MESH: Cells, Cultured, Adult, MESH: Cell Differentiation, MESH: Mutation, Adolescent, MESH : Myeloid Cells, MESH: Pedigree, MESH: Bacterial Infections, MESH : Male, Immunology, Biology, Article, MESH: Interleukin-1 Receptor-Associated Kinases, MESH: Leukocytes, IL-1 RECEPTOR, 03 medical and health sciences, Immunity, MESH : Adolescent, MESH : Cells, Cultured, medicine, Humans, 030304 developmental biology, TOLL-LIKE RECEPTORS, MESH: Adolescent, CUTTING EDGE, MESH: Humans, Innate immune system, MESH : Humans, MESH: Child, Preschool, HERPES-SIMPLEX-VIRUS, Infant, MESH: Adult, medicine.disease, MESH: Myeloid Cells, MESH: Male, Gene Expression Regulation, chemistry, MESH : Pedigree, MESH : Toll-Like Receptors, Mutation, PLASMACYTOID DENDRITIC CELLS, INNATE IMMUNITY, Primary immunodeficiency, MESH : Interleukin-1 Receptor-Associated Kinases, MESH: Female, 030215 immunology
Abstract: Human interleukin ( IL) 1 receptor - associated kinase 4 ( IRAK- 4) deficiency is a recently discovered primary immunodefi ciency that impairs Toll/ IL- 1R immunity, except for the Toll- like receptor ( TLR) 3 - and TLR4 - interferon ( IFN)-alpha/beta pathways. The clinical and immunological phenotype remains largely unknown. We diagnosed up to 28 patients with IRAK- 4 deficiency, tested blood TLR responses for individual leukocyte subsets, and TLR responses for multiple cytokines. The patients' peripheral blood mononuclear cells ( PBMCs) did not induce the 11 non- IFN cytokines tested upon activation with TLR agonists other than the nonspecific TLR3 agonist poly( I: C). The patients' individual cell subsets from both myeloid ( granulocytes, monocytes, monocyte- derived dendritic cells [ MDDCs], myeloid DCs [ MDCs], and plasmacytoid DCs) and lymphoid ( B, T, and NK cells) lineages did not respond to the TLR agonists that stimulated control cells, with the exception of residual responses to poly( I: C) and lipopolysaccharide in MDCs and MDDCs. Most patients ( 22 out of 28; 79%) suffered from invasive pneumococcal disease, which was often recurrent ( 13 out of 22; 59%). Other infections were rare, with the exception of severe staphylococcal disease ( 9 out of 28; 32%). Almost half of the patients died ( 12 out of 28; 43%). No death and no invasive infection occurred in patients older than 8 and 14 yr, respectively. The IRAK- 4 - dependent TLRs and IL- 1Rs are therefore vital for childhood immunity to pyogenic bacteria, particularly Streptococcus pneumoniae. Conversely, IRAK- 4 - dependent human TLRs appear to play a redundant role in protective immunity to most infections, at most limited to childhood immunity to some pyogenic bacteria.
Published: 2007

23. Characteristics of patients and physicians correlated with regular influenza vaccination in patients treated for type 2 diabetes: a follow-up study from 2008 to 2011 in southeastern France

Author: Céline Pulcini, Pierre Verger, Ludovic Casanova, Sébastien Cortaredona, Patrick Peretti-Watel, Odile Launay, Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale ( SESSTIM ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -ORS PACA-Institut National de la Santé et de la Recherche Médicale ( INSERM ), ORS PACA, REseau national d'Investigation clinique en VACcinologie ( REIVAC ), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Service des Maladies Infectieuses et Tropicales [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), CIC Cochin Pasteur ( CIC 1417 ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 ( UPD5 ) -Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Sciences Economiques et Sociales de la Santé & Traitement de l'Information Médicale (SESSTIM - U912 INSERM - Aix Marseille Univ - IRD), Institut de Recherche pour le Développement (IRD)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Aix Marseille Université (AMU), REseau national d'Investigation clinique en VACcinologie (REIVAC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de Gestion des Essais de Produits de Santé (CeNGEPS), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), CIC Cochin Pasteur (CIC 1417), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Cochin [AP-HP]-Hôtel-Dieu-Université Paris Descartes - Paris 5 (UPD5)-Groupe hospitalier Broca-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre National de Gestion des Essais de Produits de Santé (CeNGEPS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Hôtel-Dieu-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupe hospitalier Broca-Université Paris Descartes - Paris 5 (UPD5)-Hôtel-Dieu-Hôpital Cochin [AP-HP]
Subjects: Male, Pediatrics, MESH : Aged, Type 2 diabetes, Care management, Logistic regression, MESH: Influenza Vaccines, MESH: Aged, 80 and over, MESH : Diabetes Mellitus, Type 2, Epidemiology, MESH : Socioeconomic Factors, MESH: Physicians, MESH : Female, MESH : Influenza, Human, Reimbursement, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Influenza, Human, Age Factors, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, 3. Good health, Vaccination, Infectious Diseases, Influenza Vaccines, MESH: Young Adult, Cohort, Female, epidemiology, multilevel analysis, France, patient, MESH: Diabetes Mellitus, Type 2, Adult, Microbiology (medical), medicine.medical_specialty, MESH: Socioeconomic Factors, diabetes mellitus type 2, Adolescent, Influenza vaccine, MESH : Male, MESH : Physicians, MESH : Young Adult, determinant, Young Adult, Physicians, Diabetes mellitus, MESH : Adolescent, Influenza, Human, medicine, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, MESH : France, Aged, MESH: Adolescent, MESH: Age Factors, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, MESH: Vaccination, medicine.disease, vaccination, MESH: Male, MESH : Influenza Vaccines, MESH: France, Diabetes Mellitus, Type 2, Socioeconomic Factors, MESH : Vaccination, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, influenza vaccine, business, MESH: Female, Follow-Up Studies
Abstract: International audience; We studied a cohort of 110 823 patients treated with oral hypoglycaemic agents for type 2 diabetes in southeastern France from 1 January 2008 to 31 December 2011, to identify influenza vaccination coverage trends and the patient and physician correlates of influenza vaccine (IFV) uptake. We used French national health insurance fund (NHIF) databases to identify these patients and collect data on their IFV reimbursement claims (IFVC) and patient and physician characteristics. We used multilevel multivariate polytomous logistic regressions to test the correlates of IFVC. Between 2008 and 2011 the annual IFVC rate varied from 33.7% to 32.3% in the 18-64 age group and from 69.5% to 61.1% in the 65 + age group, among whom we saw a clear trend towards reduced vaccination after 2008. In the younger group, the probability of regular vaccination each year from 2008 to 2011 increased with diabetes severity and duration, comorbidities, and the number of general practitioner and nurse visits; it was higher among patients seeing endocrinologists and lower among low-income patients than in other patients. In the older group, there was no association with either diabetes severity or physician specialty. These results suggest different patterns of correlates of influenza vaccination according to age. Endocrinologists might help to improve IFV uptake in the younger group of patients with type 2 diabetes. Communication strategies regarding influenza vaccination should be adapted to age, and collaboration between healthcare professionals should be reinforced to achieve vaccination objectives for these patients.
Published: 2015

24. Simultaneous alveolar and cystic echinococcosis of the liver

Author: Dominique A. Vuitton, Yu Rong Yang, Donald P. McManus, Yunhai Wang, Brigitte Bartholomot, Philip S. Craig, Xong Zhou Liu, Akira Ito, Ningxia Medical College, WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, SERF Unit, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Xinjiang Medical University, Chinese Government, Department of Parasitology, Asahikawa Medical College, Biomedical Sciences Research Institute, University of Salford, Molecular Parasitology Laboratory, University of Queensland [Brisbane], Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, Pathology, MESH : Aged, Alveolar echinococcosis, MESH : Echinococcus multilocularis, MESH: Echinococcus granulosus, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 030308 mycology & parasitology, 0302 clinical medicine, MESH : Female, Echinococcus granulosus, Ultrasonography, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, MESH: Echinococcosis, Hepatic, General Medicine, Middle Aged, MESH : Adult, Echinococcosis, MESH: China, 3. Good health, Infectious Diseases, Female, Adult, China, Echinococcosis, Hepatic, medicine.medical_specialty, Adolescent, MESH : Male, 030231 tropical medicine, Cestoda, Helminthiasis, [SDV.CAN]Life Sciences [q-bio]/Cancer, Echinococcus multilocularis, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : China, MESH : Middle Aged, Aged, MESH: Adolescent, MESH: Echinococcus multilocularis, MESH: Humans, MESH : Echinococcus granulosus, business.industry, Cystic echinococcosis, MESH : Humans, Public Health, Environmental and Occupational Health, MESH: Adult, biology.organism_classification, medicine.disease, MESH: Male, Tropical medicine, Parasitology, MESH : Echinococcosis, Hepatic, business, MESH: Female
Abstract: International audience; Alveolar echinococcosis (AE) and cystic echinococcosis (CE), caused by infection with the larval stages of Echinococcus multilocularis and E. granulosus, respectively, are of major clinical importance. Reports of infection with AE or CE are very common, but instances of simultaneous or dual infection are rare. We report on four cases with mixed AE/CE infections in the liver, diagnosed using retrospective surgical records and active community surveys in southern Ningxia Hui Autonomous Region (NHAR), PR China, a recognized hyperendemic area for echinococcosis.
Published: 2006

25. Expression colique de l’interféron-γ et de l’interleukine-10 au cours de la maladie de Crohn et de la rectocolite ulcéro-hémorragique

Author: A. Sassi, Lamia Kallel, M. Ben Ahmed, Samir Boubaker, Hechmi Louzir, Béchir Zouari, Azza Filali, Jalel Boubaker, Service de gastroentérologie A, Hôpital de La Rabta Tunis, Laboratoire de Transmission, Contrôle et Immunobiologie des Infections ( LR11IPT02 ), Institut Pasteur de Tunis-Réseau International des Instituts Pasteur ( RIIP ), Institut Pasteur de Tunis, Département de médecine préventive et de statistiques, Faculté de Médecine de Tunis, Hôpital La Rabta [Tunis], Laboratoire de Transmission, Contrôle et Immunobiologie des Infections - Laboratory of Transmission, Control and Immunobiology of Infection (LR11IPT02), Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), and Réseau International des Instituts Pasteur (RIIP)
Subjects: MESH: Interleukin-10, MESH : RNA, Messenger, [SDV]Life Sciences [q-bio], MESH: Down-Regulation, MESH : Down-Regulation, MESH: Biopsy, 0302 clinical medicine, MESH : Child, MESH: Reverse Transcriptase Polymerase Chain Reaction, MESH: Child, Gamma interferon, Medicine, MESH : Female, MESH : Colonoscopy, 0303 health sciences, MESH: Middle Aged, MESH : Immunity, Mucosal, MESH : RNA, Ribosomal, MESH : Reverse Transcriptase Polymerase Chain Reaction, General Medicine, MESH : Adult, MESH : Colitis, Ulcerative, MESH: Case-Control Studies, MESH: Colonoscopy, MESH: Intestinal Mucosa, MESH : Severity of Illness Index, [ SDV.MHEP.HEG ] Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, 030211 gastroenterology & hepatology, MESH : Case-Control Studies, MESH: Gene Expression, MESH: Interferon-gamma, MESH : Male, MESH: Colitis, Ulcerative, MESH : Crohn Disease, MESH : Intestinal Mucosa, MESH: Gene Expression Profiling, 03 medical and health sciences, MESH: Severity of Illness Index, MESH : Adolescent, MESH : Interleukin-10, MESH : Middle Aged, MESH: Colon, MESH : Interferon-gamma, MESH: RNA, Messenger, 030304 developmental biology, MESH: Adolescent, MESH: Humans, MESH: Crohn Disease, [ SDV ] Life Sciences [q-bio], Crohn disease, business.industry, MESH: Transcription, Genetic, MESH : Gene Expression Profiling, MESH : Humans, MESH : Transcription, Genetic, MESH: Adult, [SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and Gastroenterology, MESH : Colon, Molecular biology, MESH: Male, MESH : Gene Expression, MESH: Immunity, Mucosal, MESH : Biopsy, MESH: RNA, Ribosomal, business, MESH: Female
Abstract: Resume Objectif Le but de ce travail etait d’explorer l’expression colique de l’INF-γ et de l’IL-10 chez des patients atteints de maladie de Crohn (MC) ou de rectocolite ulcero-hemorragique (RCH). Methodes Quatorze patients atteints de MC et 11 atteints de RCH ont ete inclus, ainsi que 7 sujets temoins. L’etude de l’expression colique de l’INF-γ et de l’IL-10 a ete realisee sur des biopsies de colon sain et malade, en utilisant la technique de transcription inverse et d’amplification genique (RT-PCR) en temps reel (Taqman). Les resultats ont ete exprimes sous forme de rapport entre la quantite d’ARN messager (ARNm) de la cytokine et celle d’une molecule de reference, l’ARN ribosomal 18S, puis multiplie par 10 8 . Resultats En cas de maladie de Crohn, le colon exprimait plus d’INF-γ et d’IL-10 par rapport aux temoins (medianes respectives : 23,03 vs 1,87, p = 0,042 et 20,61 vs 2,13, p = 0,08). Une puissante correlation positive a ete trouvee entre l’expression colique de l’IL-10 et celle de l’INF-γ au cours de la MC (r = 0,9, p Au niveau des sites lesionnels de RCH, l’expression de l’INF-γ ainsi que celle de l’IL-10 etaient comparables a celles observees chez les temoins (7,18 vs 2,18, p = 0,36 et 3,66 vs 1,87, p = 0,44). Conclusion Au cours de la maladie de Crohn, l’expression de l’IL-10 et celle de l’INF-γ etaient plus elevees que chez les temoins et etroitement correlees.
Published: 2005

26. Combined ultrasound and serologic screening for hepatic alveolar echinococcosis in central China

Author: Yunhai Wang, Philip S. Craig, Patrick Giraudoux, Gitte Bartholomot, Calum N. L. Macpherson, Da Zhong Shi, S Harraga, Guy Barnish, Dominique A. Vuitton, WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, SERF Unit, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Xinjiang Medical University, Chinese Government, Biomedical Sciences Research Institute, University of Salford, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement ( LCE ), and Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC )
Subjects: Male, Pathology, MESH : Aged, MESH: Echinococcus, Serology, 0302 clinical medicine, MESH : Child, Seroepidemiologic Studies, MESH: Child, Surveys and Questionnaires, MESH : Seroepidemiologic Studies, MESH : Echinococcus, MESH : Female, MESH: Animals, Child, Ultrasonography, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, Ultrasound, MESH: Echinococcosis, Hepatic, MESH : Questionnaires, MESH: Enzyme-Linked Immunosorbent Assay, MESH : Adult, Middle Aged, MESH : Enzyme-Linked Immunosorbent Assay, Echinococcosis, MESH: China, 3. Good health, Infectious Diseases, Female, medicine.symptom, Adult, [ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, China, Echinococcosis, Hepatic, medicine.medical_specialty, Adolescent, MESH : Male, 030231 tropical medicine, Antibodies, Helminth, Helminthiasis, Enzyme-Linked Immunosorbent Assay, Echinococcus multilocularis, Malignancy, Lesion, 03 medical and health sciences, MESH: Antibodies, Helminth, MESH : Adolescent, Virology, medicine, MESH : China, Animals, Humans, MESH : Middle Aged, [SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology, MESH : Antibodies, Helminth, Aged, MESH: Adolescent, MESH: Humans, MESH: Seroepidemiologic Studies, 030306 microbiology, business.industry, MESH: Questionnaires, MESH : Humans, MESH: Adult, biology.organism_classification, medicine.disease, MESH: Male, Echinococcus, Parasitology, MESH : Animals, MESH : Echinococcosis, Hepatic, business, MESH: Female
Abstract: International audience; Alveolar echinococcosis (AE), caused by Echinococcus multilocularis, is a zoonotic helminthic disease that can mimic malignancy. In the 1970s, foci of the disease were found in central China. The aim of the present study was to estimate the prevalence of AE in humans in 2 districts of south Gansu Province, China, by use of ultrasound and Echinococcus serology. After answering an epidemiological questionnaire, 2,482 volunteers from 28 villages underwent ultrasound. Serology via enzyme-linked immunosorbent assay for antibody activity was performed on whole blood collected on filter paper in all subjects; on serum from subjects with an abnormal ultrasound image; and on randomly chosen subjects that either had no lesions or had atypical lesions. At least one (25.3%) abnormal ultrasound image was observed in 630 of the subjects screened. A typical lesion of progressive AE was found in 84 subjects (3.4%). Serologies were positive in 77 (96%) of 80 of patients who had lesions typical of progressive AE. Ultrasound is useful for screening for AE in endemic regions.
Published: 2002

27. The effect on treatment response of fibromyalgic symptoms in early rheumatoid arthritis patients: results from the ESPOIR cohort

Author: Jingbo Niu, Nathalie Rincheval, Bernard Combe, Josefina Durán, David T. Felson, Cécile Gaujoux-Viala, Clinical Epidemiology Research and Training Unit ( BOSTON - Clin Epid Research ), Boston University School, Rheumatology Department ( Rheum Dep - SANTIAGO ), Pontificia Universidad Catolica del Chile, Département de Rhumatologie[Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Department of rheumatology, University of Nimes, Arthritis Research UK Epidemiology Unit ( MANCHESTER - Arthritis Research ), University of Manchester [Manchester], Centre d'Investigation Clinique INSERM 1412 ( CIC 1412 - BREST ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato ), Lymphocyte B et Auto-immunité ( LBAI ), Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Clinical Epidemiology Research and Training Unit (BOSTON - Clin Epid Research), Boston University School of Medicine (BUSM), Boston University [Boston] (BU)-Boston University [Boston] (BU), Rheumatology Department (Rheum Dep - SANTIAGO), Pontificia Universidad Católica de Chile (UC), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Lapeyronie, Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Aide à la Décision pour une Médecine Personnalisé - Laboratoire de Biostatistique, Epidémiologie et Recherche Clinique - EA 2415 (AIDMP), Université Montpellier 1 (UM1)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Arthritis Research UK Epidemiology Unit (MANCHESTER - Arthritis Research), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Lymphocyte B et Auto-immunité (LBAI), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Boston University [Boston] (BU), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO), CIC Brest, Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital de la Cavale Blanche, and Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)
Subjects: Male, rheumatoid arthritis, MESH: Remission Induction, MESH: Antirheumatic Agents, MESH : Fibromyalgia, [SDV]Life Sciences [q-bio], early rheumatoid arthritis, MESH : Aged, Arthritis, Severity of Illness Index, DMARDs, Arthritis, Rheumatoid, Cohort Studies, fibromyalgic RA, 0302 clinical medicine, Fibromyalgia, MESH : Female, Pharmacology (medical), 030212 general & internal medicine, Prospective cohort study, skin and connective tissue diseases, MESH: Cohort Studies, ComputingMilieux_MISCELLANEOUS, MESH: Treatment Outcome, MESH: Aged, MESH: Arthritis, Rheumatoid, MESH: Middle Aged, Remission Induction, MESH: Follow-Up Studies, Middle Aged, Clinical Science, MESH : Adult, Corrigenda, MESH : Antirheumatic Agents, Treatment Outcome, [SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, MESH: Young Adult, Antirheumatic Agents, Rheumatoid arthritis, Cohort, Female, fibromyalgia, MESH : Severity of Illness Index, Adult, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Young Adult, MESH : Cohort Studies, MESH : Treatment Outcome, [ SDV.MHEP.RSOA ] Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system, Young Adult, outcome measures, 03 medical and health sciences, Rheumatology, Internal medicine, MESH: Severity of Illness Index, disease activity scores, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, medicine, Humans, MESH : Middle Aged, Aged, MESH: Adolescent, 030203 arthritis & rheumatology, therapy, MESH : Remission Induction, MESH: Fibromyalgia, MESH: Humans, DASS, [ SDV ] Life Sciences [q-bio], Surrogate endpoint, business.industry, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, medicine.disease, Crohn's Disease Activity Index, MESH: Male, MESH : Arthritis, Rheumatoid, Physical therapy, business, treat to target, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract: International audience; OBJECTIVE:To evaluate whether patients with RA who belong to the spectrum of fibromyalgic RA (FRA) have an impaired response to treatment measured by traditional activity scores.METHODS:Patients from the ESPOIR cohort were analysed. This prospective cohort included 813 patients with early arthritis not initially receiving DMARDs. Among the 697 patients who met RA classification criteria, we studied two groups, one with and the other without FRA. The following endpoints were compared at 6, 12 and 18 months using a mixed linear regression model: 28-joint DAS (DAS28), Simple Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI) and HAQ. In addition, attainment of low disease activity (LDA; DAS28
Published: 2017

28. Posttraumatic mucormycosis: a nationwide study in France and review of the literature

Author: Emmanuel GYAN, Norbert IFRAH, Stéphane Bretagne, Frédéric GRENOUILLET, Marcio Junior, Sophie Cassaing, Jean-Francois Viel, Bruno MARCHOU, Raoul Herbrecht, Daniel Ajzenberg, Catherine Quantin, Cedric Arvieux, Mikael Hivelin, Stéphane Ranque, Boualem Sendid, Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP], Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service de Chirurgie plastique, reconstructrice et esthétique [Pompidou], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Service de parasitologie et de mycologie médicales [Amiens], Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Matrice extracellulaire et dynamique cellulaire - UMR 7369 (MEDyC), SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Universitaire de Reims (CHU Reims), Pathogénie des infections systémiques (UMR_S 570), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Université Paris Descartes - Paris 5 (UPD5), Laboratoire de parasitologie et de mycologie médicales [CHU Amiens], CHU Amiens-Picardie, Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP), Université de Reims Champagne-Ardenne (URCA)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire ( CNRMA ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ) -Université Paris Descartes - Paris 5 ( UPD5 ), Université de Picardie Jules Verne ( UPJV ) -CHU Amiens-Picardie, Matrice extracellulaire et dynamique cellulaire - UMR 7369 ( MEDyC ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Reims Champagne-Ardenne ( URCA ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ), Centre Hospitalier Universitaire de Reims ( CHU Reims ), Pathogénie des infections systémiques ( UMR_S 570 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS )
Subjects: MESH : Aged, Poison control, MESH: Aged, 80 and over, MESH : Child, MESH: Child, MESH : Female, Young adult, MESH: Aged, MESH: Middle Aged, biology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Adult, MESH : Wounds and Injuries, 3. Good health, MESH : Mucorales, MESH: Young Adult, Cohort, Coinfection, MESH: Mucorales, Antifungal, medicine.medical_specialty, medicine.drug_class, MESH : Male, MESH : Young Adult, MESH : Adolescent, Internal medicine, Injury prevention, medicine, MESH : Middle Aged, MESH : Mucormycosis, MESH : France, MESH : Aged, 80 and over, MESH: Mucormycosis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Mucormycosis, MESH: Adult, Saksenaea vasiformis, medicine.disease, biology.organism_classification, MESH: Male, Surgery, MESH: France, MESH: Wounds and Injuries, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female
Abstract: International audience; Data on clinical, mycologic characteristics, and outcome of posttraumatic mucormycosis are scarce and often limited to case reports. From the French nationwide "RetroZygo" study, we compared posttraumatic mucormycosis cases with other forms of mucormycosis. We also reviewed reports of posttraumatic mucormycosis in the English-language literature from 1993 to 2013. We included all proven or probable cases for which underlying condition, route of infection, surgical and antifungal treatments, and outcome were detailed. From our cohort, posttraumatic mucormycosis (n = 16) differed significantly from other forms (n = 85) by rarity of underlying disease (31.2% vs 81%, p
Published: 2014

29. Pooled analysis of iron-related genes in Parkinson's disease: Association with transferrin

Author: Alexis Elbaz, Janet S. Sinsheimer, Marie-Anne Loriot, Beate Ritz, Daniel D. Buchanan, George D. Mellick, Jerome I. Rotter, Ismaïl Ahmed, Shannon L. Rhodes, Jeff M. Bronstein, Kent D. Taylor, SZTAJNBOK, Pascale, Department of Biology, Indiana University [Bloomington], Indiana University System-Indiana University System-School of Science, Queensland Institute of Medical Research, Laboratoire brestois de mécanique et des systèmes (LBMS), École Nationale d'Ingénieurs de Brest (ENIB)-Université de Brest (UBO)-École Nationale Supérieure de Techniques Avancées Bretagne (ENSTA Bretagne), Cedars-Sinai Medical Center, Bases moléculaires de la réponse aux xénobiotiques (U775 (IFR95)), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Department of Human Genetics, University of California [Los Angeles] (UCLA), University of California (UC)-University of California (UC), Department of Neurology [UCLA], University of California (UC)-University of California (UC)-David Geffen School of Medicine [Los Angeles], Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Eskitis Institute for Cell and Molecular Therapies, Griffith University [Brisbane], Department of Epidemiology, University of California-University of California, University of California-University of California-David Geffen School of Medicine [Los Angeles], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Indiana University [Bloomington]-School of Science, Laboratoire brestois de mécanique et des systèmes ( LBMS ), École Nationale d'Ingénieurs de Brest ( ENIB ) -Université de Brest ( UBO ) -ENSTA Bretagne, Medical Genetics Institute, Cedars-Sinai Medical Center, Bases moléculaires de la réponse aux xénobiotiques ( U775 (IFR95) ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), University of California at Los Angeles [Los Angeles] ( UCLA ), University of California at Los Angeles [Los Angeles] ( UCLA ) -David Geffen School of Medicine, Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Griffith University
Subjects: Male, Aging, Parkinson's disease, Epidemiology, MESH : Aged, Neurodegenerative, MESH : Iron, 0302 clinical medicine, Receptors, 2.1 Biological and endogenous factors, MESH : Female, Aetiology, Transferrin receptor 2, MESH: Genetic Association Studies, Genetics, chemistry.chemical_classification, MESH: Aged, 0303 health sciences, MESH: Iron, Parkinson's Disease, MESH: Middle Aged, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, Neurodegeneration, Transferrin, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Parkinson Disease, Single Nucleotide, Pooled-analysis, MESH : Adult, Middle Aged, MESH : Transferrin, MESH: Case-Control Studies, 3. Good health, MESH : Parkinson Disease, Neurology, MESH: Young Adult, Neurological, Female, MESH: Transferrin, Adult, MESH : Case-Control Studies, Adolescent, MESH : Male, Iron, Clinical Sciences, MESH : Young Adult, Transferrin receptor, Single-nucleotide polymorphism, Substantia nigra, Biology, Polymorphism, Single Nucleotide, Article, lcsh:RC321-571, 03 medical and health sciences, Young Adult, MESH : Adolescent, Iron homeostasis, Receptors, Transferrin, medicine, Humans, MESH : Middle Aged, MESH : Receptors, Transferrin, MESH: Receptors, Transferrin, Allele, Polymorphism, lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry, Genetic Association Studies, 030304 developmental biology, Aged, MESH: Adolescent, Neurology & Neurosurgery, MESH: Humans, MESH : Humans, Haplotype, Neurosciences, MESH: Adult, MESH : Genetic Association Studies, medicine.disease, MESH: Male, Brain Disorders, chemistry, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Case-Control Studies, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Female, 030217 neurology & neurosurgery, MESH: Parkinson Disease
Abstract: Pathologic features of Parkinson's disease (PD) include death of dopaminergic neurons in the substantia nigra, presence of α-synuclein containing Lewy bodies, and iron accumulation in PD-related brain regions. The observed iron accumulation may be contributing to PD etiology but it also may be a byproduct of cell death or cellular dysfunction. To elucidate the possible role of iron accumulation in PD, we investigated genetic variation in 16 genes related to iron homeostasis in three case-control studies from the United States, Australia, and France. After screening 90 haplotype tagging single nucleotide polymorphisms (SNPs) within the genes of interest in the US study population, we investigated the five most promising gene regions in two additional independent case-control studies. For the pooled data set (1289 cases, 1391 controls) we observed a protective association (OR. = 0.83, 95% CI: 0.71-0.96) between PD and a haplotype composed of the A allele at rs1880669 and the T allele at rs1049296 in transferrin (TF; GeneID: 7018). Additionally, we observed a suggestive protective association (OR. = 0.87, 95% CI: 0.74-1.02) between PD and a haplotype composed of the G allele at rs10247962 and the A allele at rs4434553 in transferrin receptor 2 (TFR2; GeneID: 7036). We observed no associations in our pooled sample for haplotypes in SLC40A1, CYB561, or HFE. Taken together with previous findings in model systems, our results suggest that TF or a TF- TFR2 complex may have a role in the etiology of PD, possibly through iron misregulation or mitochondrial dysfunction within dopaminergic neurons. © 2013 Elsevier Inc.
Published: 2014

30. Bone oedema on MRI is highly associated with low bone mineral density in patients with early inflammatory back pain: results from the DESIR cohort

Author: Anne Durnez, Maxime Dougados, Simon Paternotte, Corinne Miceli-Richard, Christian Roux, Karine Briot, Service de rhumatologie [CHU Cochin], CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Groeninge Hospital, Service de rhumatologie [Strasbourg], CHU Strasbourg-Hôpital de Hautepierre [Strasbourg], Physiopathologie des arthrites, Université Louis Pasteur - Strasbourg I, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) - CHU Cochin [AP-HP], and CHU Strasbourg - Hôpital de Hautepierre [Strasbourg]
Subjects: Male, MESH : Bone Diseases, [SDV]Life Sciences [q-bio], Osteoporosis, Logistic regression, Gastroenterology, MESH: Magnetic Resonance Imaging, Cohort Studies, MESH: Lumbar Vertebrae, MESH : Back Pain, Absorptiometry, Photon, 0302 clinical medicine, MESH : Edema, Bone Density, Risk Factors, MESH: Risk Factors, Edema, Immunology and Allergy, MESH : Female, MESH : Bone Density, Young adult, MESH: Bone Density, MESH: Cohort Studies, MESH : Lumbar Vertebrae, Bone mineral, Sacroiliac joint, 0303 health sciences, Univariate analysis, Lumbar Vertebrae, MESH: Middle Aged, medicine.diagnostic_test, MESH : Spondylarthritis, MESH : Adult, Middle Aged, MESH : Hip Joint, MESH : Risk Factors, Magnetic Resonance Imaging, [SDV] Life Sciences [q-bio], MESH: Edema, C-Reactive Protein, medicine.anatomical_structure, MESH: Young Adult, Erythrocyte sedimentation rate, Female, Hip Joint, France, MESH: Bone Diseases, Bone Diseases, MESH: Osteoporosis, Adult, musculoskeletal diseases, MESH: Hip Joint, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Blood Sedimentation, MESH: Spondylarthritis, Immunology, MESH : Young Adult, MESH : Cohort Studies, Blood Sedimentation, MESH: Absorptiometry, Photon, General Biochemistry, Genetics and Molecular Biology, Young Adult, 03 medical and health sciences, Rheumatology, MESH : Adolescent, MESH : Magnetic Resonance Imaging, Internal medicine, Spondylarthritis, MESH: C-Reactive Protein, medicine, Humans, MESH : Middle Aged, Risk factor, MESH : France, MESH: Blood Sedimentation, MESH : Absorptiometry, Photon, 030304 developmental biology, 030203 arthritis & rheumatology, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, MESH : C-Reactive Protein, medicine.disease, MESH: Male, Surgery, MESH: France, Back Pain, MESH: Back Pain, MESH : Osteoporosis, business, MESH: Female
Abstract: ObjectivesTo assess bone mineral density (BMD) at lumbar spine and hip in a large cohort of patients with early inflammatory back pain (IBP) suggestive of axial spondyloarthritis (SpA), and to assess systemic and bone inflammation (according to MRI) as risk factors of low BMD.Patients and Methods332 (52.4% male) patients with IBP suggestive of axial SpA defined by Calin or Berlin criteria were recruited; they had lumbar spine and hip BMD and body composition measurements. Low BMD was defined by Z≤−2 (at least one site). Clinical, biological (erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP)) and imaging (x-rays, spine and sacroiliac joint MRI) parameters were compared in patients with and without low BMD (Z≤−2). Significant parameters in univariate analysis were tested in multivariate models.ResultsPatients (mean age 33.8 years) had a short duration of axial symptoms (mean 1.6 years); 71.4% fulfilled the Assessment of Spondyloarthritis International Society criteria for axial SpA and HLA-B27 was present in 62.1%. 43 (13.0%) had low BMD (88% male). Multivariate logistic regression showed that parameters significantly associated with low BMD (any site) were the presence of bone marrow oedema (inflammatory lesions) on MRI (OR 4.63, p=0.001), either ESR or CRP (OR 2.60, p=0.037) and male gender (OR 9.60, p=0.0004).ConclusionsThis study conducted in a large cohort of young adults with early IBP suggestive of SpA shows that 13.0% of patients have a low BMD and that the main risk factor associated with low BMD was inflammation on MRI.
Published: 2013

31. Epidemiology of alveolar echinococcosis in Xinjiang Uygur autonomous region, China: a preliminary analysis

Author: Philip S. Craig, Dominique-Angèle Vuitton, Francis Raoul, Hao Wen, Jean-Pierre Quéré, H. X. Zhou, Pierre Delattre, Patrick Giraudoux, S. X. Chai, Xinjiang Medical University, Biomedical Sciences Research Institute, University of Salford, Centre de Biologie pour la Gestion des Populations (UMR CBGP), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-Institut National de la Recherche Agronomique (INRA)-Centre international d'études supérieures en sciences agronomiques (Montpellier SupAgro)-Université de Montpellier (UM)-Institut de Recherche pour le Développement (IRD [France-Sud])-Institut national d’études supérieures agronomiques de Montpellier (Montpellier SupAgro), Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), WHO Collaborating Center on Prevention and Treatment of Human Echinococcosis, SERF Unit, Université de Franche-Comté (UFC), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Raoul, Francis, Centre de Biologie pour la Gestion des Populations ( CBGP ), Centre de Coopération Internationale en Recherche Agronomique pour le Développement ( CIRAD ) -Centre international d'études supérieures en sciences agronomiques ( Montpellier SupAgro ) -Institut national de la recherche agronomique [Montpellier] ( INRA Montpellier ) -Université de Montpellier ( UM ) -Institut de Recherche pour le Développement ( IRD [France-Sud] ) -Institut national d’études supérieures agronomiques de Montpellier ( Montpellier SupAgro ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), and Université de Franche-Comté ( UFC )
Subjects: Male, Veterinary medicine, MESH : Retrospective Studies, MESH : Prevalence, MESH : Age Distribution, Prevalence, Kazakh, 0302 clinical medicine, MESH : Child, MESH: Child, Epidemiology, MESH : Female, Child, MESH: Echinococcosis, Pulmonary, MESH : Sex Distribution, [SDV.EE]Life Sciences [q-bio]/Ecology, environment, MESH: Middle Aged, biology, Transmission (medicine), MESH: Sex Distribution, Pulmonary, MESH : Adult, Middle Aged, Echinococcosis, MESH: China, 3. Good health, [SDV.EE] Life Sciences [q-bio]/Ecology, environment, Infectious Diseases, Geography, language, Female, MESH : Echinococcosis, Pulmonary, Adult, China, medicine.medical_specialty, Echinococcosis, Pulmonary, Adolescent, MESH : Male, 030231 tropical medicine, Helminthiasis, Zoology, Echinococcus multilocularis, [ SDV.EE ] Life Sciences [q-bio]/Ecology, environment, 03 medical and health sciences, Age Distribution, MESH : Adolescent, 030225 pediatrics, medicine, MESH : China, Humans, Helminths, MESH : Middle Aged, Sex Distribution, MESH: Age Distribution, MESH: Prevalence, Retrospective Studies, MESH: Adolescent, MESH: Humans, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, medicine.disease, biology.organism_classification, MESH: Male, language.human_language, Parasitology, MESH: Female
Abstract: International audience; The Xinjiang Uygur autonomous region (XUAR) in north-western China is known to be endemic for Echinococcosis multilocularis, the causative agent of human alveolar echinococcosis (HAE). Despite regular reports of HAE cases in their region, very little is known about the local epidemiology of the disease or the transmission of E. multilocularis. The epidemiology of HAE in Xinjiang has now been investigated by the analysis of data collected from the medical records of 157 clinical cases who had attended the four main hospitals in the region. These data indicate that the disease is relatively common in the Altai, western Junggar, and Tianshan mountain ranges, whereas the Tarim and Junggar basins are likely to be of low endemicity. The prevalence of the disease in the Kunlun mountains is not clear. Semi-nomadic groups, especially those of Kazakh or Mongol origin, have a higher risk of infection than other ethnic groups. Prevalence of the disease in humans appears to be correlated with aspects of the local climate, such as annual precipitation and temperature. Red foxes, Microtinae, Ochotona spp. and Marmota spp. may be important hosts of E. multilocularis in the XUAR, sustaining the transmission cycles of the parasite.
Published: 2000

32. Candida albicans is not always the preferential yeast colonizing humans: a study in Wayampi Amerindians

Author: Mouna Ben Soltana, Laure Diancourt, Antoine Andremont, Paul-Louis Woerther, Sophie Abélanet, Félix Djossou, Emmanuelle Permal, Cécile Angebault, Christiane Bouchier, Christophe d'Enfert, François Catzeflis, Marie-Elisabeth Bougnoux, CHU Necker - Enfants Malades [AP-HP], Université Paris Descartes - Paris 5 (UPD5), Laboratoire de bactériologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Biologie et Pathogénicité fongiques, Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris], Unité des Maladies Infectieuses et Tropicales [Cayenne, Guyanne Française], Centre Hospitalier Andrée Rosemon [Cayenne, Guyane Française], Génotypage des Pathogènes et Santé Publique (Plate-forme) (PF8), Institut Pasteur [Paris], Génomique (Plate-Forme), Institut des Sciences de l'Evolution de Montpellier (UMR ISEM), Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École pratique des hautes études (EPHE)-Université de Montpellier (UM)-Institut de recherche pour le développement [IRD] : UR226-Centre National de la Recherche Scientifique (CNRS), The ERAES project was supported in part by the Agence Française de Sécurité Sanitaire de l’Environnement et du Travail(contracts ES-05-01 and EST-09-21), the Agence Nationale pour la Recherche (contract 05-9-114), the Institut National de la Santé et de la Recherche Médicale (INSERM, contracts C06-18 and C10-19), the Centre National de Référence' Résistance bactérienne dans les flores commensales, 'the Fondation pour la Recherche Médicale (grants FDM20090615761 andFDM20100619023 to C. A.), and the French government ’ s Investissement d'Avenir program, Laboratoire d’Excellence'Integrative Biology of Emerging Infectious Diseases' (grant ANR-10-LABX-62-IBEID), ANR: the Agence Nationale pour la Recher- che (contract 05-9-114),the Agence Nationale pour la Recher- che (contract 05-9-114),05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-62-IBEID,IBEID,Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), Assistance publique - Hôpitaux de Paris (AP-HP) - AP-HP - Hôpital Bichat - Claude Bernard [Paris] - Université Paris Diderot - Paris 7 (UPD7), Institut National de la Recherche Agronomique (INRA) - Institut Pasteur [Paris], Institut des Sciences de l'Evolution de Montpellier (ISEM), Université de Montpellier (UM) - Institut de recherche pour le développement [IRD] : UR226 - Centre National de la Recherche Scientifique (CNRS), ANR : the Agence Nationale pour la Recher- che (contract 05-9-114), the Agence Nationale pour la Recher- che (contract 05-9-114), 05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-62-IBEID, IBEID, Laboratoire d'Excellence 'Integrative Biology of Emerging Infectious Diseases'(2010), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut Pasteur [Paris]-Institut National de la Recherche Agronomique (INRA), Génomique (Plate-Forme) - Genomics Platform, Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École pratique des hautes études (EPHE), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Université de Montpellier (UM)-Institut de recherche pour le développement [IRD] : UR226-Centre National de la Recherche Scientifique (CNRS), 05-9-114 the Agence Nationale pour la Recher- che (contract 05-9-114) the Agence Nationale pour la Recher- che (contract 05-9-114), ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), Biologie et Pathogénicité fongiques (BPF), Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris] (IP), Institut Pasteur [Paris] (IP), and Centre de Coopération Internationale en Recherche Agronomique pour le Développement (Cirad)-École Pratique des Hautes Études (EPHE)
Subjects: Male, MESH : Prevalence, MESH : Multilocus Sequence Typing, MESH : Aged, MESH : Candidiasis, MESH: Aged, 80 and over, Prevalence, Immunology and Allergy, Colonization, MESH : Female, MESH: Animals, Candida albicans, MESH: Phylogeny, Phylogeny, MESH: Evolution, Molecular, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Aged, 80 and over, 2. Zero hunger, MESH : Intestines, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, MESH: Yeasts, Candidiasis, intestinal colonization, Middle Aged, MESH : Adult, Corpus albicans, MESH: Candidiasis, French Guiana, Intestines, Infectious Diseases, MESH : Carrier State, MESH: Multilocus Sequence Typing, whole-genome sequencing, MESH: Young Adult, Carrier State, MESH: Genome, Fungal, Female, Genome, Fungal, MESH: Carrier State, MLST, MESH: Intestines, Adult, MESH : French Guiana, Adolescent, Human intestine, MESH : Candida albicans, MESH : Male, Saccharomyces cerevisiae, MESH : Young Adult, yeasts, Microbiology, Evolution, Molecular, Young Adult, 03 medical and health sciences, MESH: Mycoses, Candida krusei, MESH : Adolescent, MESH: French Guiana, Animals, Humans, MESH : Middle Aged, MESH : Evolution, Molecular, MESH : Aged, 80 and over, MESH: Prevalence, Aged, 030304 developmental biology, MESH : Mycoses, MESH: Adolescent, MESH : Yeasts, MESH: Humans, 030306 microbiology, amerindians, MESH : Genome, Fungal, MESH: Candida albicans, MESH : Humans, MESH : Phylogeny, MESH: Adult, biology.organism_classification, [SDV.MP.MYC] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Yeast, MESH: Male, Carriage, Mycoses, candida albicans, MESH : Animals, MESH: Female, Multilocus Sequence Typing
Abstract: Chantier qualité GA; International audience; In industrialized countries Candida albicans is considered the predominant commensal yeast of the human intestine, with approximately 40% prevalence in healthy adults. We discovered a highly original colonization pattern that challenges this current perception by studying in a 4- year interval a cohort of 151 Amerindians living in a remote community (French Guiana), and animals from their environment. The prevalence of C. albicans was persistently low (3% and 7% of yeast carriers). By contrast, Candida krusei and Saccharomyces cerevisiae were detected in over 30% of carriers. We showed that C. krusei and S. cerevisiae carriage was of food or environmental origin, whereas C. albicans carriage was associated with specific risk factors (being female and living in a crowded household). We also showed using whole-genome sequence comparison that C. albicans strains can persist in the intestinal tract of a healthy individual over a 4-year period.
Published: 2013

33. [Medical indoor environment counsellor (MIEC) in Burgundy: evaluation by physicians and patients]

Author: Vagner , A, Reboux , G, Nicoullaud , V, Blanchon , L, Scherer , P, Collet , E, Camus , P, Foglia , T, Gardin , G, Bonniaud , P, Service de Pneumologie et unité de soins intensifs respiratoire, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre National de la Recherche Scientifique ( CNRS ), Retinoids, Development and Developmental Diseases ( R2D2 ), Université d'Auvergne - Clermont-Ferrand I ( UdA ), Departments of Cell Biology and Medicine, Diabetes Research and Training Center, Albert Einstein College of Medicine, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service des maladies respiratoires [CHU de Dijon], Millon, Laurence, Service de Pneumologie Soins Intensifs, Appareillage Respiratoire [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Retinoids, Development and Developmental Diseases (R2D2), Université d'Auvergne - Clermont-Ferrand I (UdA), Albert Einstein College of Medicine [New York], and Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE)
Subjects: Counseling, Male, MESH: Asthma, MESH : Aged, MESH : Child, Preschool, MESH: Aged, 80 and over, MESH : Child, MESH: Child, MESH: Physicians, MESH: Animals, MESH : Female, Child, Rhinitis, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, MESH : Rhinitis, MESH: Counseling, MESH: Rhinitis, Pyroglyphidae, MESH: Patient Acceptance of Health Care, MESH : Infant, Middle Aged, MESH : Adult, MESH: Infant, MESH : Patient Acceptance of Health Care, MESH : Counseling, MESH : Air Pollution, Indoor, MESH: Young Adult, Patient Satisfaction, Air Pollution, Indoor, Child, Preschool, Female, France, MESH : Skin Tests, Adult, MESH : Patient Satisfaction, Adolescent, MESH : Male, MESH : Physicians, MESH : Young Adult, MESH : Asthma, [ SDV.EE.SANT ] Life Sciences [q-bio]/Ecology, environment/Health, Young Adult, MESH: Skin Tests, Physicians, MESH : Adolescent, [SDV.EE.SANT] Life Sciences [q-bio]/Ecology, environment/Health, Animals, Humans, MESH : Middle Aged, MESH : Pyroglyphidae, MESH: Pyroglyphidae, MESH : France, MESH : Aged, 80 and over, Aged, Skin Tests, MESH: Adolescent, [SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health, MESH: Humans, MESH: Child, Preschool, MESH : Humans, Infant, MESH: Adult, Patient Acceptance of Health Care, MESH: Male, MESH: Patient Satisfaction, Asthma, respiratory tract diseases, MESH: France, MESH : Animals, MESH: Air Pollution, Indoor, MESH: Female
Abstract: International audience; Since December 2009, chest physicians and allergologists in Burgundy have been able to call upon a medical indoor environment counsellor (MIEC). The consultations are free for the patient and are undertaken following a medical referal after systematic cutaneous prick tests. To describe the indications, the distribution of prescriptions and to measure the impact of the counsellor's visits on the first 100 patients at 6 months and on the physicians at 18 months. Telephone interviews with the 67 physicians (whether prescribers or not) concerning their motivation and/or expectations, and with the first 100 patients concerning follow up of the recommendations. Seventy percent of the physicians replied (n=47). The satisfaction of prescribers (n=22) was 8.42/10. The indications were rhinitis and a poorly controlled asthma. The requests concerned the search for dust mite (50%) and moulds (46%). Eighty-four percent of the physicians discussed the MIEC's report with the patients. The patients' symptoms were rhinitis (79%), asthma (57%) and conjunctivitis (33%). The Acarex test(®), performed in cases of positive prick tests to house dust mites (n=72), was strongly positive for 67 patients. Sixteen mould samples out of 21 were above the standard concentrations. Sixty-nine patients had followed the recommendations of the MIEC. The impact of the MIEC visits was perceived as positive by the physicians and the patients. The medico-economic impact warrants further evaluation.
Published: 2013

34. Acute lower respiratory infections on lung sequelae in Cambodia, a neglected disease in highly tuberculosis-endemic country

Author: Arnaud Tarantola, Patrich Lorn Try, Sophie Goyet, Sopheak Hem, Blandine Rammaert, Bertrand Guillard, Sokleaph Cheng, Charles Mayaud, Sirenda Vong, Laurence Borand, Sareth Rith, Philippe Buchy, Vantha Te, Institut Pasteur du Cambodge, Institut Pasteur du Cambodge-Réseau International des Instituts Pasteur ( RIIP ), Centre d'infectiologie Necker-Pasteur, Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Donkeo Provincial Hospital, CHU Tenon [APHP], Rammaert B, Goyet S, Mayaud C, Buchy P, Borand L., Tarantola A, Hem S, Rith S, Cheng S, Te V, Try PL, Guillard B, Vong S, CHU Necker - Enfants Malades [AP-HP], Kampong Cham Provincial hospital, Kampong Cham Provincial hospital [Cambodia], Surveillance and Investigation of endemic situations in South-East Asia (SISEA) was funded by the French Agency for Development (Agence Française de Développement, AFD) and the US Department of Human and Health Services (US DHHS). Blandine Rammaert received a grant from the Fondation Pierre Ledoux Jeunesse Internationale and the Société de Pathologie Infectieuse de Langue Française., Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Réseau International des Instituts Pasteur (RIIP), CHU Tenon [AP-HP], and Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Male, MESH : Prospective Studies, MESH : Aged, Haemophilus influenzae, 0302 clinical medicine, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Prospective Studies, MESH: Developing Countries, Respiratory Tract Infections, Aged, 80 and over, MESH: Middle Aged, MESH : Acute Disease, Neglected Diseases, MESH : Superinfection, MESH : Diagnosis, Differential, Countries, 3. Good health, Bronchiectasis, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, MESH: Young Adult, Acute Disease, MESH: Acute Disease, MESH : Hospitalization, MESH : Endemic Diseases, MESH : Community-Acquired Infections, Pulmonary and Respiratory Medicine, medicine.medical_specialty, Tuberculosis, MESH : Young Adult, [ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, Article, 03 medical and health sciences, MESH: Anti-Bacterial Agents, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Developing Countries, Intensive care medicine, MESH : Aged, 80 and over, MESH: Age Distribution, Developing Countries, Tuberculosis, Pulmonary, Aged, MESH: Adolescent, MESH: Tuberculosis, Pulmonary, MESH: Humans, MESH : Cambodia, MESH : Humans, MESH: Adult, medicine.disease, 030228 respiratory system, Superinfection, Developing, Chest radiograph, MESH: Female, MESH : Tuberculosis, Pulmonary, Endemic Diseases, MESH : Age Distribution, MESH : Respiratory Tract Infections, MESH: Hospitalization, medicine.disease_cause, MESH: Aged, 80 and over, MESH : Female, 030212 general & internal medicine, Respiratory system, MESH : Anti-Bacterial Agents, MESH: Aged, medicine.diagnostic_test, Airway remodeling, MESH : Adult, Middle Aged, Anti-Bacterial Agents, Community-Acquired Infections, Hospitalization, medicine.anatomical_structure, MESH: Community-Acquired Infections, MESH: Endemic Diseases, Pseudomonas aeruginosa, Female, Abnormality, Cambodia, Adult, Adolescent, MESH : Male, Diagnosis, Differential, Young Adult, Age Distribution, MESH: Diagnosis, Differential, Internal medicine, Streptococcus pneumoniae, medicine, Lung, business.industry, MESH: Cambodia, MESH: Male, MESH: Prospective Studies, MESH: Superinfection, MESH: Respiratory Tract Infections, MESH: Neglected Diseases, business, MESH : Neglected Diseases
Abstract: International audience; BACKGROUND: Little is known about post-infectious pulmonary sequelae in countries like Cambodia where tuberculosis is hyper-endemic and childhood pulmonary infections are highly frequent. We describe the characteristics of hospitalized Cambodian patients presenting with community-acquired acute lower respiratory infections (ALRI) on post-infectious pulmonary sequelae (ALRIPS). METHODS: Between 2007 and 2010, inpatients ≥15 years with ALRI were prospectively recruited. Clinical, biological, radiological and microbiological data were collected. Chest radiographs were re-interpreted by experts to compare patients with ALRIPS, on previously healthy lungs (ALRIHL) and active pulmonary tuberculosis (TB). Patients without chest radiograph abnormality or with abnormality suggestive as other chronic respiratory diseases were excluded from this analysis. RESULTS: Among the 2351 inpatients with community-acquired ALRI, 1800 were eligible: 426 (18%) ALRIPS, 878 (37%) ALRIHL and 496 (21%) TB. ALRIPS patients had less frequent fever than other ALRI (p
Published: 2013

35. Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials

Author: Geneviève Plu-Bureau, Barbara B. Cochrane, Marianne Canonico, Marcia L. Stefanick, JoAnn E. Manson, Pierre-Yves Scarabin, Mary Jo O'Sullivan, Centre de recherche en épidémiologie et santé des populations (CESP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Paris Descartes - Paris 5 (UPD5), Recherche en épidémiologie et biostatistique, Université Paris-Sud - Paris 11 (UP11)-Institut National de la Santé et de la Recherche Médicale (INSERM), Maison du patrimoine Oral de Bourgogne (Anost) (MPOB), Stanford Prevention Research Center, Stanford Medicine, Stanford University-Stanford University, University of Washington [Seattle], Departments of Ophthalmology and Microbiology and Molecular Genetics, Harvard Medical School [Boston] (HMS), National Heart, Lung, and Blood Institute, Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), SZTAJNBOK, Pascale, Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Maison du patrimoine Oral de Bourgogne ( MPO ), Maison du patrimoine Oral de Bourgogne, Stanford University School of Medicine, and Harvard Medical School [Boston] ( HMS )
Subjects: MESH : Venous Thromboembolism, MESH: Reproductive History, MESH: Menopause, medicine.medical_treatment, MESH : Aged, 030204 cardiovascular system & hematology, MESH: Venous Thromboembolism, MESH: Pregnancy, 0302 clinical medicine, MESH : Child, MESH: Risk Factors, Pregnancy, Risk Factors, MESH: Child, MESH : Female, 030212 general & internal medicine, Child, Reproductive History, MESH: Aged, Clinical Trials as Topic, MESH : Estrogen Replacement Therapy, MESH: Middle Aged, Obstetrics, Women's Health Initiative, Hazard ratio, Estrogen Replacement Therapy, MESH : Menopause, Age Factors, MESH : Menarche, Obstetrics and Gynecology, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Venous Thromboembolism, MESH : Adult, Middle Aged, MESH : Risk Factors, 3. Good health, MESH : Women's Health, Menopause, Postmenopause, Parity, MESH : Ovariectomy, MESH: Menarche, MESH : Postmenopause, Menarche, Female, MESH: Postmenopause, Adult, medicine.medical_specialty, MESH: Clinical Trials as Topic, Adolescent, Ovariectomy, MESH: Ovariectomy, Article, 03 medical and health sciences, MESH : Adolescent, MESH : Reproductive History, medicine, Humans, MESH : Middle Aged, cardiovascular diseases, MESH : Parity, Aged, MESH: Adolescent, MESH: Age Factors, Gynecology, MESH: Humans, Proportional hazards model, business.industry, MESH : Humans, MESH: Parity, Oophorectomy, MESH: Adult, equipment and supplies, medicine.disease, MESH: Estrogen Replacement Therapy, MESH : Clinical Trials as Topic, MESH : Pregnancy, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Women's Health, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, Hormone therapy, business, MESH: Women's Health, MESH: Female
Abstract: International audience; This study aims to investigate venous thromboembolism (VTE) risk in relation to age at menopause, age at menarche, parity, bilateral oophorectomy, and time since menopause, as well as any interaction with randomized hormone therapy (HT) assignment, among postmenopausal women. Using pooled data from the Women's Health Initiative HT clinical trials including 27,035 postmenopausal women aged 50 to 79 years who had no history of VTE, we assessed the risk of VTE in relation to age at menopause, age at menarche, parity, bilateral oophorectomy, and time since menopause by Cox proportional hazards models. Linear trends, quadratic relationships, and interactions of reproductive life characteristics with HT on VTE risk were systematically tested. During follow-up, 426 women reported a first VTE, including 294 non-procedure-related events. No apparent interaction of reproductive life characteristics with HT assignment on VTE risk was detected, and there was not a significant association between VTE and age at menarche, age at menopause, parity, oophorectomy, or time since menopause. However, analyses restricted to non-procedure-related VTE showed a U-shaped relationship between age at menopause and thrombotic risk that persisted after multivariable analysis (P < 0.01). Compared with women aged 40 to 49 years at menopause, those who had early menopause (age 55 y) had a significantly increased VTE risk (hazard ratio [95% CI]: 1.8 [1.2-2.7] and 1.5 [1.0-2.4], respectively). Reproductive life characteristics have little association with VTE and do not seem to influence the effect of HT on thrombotic risk among postmenopausal women. Nevertheless, early and late onset of menopause might be newly identified risk factors for non-procedure-related VTE.
Published: 2013

36. In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy

Author: Olivier Humbert, Alexandre Cochet, Salim Kanoun, Caroline Legouge, François Brunotte, Olivier Casasnovas, Inna Dygai-Cochet, Alina Berriolo-Riedinger, Michel Toubeau, Louis Berthet, Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Service de Médecine Nucléaire, UNICANCER-UNICANCER, Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, and Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )
Subjects: MESH : Bone Marrow, Male, MESH : Retrospective Studies, Biopsy, MESH : Aged, Iliac crest, MESH : Lymphoma, Large B-Cell, Diffuse, Multimodal Imaging, 030218 nuclear medicine & medical imaging, [ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Biopsy, 0302 clinical medicine, International Prognostic Index, MESH: Aged, 80 and over, MESH: Fluorodeoxyglucose F18, Bone Marrow, MESH : Tomography, X-Ray Computed, MESH : Neoplasm Staging, MESH : Female, MESH: Aged, Aged, 80 and over, MESH : Prognosis, MESH: Middle Aged, medicine.diagnostic_test, MESH: Multimodal Imaging, MESH: Neoplasm Staging, MESH : Adult, Middle Aged, Prognosis, MESH: Positron-Emission Tomography, 3. Good health, medicine.anatomical_structure, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, MESH: Bone Marrow, Female, Radiology, Lymphoma, Large B-Cell, Diffuse, MESH: Tomography, X-Ray Computed, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Multimodal Imaging, MESH : Young Adult, [SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine, MESH: Prognosis, 03 medical and health sciences, Young Adult, Fluorodeoxyglucose F18, MESH : Adolescent, medicine, Humans, Radiology, Nuclear Medicine and imaging, MESH : Middle Aged, MESH : Aged, 80 and over, Aged, Neoplasm Staging, Retrospective Studies, MESH: Adolescent, PET-CT, MESH: Humans, business.industry, MESH : Humans, MESH : Positron-Emission Tomography, MESH: Adult, MESH: Retrospective Studies, MESH : Fluorodeoxyglucose F18, medicine.disease, Survival Analysis, MESH: Male, Lymphoma, Concomitant, MESH : Biopsy, Positron-Emission Tomography, MESH: Lymphoma, Large B-Cell, Diffuse, Bone marrow, MESH : Survival Analysis, business, Nuclear medicine, Tomography, X-Ray Computed, Diffuse large B-cell lymphoma, MESH: Female
Abstract: International audience; UNLABELLED: In newly diagnosed diffuse large B-cell lymphoma (DLBCL), the sensitivity of bone marrow biopsy (BMB) for the detection of bone marrow involvement (BMI) can be low because of sampling error if the BMI is focal and not diffuse. Although (18)F-FDG PET/CT is now recommended for initial staging of DLBCL, its role regarding BMI is not well defined. This study evaluated whether (18)F-FDG PET/CT, in comparison with BMB, is useful for the detection of BMI and predictive of outcome. METHODS: From the 142 patients who were referred to our institution for newly diagnosed DLBCL from June 2006 to October 2011, 133 were retrospectively enrolled in our study. All patients underwent whole-body (18)F-FDG PET/CT and a BMB from the iliac crest before any treatment. (18)F-FDG PET/CT was considered positive for BMI in cases of uni- or multifocal bone marrow (18)F-FDG uptake that could not be explained by benign findings on the underlying CT image or history. A final diagnosis of BMI was considered if the BMB was positive or if the positive (18)F-FDG PET/CT was confirmed by guided biopsy or targeted MR imaging or in cases of disappearance of focal bone marrow uptake concomitant with the disappearance of uptake in other lymphoma lesions on (18)F-FDG PET/CT monitoring. Progression-free survival and overall survival were analyzed using the Cox proportional hazards regression model. RESULTS: Thirty-three patients were considered to have BMI. Of these, 8 were positive according to the BMB and 32 were positive according to (18)F-FDG PET/CT. (18)F-FDG PET/CT was more sensitive (94% vs. 24%; P < 0.001), showed a higher negative predictive value (98% vs. 80%), and was more accurate (98% vs. 81%) than BMB. Median follow-up was 24 mo (range, 1-67 mo). Twenty-nine patients (22%) experienced recurrence or disease progression during follow-up, and 20 patients died (15%). In multivariate analysis, only the International Prognostic Index and the (18)F-FDG PET/CT bone marrow status were independent predictors of progression-free survival (P = 0.005 and 0.02, respectively), whereas only the International Prognostic Index remained an independent predictor of overall survival (P = 0.004). CONCLUSION: Assessment of BMI with (18)F-FDG PET/CT provides better diagnostic performance and prognostic stratification in newly diagnosed DLBCL than does BMB.
Published: 2013

37. Quantitative polymerase chain reaction detection of circulating DNA in serum for early diagnosis of mucormycosis in immunocompromised patients

Author: Etienne Daguindau, Fabrice Larosa, Steffi Rocchi, Laurence Millon, Faezeh Legrand, Emeline Scherer, Frédéric Grenouillet, Joel Leroy, Anne-Pauline Bellanger, Quentin Lepiller, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Parasitologie-Mycologie CHU Besançon, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service d'hématologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -hopital Jean Minjoz, Agents pathogènes et inflammation - UFC (EA 4266) ( API ), Université de Franche-Comté ( UFC ), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Service de parasitologie et mycologie [CHRU de Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Agents pathogènes et inflammation - UFC (EA 4266) (API), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques
Subjects: Male, MESH : Retrospective Studies, MESH : Aged, Polymerase Chain Reaction, law.invention, 0302 clinical medicine, Absidia, law, Limit of Detection, MESH: Immunocompromised Host, MESH : Female, 030212 general & internal medicine, DNA, Fungal, Mycological Typing Techniques, MESH : Mycological Typing Techniques, MESH : Polymerase Chain Reaction, Polymerase chain reaction, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, [ SDV.MP.MYC ] Life Sciences [q-bio]/Microbiology and Parasitology/Mycology, Mucor, MESH: Aged, 0303 health sciences, MESH: Middle Aged, biology, MESH : Immunocompromised Host, Middle Aged, MESH : Adult, 3. Good health, MESH: Reproducibility of Results, Infectious Diseases, Real-time polymerase chain reaction, MESH : Mucorales, MESH: Mucorales, Mucorales, Female, Microbiology (medical), Adult, Adolescent, MESH : Male, MESH: Limit of Detection, Microbiology, MESH : Limit of Detection, 03 medical and health sciences, Immunocompromised Host, Rhizopus, MESH: Mycological Typing Techniques, MESH : Adolescent, medicine, Humans, Mucormycosis, MESH : Mucormycosis, MESH : Middle Aged, MESH: Mucormycosis, Aged, Retrospective Studies, MESH: Adolescent, MESH: Humans, 030306 microbiology, business.industry, MESH : Reproducibility of Results, MESH : Humans, Reproducibility of Results, MESH: Adult, MESH: Polymerase Chain Reaction, MESH: Retrospective Studies, medicine.disease, biology.organism_classification, Virology, MESH: Male, Rhizomucor, MESH: DNA, Fungal, MESH : DNA, Fungal, business, MESH: Female
Abstract: International audience; BACKGROUND: The aim of our study was to assess the detection of circulating DNA from the most common species of Mucorales for early diagnosis of mucormycosis in at-risk patients. METHODS: We retrospectively evaluated a combination of 3 quantitative polymerase chain reaction (qPCR) assays using hydrolysis probes targeting Mucor/Rhizopus, Lichtheimia (formerly Absidia), and Rhizomucor for circulating Mucorales detection. Serial serum samples from 10 patients diagnosed with proven mucormycosis (2-9 samples per patient) were analyzed. RESULTS: No cross-reactivity was detected in the 3 qPCR assays using 19 reference strains of opportunistic fungi, and the limit of detection ranged from 3.7 to 15 femtograms/10 µL, depending on the species. DNA from Mucorales was detected in the serum of 9 of 10 patients between 68 and 3 days before mucormycosis diagnosis was confirmed by histopathological examination and/or positive culture. All the qPCR results were concordant with culture and/or PCR-based identification of the causing agents in tissue (Lichtheimia species, Rhizomucor species, and Mucor/Rhizopus species in 4, 3, and 2 patients, respectively). Quantitative PCR was negative in only 1 patient with proven disseminated mucormycosis caused by Lichtheimia species. CONCLUSION: Our study suggests that using specific qPCR targeting several species of Mucorales according to local ecology to screen at-risk patients could be useful in a clinical setting. The cost and efficacy of this strategy should be evaluated. However, given the human and economic cost of mucormycosis and the need for rapid diagnosis to initiate prompt directed antifungal therapy, this strategy could be highly attractive.
Published: 2013

38. Associated factors with adherence to antiepileptic drug in the capital city of Lao PDR

Author: Freddy Perez, Hubert Barennes, Pierre-Marie Preux, Sebastien Clavel, Phetvongsinh Chivorakul, Aina Harimanana, Neuroépidémiologie Tropicale ( NET ), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] ( SIME ), CHU Limoges, Laboratoire de Biostatistique et d'Informatique Médicale, Université de Limoges ( UNILIM ), Neuroépidémiologie Tropicale (NET), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de l'Information Médicale et de l'Évaluation [CHU Limoges] (SIME), and Université de Limoges (UNILIM)
Subjects: Male, Pediatrics, Urban Population, Cross-sectional study, Psychological intervention, Logistic regression, law.invention, Epilepsy, 0302 clinical medicine, MESH : Cross-Sectional Studies, Randomized controlled trial, law, Medicine, MESH : Female, 030212 general & internal medicine, Functional illiteracy, MESH : Epilepsy, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, 3. Good health, MESH: Urban Population, Neurology, MESH: Young Adult, Laos, MESH: Epilepsy, MESH : Urban Population, Anticonvulsants, Female, Adult, MESH : Anticonvulsants, medicine.medical_specialty, Adolescent, MESH : Male, MESH : Young Adult, Medication Adherence, Young Adult, 03 medical and health sciences, MESH: Anticonvulsants, MESH: Cross-Sectional Studies, MESH : Adolescent, MESH : Medication Adherence, Humans, Medical prescription, MESH: Adolescent, MESH: Humans, business.industry, Public health, MESH : Humans, MESH: Adult, MESH: Medication Adherence, medicine.disease, MESH: Male, Cross-Sectional Studies, MESH: Laos, Family medicine, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Neurology (clinical), business, MESH: Female, 030217 neurology & neurosurgery, MESH : Laos
Abstract: International audience; Available medical care for epilepsy and antiepileptic drugs (AED) are provided in Vientiane Municipality by district hospitals supported by a non-governmental organization, which is referred to as a community-based intervention (CB), and reference hospital which is referred to as hospital-based interventions (HB). Identifying underlying factors of AED adherence is of public health interest. A community-based cross-sectional survey among randomly selected patients with epilepsy (PWE) who were being cared in Vientiane Municipality was undertaken in 2010. The Morisky scale was used to assess the level of adherence. Univariate and multivariate logistic regression analyses were performed to address predictive factors. Overall, 99 PWE were included in the study. Overall adherence was estimated at 57.6%, 57.1% and 58.0% for the HB and CB group, respectively. High level of adherence was related to illiteracy, being on monotherapy and experiencing fewer seizures. Implementing closer medical care at primary level to PWE improves the likelihood of reducing primary and secondary treatment gap which is related to PWEs' adherence. An active intervention through a downstream channel of training of medical health staff from reference level to community level enhances the prescription of adequate AED, the improvement of the quality of relation between PWE and medical staff.
Published: 2013

39. Novel risk factors for premature peripheral arterial occlusive disease in non-diabetic patients: a case-control study

Author: Brigitte Colombies, Claude Conri, Philippe Lacroix, Anne-Marie Deletraz, V. Guérin, Joël Constans, Joseph Emmerich, Alessandra Bura-Rivière, Gabriel Camelot, Jean-Pierre Cambou, Rémi Le Trequesser, Geneviève Freyburger, Samir Mesli, Virginie Vanbrugghe, Aurélie Bedel, Alan T. Nurden, Luc Bressolette, Annie M. Bérard, Michel Darmon, François Becker, Marie-Christine Vergnes, Sylvie Colomer, Biothérapies des maladies génétiques et cancers, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire d'Hématologie, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Gironde, Laboratoire d'hémostase, Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-CHU Bordeaux [Bordeaux], Hager Group, Département de Médecine Interne et Pneumologie [Brest] (DMIP - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Neuroépidémiologie Tropicale (NET), CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Service de Chirurgie Thoracique et Vasculaire - Médecine vasculaire [CHU Limoges], CHU Limoges, Risque Thrombotique et Mecanismes de l'Hemostase (U765), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement (IFR71), Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris - Chimie ParisTech-PSL (ENSCP), Université Paris sciences et lettres (PSL)-Université Paris sciences et lettres (PSL)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Biology, CHU Bordeaux [Bordeaux], Imagerie Fonctionnelle et Métabolique en Oncologie, Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU), Départment de Neuroradiologie [CHU Caen], Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département de Médecine Interne et Pneumologie [Brest] ( DMIP - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Neuroépidémiologie Tropicale ( NET ), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ) -CHU Limoges-Institut d'Epidémiologie Neurologique et de Neurologie Tropicale-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Risque Thrombotique et Mecanismes de l'Hemostase ( U765 ), Institut des sciences du Médicament -Toxicologie - Chimie - Environnement ( IFR71 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL ( ENSCP ) -Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Unité de Neuroradiologie, CHU Caen, Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Ecole Nationale Supérieure de Chimie de Paris- Chimie ParisTech-PSL (ENSCP)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Paris Descartes - Paris 5 (UPD5)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), and Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)
Subjects: Male, Pathology, Apolipoprotein B, MESH : Polymorphism, Genetic, Epidemiology, lcsh:Medicine, 030204 cardiovascular system & hematology, Cardiovascular, Biochemistry, Gastroenterology, MESH : Thromboangiitis Obliterans, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH: Peripheral Arterial Disease, Medicine, MESH : Female, Platelet, 030212 general & internal medicine, Young adult, Family history, lcsh:Science, Peripheral Vascular Diseases, Multidisciplinary, MESH: Middle Aged, biology, Smoking, Age Factors, Thromboangiitis Obliterans, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Genomics, MESH : Adult, Middle Aged, MESH : Risk Factors, Lipids, MESH: Case-Control Studies, 3. Good health, Peripheral, MESH : Smoking, MESH : Histocompatibility Antigens Class II, MESH: Young Adult, Blood Chemistry, Female, Research Article, Adult, MESH: Thromboangiitis Obliterans, MESH : Case-Control Studies, medicine.medical_specialty, MESH: Smoking, Adolescent, Clinical Research Design, MESH : Male, MESH : Young Adult, Peripheral Arterial Disease, Young Adult, 03 medical and health sciences, Genomic Medicine, Diagnostic Medicine, MESH : Adolescent, Internal medicine, MESH: Polymorphism, Genetic, Factor V Leiden, Humans, MESH : Middle Aged, Genetic Testing, Biology, MESH: Adolescent, MESH: Age Factors, Polymorphism, Genetic, MESH: Humans, Population Biology, business.industry, lcsh:R, MESH : Humans, Histocompatibility Antigens Class II, Case-control study, MESH: Adult, MESH : Peripheral Arterial Disease, medicine.disease, MESH: Male, Case-Control Studies, biology.protein, MESH: Histocompatibility Antigens Class II, lcsh:Q, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Age Factors, business, MESH: Female, Lipoprotein
Abstract: International audience; BACKGROUND: This study aimed to determine the prevalence of genetic and environmental vascular risk factors in non diabetic patients with premature peripheral arterial disease, either peripheral arterial occlusive disease or thromboangiitis obliterans, the two main entities of peripheral arterial disease, and to established whether some of them are specifically associated with one or another of the premature peripheral arterial disease subgroups. METHODS AND RESULTS: This study included 113 non diabetic patients with premature peripheral arterial disease (diagnosis
Published: 2013

40. Responsiveness of the motor function measure in neuromuscular diseases

Author: Vuillerot, Carole, Payan, Christine, Girardot, Françoise, Fermanian, Jacques, Iwaz, Jean, Bérard, Carole, Ecochard, René, Salle, Jean-Yves, Study Group, Mfm, Renseigné, Non, CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'informatique médicale et biostatistiques [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques [Lyon], Hospices Civils de Lyon (HCL), Service de Médecine Physique et de Réadaptation [CHU Limoges], CHU Limoges, Handicap, Activité, Vieillissement, Autonomie, Environnement (HAVAE), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Pharmacologie Clinique, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Laboratoire Biostatistique-Santé ( LBS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Handicap, Activité, Vieillissement, Autonomie, Environnement ( HAVAE ), Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), and Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM )
Subjects: Male, MESH: Neuromuscular Diseases, medicine.medical_treatment, Psychological intervention, MESH : Prospective Studies, MESH : Aged, Poison control, MESH: Perception, Disability Evaluation, 0302 clinical medicine, MESH : Child, MESH: Child, MESH : Neuromuscular Diseases, Medicine, MESH : Female, 030212 general & internal medicine, Prospective Studies, Prospective cohort study, Child, MESH: Physical Therapy Modalities, MESH: Aged, Rehabilitation, MESH: Middle Aged, MESH: Disability Evaluation, Neuromuscular Diseases, Middle Aged, MESH : Adult, MESH : Mobility Limitation, 3. Good health, Motor Skills, MESH: Young Adult, MESH : Motor Skills, Female, Adult, medicine.medical_specialty, Neuromuscular disease, Adolescent, MESH : Male, MESH : Young Adult, Physical Therapy, Sports Therapy and Rehabilitation, MESH : Disability Evaluation, 03 medical and health sciences, Young Adult, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Injury prevention, MESH: Mobility Limitation, MESH: Muscular Dystrophy, Duchenne, Humans, MESH : Middle Aged, Mobility Limitation, MESH : Perception, Physical Therapy Modalities, Aged, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Clinical trial, Muscular Dystrophy, Duchenne, MESH : Physical Therapy Modalities, Physical therapy, Observational study, Perception, sense organs, business, MESH : Muscular Dystrophy, Duchenne, MESH: Female, 030217 neurology & neurosurgery, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, MESH: Motor Skills
Abstract: International audience; OBJECTIVES: To study the responsiveness (sensitivity to change) of the Motor Function Measure (MFM) in detecting change in neuromuscular disease patients with the intent of using this measure in future clinical trials. DESIGN: Prospective cohort observational study. SETTING: Inpatient and outpatient facilities for follow-up and treatment of neuromuscular diseases. PARTICIPANTS: Patients (N=152) with various neuromuscular diseases aged 6 to 60 years. INTERVENTIONS: Not applicable. MAIN OUTCOME MEASURE(S): We used the MFM total score and its 3 subscores on 2 measurements grossly 1 year apart. The physicians and the patients (or proxy) were asked to provide their perceived change in functional status since the first MFM. These changes were expressed in 3 outcomes: deterioration, stability, or improvement. RESULTS: The overall 12-month-standardized mean change of the total score mean ± SD annual total score change was -2.4±5.5 points (P
Published: 2012

41. Factors associated with post-seasonal serological titer and risk factors for infection with the pandemic A/H1N1 virus in the French general population

Author: Nathanael Lapidus, Laurent Abel, Nicolas Salez, Pierre Le Cann, Pierre-Yves Boëlle, Nanikaly Moyen, Michaël Schwarzinger, Marianne Leruez-Ville, Simon Cauchemez, Xavier de Lamballerie, Eric Vivier, Pascal Ferrari, Laurent Andreoletti, Frédéric Vély, Fabrice Carrat, Antoine Flahault, Rosemary M. Delabre, Michèle Legeas, Marie-Lise Gougeon, Michel Setbon, Epidémiologie des maladies infectieuses et modélisation (ESIM), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pôle des Maladies Infectieuses et Tropicales Clinique et Biologique, Fédération de Bactériologie-Hygiène-Virologie, Assistance Publique - Hôpitaux de Marseille (APHM), Emergence des Pathologies Virales (EPV), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Assistance Publique - Hôpitaux de Marseille (APHM)-Institut National de la Santé et de la Recherche Médicale (INSERM), École des Hautes Études en Santé Publique [EHESP] (EHESP), Centro Ricerche Produzioni Animali (CRPA), Immunité Anti-virale, Biothérapie et Vaccins (IABV), Institut Pasteur [Paris] (IP), Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Infections à Vih, Réservoirs, Pharmacologie des Antirétroviraux et Prévention de la Transmission Mère Enfant, Université Paris Descartes - Paris 5 (UPD5), Laboratoire de Virologie, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire de Virologie Médicale et Moléculaire - EA 4684 (CardioVir), Université de Reims Champagne-Ardenne (URCA)-Centre Hospitalier Universitaire de Reims (CHU Reims)-SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne (URCA)-Université de Reims Champagne-Ardenne (URCA), Modélisation mathématique des maladies infectieuses, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Centre d'études et de recherche en informatique et communications (CEDRIC), Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise (ENSIIE)-Conservatoire National des Arts et Métiers [CNAM] (CNAM), HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM), Imagine - Institut des maladies génétiques (IMAGINE - U1163), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Infection, Anti-microbiens, Modélisation, Evolution (IAME (UMR_S_1137 / U1137)), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ESIM - Déterminants Sociaux de la Santé et du Recours aux Soins (DS3), This study was supported by the Institut de Microbiologie et Maladies Infectieuses (IMMI-AVIESAN), the Institut de Santé Publique (ISP-AVIESAN), theFrench Ministry of Health and Assistance Publique Hôpitaux de Paris – PHRC 2010#AOM10199, the French Ministry of research and the Institut de Recherche enSante Publique (IReSP – TGIR 2009, Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Aix Marseille Université (AMU), Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV)-Université de Reims Champagne-Ardenne (URCA)-Université de Picardie Jules Verne (UPJV), Centre National de la Recherche Scientifique (CNRS)-Institut Pasteur [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Université Sorbonne Paris Cité (USPC), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Epidémiologie des maladies infectieuses et modélisation ( ESIM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance Publique - Hôpitaux de Marseille ( APHM ), Emergence des Pathologies Virales ( EPV ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Assistance Publique - Hôpitaux de Marseille ( APHM ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), École des Hautes Études en Santé Publique [EHESP] ( EHESP ), Centro Ricerche Produzioni Animali ( CRPA ), Immunité Anti-virale, Biothérapie et Vaccins ( IABV ), Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ), Laboratoire de Virologie Médicale et Moléculaire ( CardioVir ), Université de Reims Champagne-Ardenne ( URCA ) -Centre Hospitalier Universitaire de Reims ( CHU Reims ) -SFR CAP Santé (Champagne-Ardenne Picardie Santé), Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ) -Université de Reims Champagne-Ardenne ( URCA ) -Université de Picardie Jules Verne ( UPJV ), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), CHU Saint-Antoine [APHP], Institut Pierre Louis d'Epidémiologie et de Santé Publique ( iPLESP ), Centre d'étude et de recherche en informatique et communications ( CEDRIC ), Ecole Nationale Supérieure d'Informatique pour l'Industrie et l'Entreprise ( ENSIIE ) -Conservatoire National des Arts et Métiers [CNAM] ( CNAM ), Imagine - Institut des maladies génétiques ( IMAGINE - U1163 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Infection, Antimicrobiens, Modélisation, Evolution ( IAME ), Université Paris Diderot - Paris 7 ( UPD7 ) -Université Paris 13 ( UP13 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Unité de Santé Publique, Assistance publique - Hôpitaux de Paris - AP-HP (FRANCE)-CHU Saint-Antoine [APHP], Epidémiologie, Systèmes dínformation et modélisation ( ESIM ), Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), and Epidémiologie, Systèmes dínformation et modélisation (ESIM)
Subjects: Male, Viral Diseases, Epidemiology, [SDV]Life Sciences [q-bio], lcsh:Medicine, MESH : Child, Preschool, France/epidemiology, Influenza A Virus, H1N1 Subtype/*pathogenicity, 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, MESH : Child, Risk Factors, MESH: Risk Factors, MESH: Child, Pandemic, Medicine, MESH : Female, 030212 general & internal medicine, MESH : Influenza, Human, lcsh:Science, Child, Epidemiological Methods, 0303 health sciences, education.field_of_study, Multidisciplinary, MESH : Pandemics, MESH: Middle Aged, MESH: Influenza, Human, MESH : Infant, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Adult, Middle Aged, MESH : Risk Factors, MESH: Infant, 3. Good health, MESH : Influenza A Virus, H1N1 Subtype, Vaccination, Infectious Diseases, Influenza, Human/*epidemiology, MESH: Young Adult, Child, Preschool, Cohort, Female, France, Research Article, Adult, MESH: Pandemics, Adolescent, Clinical Research Design, MESH : Male, Population, Protective factor, MESH : Young Adult, Infectious Disease Epidemiology, MESH: Influenza A Virus, H1N1 Subtype, 03 medical and health sciences, Young Adult, MESH : Adolescent, Influenza, Human, Humans, MESH : Middle Aged, education, MESH : France, Biology, Pandemics, 030304 developmental biology, Asthma, MESH: Adolescent, MESH: Humans, [ SDV ] Life Sciences [q-bio], Population Biology, business.industry, MESH : Humans, lcsh:R, MESH: Child, Preschool, Infant, MESH: Adult, medicine.disease, Confidence interval, Influenza, MESH: Male, Risk perception, MESH: France, Cross-Sectional Studies, Immunology, lcsh:Q, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, Demography
Abstract: International audience; The CoPanFlu-France cohort of households was set up in 2009 to study the risk factors for infection by the pandemic influenza virus (H1N1pdm) in the French general population. The authors developed an integrative data-driven approach to identify individual, collective and environmental factors associated with the post-seasonal serological H1N1pdm geometric mean titer, and derived a nested case-control analysis to identify risk factors for infection during the first season. This analysis included 1377 subjects (601 households). The GMT for the general population was 47.1 (95% confidence interval (CI): 45.1, 49.2). According to a multivariable analysis, pandemic vaccination, seasonal vaccination in 2009, recent history of influenza-like illness, asthma, chronic obstructive pulmonary disease, social contacts at school and use of public transports by the local population were associated with a higher GMT, whereas history of smoking was associated with a lower GMT. Additionally, young age at inclusion and risk perception of exposure to the virus at work were identified as possible risk factors, whereas presence of an air humidifier in the living room was a possible protective factor. These findings will be interpreted in light of the longitudinal analyses of this ongoing cohort.
Published: 2012

42. Indications and outcomes of antifungal therapy in French patients with haematological conditions or recipients of haematopoietic stem cell transplantation

Author: Raoul Herbrecht, Anne Auvrignon, Catherine Cordonnier, Mauricette Michallet, Yves Bertrand, Paul Preziosi, Nizar Mahlaoui, Jean-Pierre Gangneux, Fabrice Ruiz, Norbert-Claude Gorin, Denis Caillot, Anne Thiebaut, Benoit Brethon, Service d'Hématologie, CHU Strasbourg, Hôpital du Bocage, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Hématologie et immunologie pédiatrique, Hospices Civils de Lyon (HCL)-CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] (IHOPe), Hospices Civils de Lyon (HCL)-Hôpital Femme-Mère-Enfant (HFME), Service d'hématologie clinique et de thérapie cellulaire [CHU Saint-Antoine], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), CHU Saint-Antoine [AP-HP], Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), IFR Necker-Enfants Malades ( IRNEM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ) -CHU Lyon-Institut d'hématologie et d'oncologie pédiatrique [CHU - HCL] ( IHOPe ), Hospices Civils de Lyon ( HCL ) -Hôpital Femme-Mère-Enfant (HFME), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Saint-Antoine [APHP], Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Saint-Antoine [APHP]
Subjects: Male, medicine.medical_treatment, MESH : Prospective Studies, MESH : Aged, Hematopoietic stem cell transplantation, Aspergillosis, 0302 clinical medicine, MESH : Child, MESH: Child, MESH: Immunocompromised Host, Pharmacology (medical), Prospective Studies, Child, MESH: Treatment Outcome, Aged, 80 and over, 0303 health sciences, MESH: Middle Aged, MESH : Infant, invasive candidiasis, MESH: Infant, 3. Good health, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Young Adult, Child, Preschool, Hematologic Neoplasms, MESH : Hematologic Neoplasms, Microbiology (medical), medicine.medical_specialty, MESH : Young Adult, MESH : Stem Cell Transplantation, 03 medical and health sciences, MESH : Adolescent, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Intensive care medicine, Aged, MESH : Mycoses, Pharmacology, MESH: Adolescent, MESH: Humans, 030306 microbiology, MESH : Humans, MESH: Child, Preschool, Infant, MESH: Adult, medicine.disease, MESH: Antifungal Agents, Survival Analysis, mortality, invasive fungal disease, Mycoses, chemistry, MESH: Female, Antifungal Agents, haematopoietic stem cell transplantation, MESH : Child, Preschool, chemistry.chemical_compound, MESH: Aged, 80 and over, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, MESH : Female, 030212 general & internal medicine, Prospective cohort study, MESH: Aged, Mortality rate, MESH : Immunocompromised Host, Middle Aged, MESH : Adult, Treatment Outcome, Infectious Diseases, MESH: Survival Analysis, haematology, Female, France, MESH: Stem Cell Transplantation, Adult, Adolescent, MESH : Male, MESH : Antifungal Agents, MESH : Treatment Outcome, Neutropenia, Immunocompromised Host, Young Adult, MESH: Mycoses, Internal medicine, medicine, MESH : France, invasive aspergillosis, business.industry, MESH: Male, MESH: Prospective Studies, Transplantation, MESH: France, MESH : Survival Analysis, Caspofungin, business, Febrile neutropenia, Stem Cell Transplantation, MESH: Hematologic Neoplasms
Abstract: International audience; OBJECTIVES: Invasive fungal disease (IFD) remains a major concern in patients with haematological conditions. We describe diagnoses, therapeutic management and outcomes in unselected consecutive patients from haematological facilities treated for suspected or documented IFD. METHODS: In this observational prospective study, children/adults with haematological conditions or haematopoietic stem cell transplantation (HSCT) were recruited upon start of non-prophylactic systemic antifungal treatment in 37 French haematological facilities (December 2007 to December 2008). IFD episodes were classified according to the 2008 EORTC/MSG criteria. RESULTS: The cohort included 419 patients (298 adults and 121 children): 88% haematological malignancies, 28% HSCT recipients and 68% neutropenic. Patients had 423 IFD episodes: 21% mycologically documented (59% probable/proven aspergillosis, 32% proven candidiasis and 9% probable/proven other IFD) and 20% classified as possible IFD. The remaining cases were assigned to two groups: febrile neutropenia (34%) and unclassified (25%), 9% of which were classified as possible/probable/proven IFD by day 7. Treatment was thus initiated early in 59% of patients; liposomal amphotericin B and caspofungin were the most common single-agent therapies. The 12 week mortality was 18% for probable/proven aspergillosis, 15% for proven candidiasis, 10% for probable/proven other IFD, 9% for possible IFD, 3% for febrile neutropenia and 12% for unclassified episodes (log rank P = 0.016); it was dependent on age, complete remission of underlying haematological disease and mechanical ventilation. CONCLUSIONS: In this comprehensive sample of haematological patients receiving antifungal treatment, we observe a widespread resort to early therapy and a low mortality rate, including in patients with probable or proven IFD.
Published: 2012

43. Parental electrocardiographic screening identifies a high degree of inheritance for congenital and childhood nonimmune isolated atrioventricular block

Author: Hervé Le Marec, Caroline Bonnet, Jean-René Lusson, Raphaël P. Martins, Jean-Jacques Schott, Francis Rouault, Alban-Elouen Baruteau, Jean-Benoit Thambo, Christian Dina, Elisabeth Villain, François Godart, Philippe Mabo, Vincent Probst, Alain Fraisse, François Marçon, Albin Behaghel, Véronique Gournay, Sophie Guillaumont, Yves Dulac, Jean-Marc Schleich, Stéphanie Chatel, Swanny Fouchard, Alain Chantepie, Béatrice Delasalle, Jean-Claude Daubert, unité de recherche de l'institut du thorax UMR1087 UMR6291 ( ITX ), Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Department de Chirurgie cardiaque des cardiopathies congénitales, Centre chirurgical Marie Lannelongue, Service de cardiologie et maladies vasculaires, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CIC-IT Rennes, Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Traitement du Signal et de l'Image ( LTSI ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire de génie des procédés - environnement - agroalimentaire ( GEPEA ), Mines Nantes ( Mines Nantes ) -Université de Nantes ( UN ) -Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique ( ONIRIS ) -Centre National de la Recherche Scientifique ( CNRS ), Service de cardiologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Service cardiologie pédiatrique [Bordeaux], CHU Bordeaux [Bordeaux], Service de Cardiologie Infantile [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Service de cardiologie pédiatrique [Nantes], Centre hospitalier universitaire de Nantes ( CHU Nantes ), Cabinet de Cardiologie pédiatrique, Service de cardiologie pédiatrique [Tours], CHU Tours, Service de cardiologie Pédiatrique [Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ), Service de cardiologie Pédiatrique [Lille], Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Service de cardiologie pédiatrique et congénitale adulte [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service de cardiologie Pédiatrique [Marseille], Hôpital de la Timone [CHU - APHM] ( TIMONE ), Service de cardiologie [Clermont-Ferrand], CHU Clermont-Ferrand, Service pédiatrie-cardiologie, CHU Toulouse [Toulouse]-Hôpital des Enfants, unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de cardiologie et maladies vasculaires [Rennes] = Cardiac, Thoracic, and Vascular Surgery [Rennes], CHU Pontchaillou [Rennes], Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de génie des procédés - environnement - agroalimentaire (GEPEA), Mines Nantes (Mines Nantes)-Université de Nantes - UFR des Sciences et des Techniques (UN UFR ST), Université de Nantes (UN)-Université de Nantes (UN)-Ecole Nationale Vétérinaire, Agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Centre hospitalier universitaire de Nantes (CHU Nantes), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hôpital de la Timone [CHU - APHM] (TIMONE), Service de Cardiologie Maladies Vasculaires [CHU Clermont-Ferrand], CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, CHU Toulouse [Toulouse], Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Centre Chirurgical Marie Lannelongue (CCML), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Nantes (UN)-Université de Nantes (UN)-École nationale vétérinaire, agroalimentaire et de l'alimentation Nantes-Atlantique (ONIRIS)-Centre National de la Recherche Scientifique (CNRS), Service Cardiologie pédiatrique [CHU Toulouse], Pôle Enfants [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Le Corre, Morgane, and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)
Subjects: Male, Parents, MESH : Retrospective Studies, Heart malformation, MESH : NAV1.5 Voltage-Gated Sodium Channel, MESH : Prevalence, MESH : Aged, Electrocardiography, 0302 clinical medicine, MESH: Pregnancy, MESH : Child, Pregnancy, Prenatal Diagnosis, MESH: Child, Medicine, Sinus rhythm, genetics, Child, 0303 health sciences, MESH: Middle Aged, MESH: Genetic Testing, MESH : Infant, MESH: Infant, 3. Good health, MESH : Phenotype, MESH: Young Adult, MESH : Electrocardiography, Child, Preschool, Cardiology and Cardiovascular Medicine, medicine.medical_specialty, conduction, MESH : Young Adult, Prenatal diagnosis, MESH: Phenotype, Sudden death, 03 medical and health sciences, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), MESH : Adolescent, MESH : Genetic Testing, Humans, MESH : Middle Aged, Genetic Testing, MESH: Prenatal Diagnosis, MESH : Prenatal Diagnosis, MESH: Prevalence, Aged, Retrospective Studies, [SDV.IB] Life Sciences [q-bio]/Bioengineering, MESH: Adolescent, MESH: Parents, MESH: Humans, MESH: Child, Preschool, MESH : Humans, Infant, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH : Pregnancy, MESH : Genetic Predisposition to Disease, Atrioventricular block, MESH: Female, Pediatrics, ECG screening, 030204 cardiovascular system & hematology, MESH : Child, Preschool, NAV1.5 Voltage-Gated Sodium Channel, atrioventricular block, Prevalence, Mass Screening, MESH : Female, [ SDV.IB ] Life Sciences [q-bio]/Bioengineering, Family history, MESH : Parents, MESH: Aged, MESH: Infant, Newborn, MESH: Genetic Predisposition to Disease, Middle Aged, MESH : Adult, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH : Atrioventricular Block, Phenotype, Female, [SDV.IB]Life Sciences [q-bio]/Bioengineering, medicine.symptom, Adult, Adolescent, pediatrics, MESH : Male, MESH : Infant, Newborn, Asymptomatic, Young Adult, MESH: Atrioventricular Block, Genetic Predisposition to Disease, MESH: Mass Screening, PR interval, 030304 developmental biology, MESH : Mass Screening, business.industry, Infant, Newborn, MESH: NAV1.5 Voltage-Gated Sodium Channel, MESH: Male, MESH: Electrocardiography, business
Abstract: Background— The origin of congenital or childhood nonimmune isolated atrioventricular (AV) block remains unknown. We hypothesized that this conduction abnormality in the young may be a heritable disease. Methods and Results— A multicenter retrospective study (13 French referral centers, from 1980–2009) included 141 children with AV block diagnosed in utero, at birth, or before 15 years of age without structural heart abnormalities and without maternal antibodies. Parents and matched control subjects were investigated for family history and for ECG screening. In parents, a family history of sudden death or progressive cardiac conduction defect was found in 1.4% and 11.1%, respectively. Screening ECGs from 130 parents (mean age 42.0±6.8 years, 57 couples) were compared with those of 130 matched healthy control subjects. All parents were asymptomatic and in sinus rhythm, except for 1 with undetected complete AV block. Conduction abnormalities were more frequent in parents than in control subjects, found in 50.8% versus 4.6%, respectively ( P P P P SCN5A mutation screening identified 2 mutations in 2 patients among 97 children. Conclusions— ECG screening in parents of children affected by idiopathic AV block revealed a high prevalence of conduction abnormalities. These results support the hypothesis of an inheritable trait in congenital and childhood nonimmune isolated AV block.
Published: 2012

44. Evidence of the symptomatic and structural efficacy of methotrexate in daily practice as the first disease-modifying drug in rheumatoid arthritis despite its suboptimal use: results from the ESPOIR early synovitis cohort

Author: Gaujoux-Viala, Cécile, Paternotte, Simon, Combe, Bernard, Dougados, Maxime, Saraux, Alain, Service de rhumatologie [CHU Pitié Salpêtrière] (GRC-08 EEMOIS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Service de rhumatologie [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Immunologie et Pathologie (EA2216), Université de Brest (UBO)-IFR148, CHRU Brest - Service de Rhumatologie (CHU - BREST - Rhumato), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Centre d'Investigation Clinique (CIC - Brest), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Rhumatologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Institut de Génétique Moléculaire de Montpellier ( IGMM ), Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Immunologie et Pathologie ( EA2216 ), Université de Brest ( UBO ) -IFR148, CHRU Brest - Service de Rhumatologie ( CHU - BREST - Rhumato ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Centre d'Investigation Clinique ( CIC - Brest ), and Université de Brest ( UBO ) -Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: Male, MESH: Antirheumatic Agents, MESH: Synovitis, Health Status, MESH : Aged, Arthritis, MESH : Dose-Response Relationship, Drug, Severity of Illness Index, Gastroenterology, MESH: Dose-Response Relationship, Drug, Arthritis, Rheumatoid, Cohort Studies, 0302 clinical medicine, Outcome Assessment, Health Care, Pharmacology (medical), MESH : Female, 030212 general & internal medicine, skin and connective tissue diseases, MESH: Cohort Studies, MESH: Health Status, media_common, MESH: Treatment Outcome, MESH : Synovitis, MESH: Aged, MESH: Arthritis, Rheumatoid, Synovitis, MESH: Middle Aged, Middle Aged, MESH : Adult, MESH : Antirheumatic Agents, 3. Good health, Treatment Outcome, MESH: Methotrexate, MESH: Young Adult, Antirheumatic Agents, Rheumatoid arthritis, Cohort, Disease Progression, Drug Therapy, Combination, Female, MESH : Severity of Illness Index, MESH: Disease Progression, medicine.drug, Adult, Drug, musculoskeletal diseases, medicine.medical_specialty, Adolescent, MESH : Outcome Assessment (Health Care), media_common.quotation_subject, MESH : Male, MESH : Young Adult, MESH : Cohort Studies, MESH : Treatment Outcome, MESH: Folic Acid, Young Adult, 03 medical and health sciences, Folic Acid, Rheumatology, Internal medicine, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, MESH: Severity of Illness Index, medicine, Humans, MESH : Middle Aged, MESH : Health Status, MESH: Outcome Assessment (Health Care), Aged, 030203 arthritis & rheumatology, MESH: Adolescent, MESH : Folic Acid, MESH: Humans, Dose-Response Relationship, Drug, business.industry, MESH : Drug Therapy, Combination, MESH : Humans, MESH: Adult, MESH : Disease Progression, medicine.disease, MESH: Male, Surgery, MESH: Drug Therapy, Combination, Methotrexate, Concomitant, MESH : Methotrexate, Propensity score matching, MESH : Arthritis, Rheumatoid, business, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; OBJECTIVE: To describe the use of MTX in early arthritis (EA) in daily clinical practice and to evaluate its 6-month symptomatic efficacy and 12-month structural efficacy. METHODS: Patients included in the French observational ESPOIR cohort were assessed. Evaluation of the symptomatic and structural efficacy was performed by generalized linear regression after adjustment on propensity score (PS) in the group of patients receiving at least 3 months of MTX vs the ones receiving any other treatment except LEF, SSZ or TNF inhibitors. RESULTS: Within the first 6 months of follow-up of 777 EA patients, 59% received a DMARD, which was MTX in 68% (N = 313) of patients. The mean dose of MTX was 12.7 ± 3.8 mg/week. Only 53.7% of the patients received folic acid supplementation. MTX was initiated in patients with more active and severe disease. At 6 months, in unadjusted analysis, patients starting MTX had a significantly higher DAS-28 (3.58 vs 3.23; P = 0.001) and a significantly higher HAQ (0.60 vs. 0.48; P = 0.01) compared with controls. After adjustment by PS, there were no significant differences. Adjustment for the PS also revealed a statistically significant decrease in the radiological progression at 12 months in the MTX group [total Sharp-van der Heijde score (SHS), 1.05 ± 0.29 vs 2.02 ± 0.29, P = 0.025]. CONCLUSION: This study confirms the symptomatic and structural efficacy of MTX in EA in daily practice despite the non-optimal use of MTX, including low doses and infrequent concomitant folic acid supplementation.
Published: 2012

45. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands

Author: Didier Klug, Isabelle Denjoy, Antoine Leenhardt, Meiso Hayashi, Fabrice Extramiana, Miyuki Hayashi, Pascale Guicheney, Alice Maltret, Nathalie Roux-Buisson, Anne Messali, Philippe Maury, Jean-Marc Lupoglazoff, Biomarqueurs CArdioNeuroVASCulaires ( BioCANVAS ), Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Pediatrics Department, Nippon Medical School Hospital, Cardiology Department, Service de cardiologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], ANTE-INSERM U836, équipe 4, Muscles et pathologies, Laboratoire de biochimie et génétique moléculaire, CHU Grenoble-CHU Grenoble, Unité de Cardiologie Néonatale, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré, Service de Cardiologie A, Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Unité de Rythmologie et de Stimulation Cardiaque, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], Génétique, pharmacologie et physiopathologie des maladies cardiovasculaires, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), French National government (PHRC no. AOR04070, P040411), Roux-Buisson, Nathalie, Biomarqueurs CArdioNeuroVASCulaires (BioCANVAS), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service Cardiologie [CHU Toulouse], Pôle Cardiovasculaire et Métabolique [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
Subjects: Tachycardia, Proband, Male, Pathology, Genetic testing, 030204 cardiovascular system & hematology, Ventricular tachycardia, Electrocardiography, 0302 clinical medicine, MESH : Child, Heart Rate, MESH: Child, MESH : Female, 030212 general & internal medicine, MESH: Heart Rate, Child, medicine.diagnostic_test, MESH: Adrenergic beta-Antagonists, MESH : Adult, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Ventricular Premature Complexes, 3. Good health, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH: Young Adult, MESH : Electrocardiography, Catecholaminergic polymorphic ventricular tachycardia, Cardiology, Female, medicine.symptom, MESH : Mutation, Cardiology and Cardiovascular Medicine, Adult, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH : Male, Adrenergic beta-Antagonists, MESH : Adrenergic beta-Antagonists, MESH : Young Adult, Follow-up studies, MESH : Tachycardia, Ventricular, Asymptomatic, MESH : Syncope, Syncope, 03 medical and health sciences, Young Adult, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Physiology (medical), Internal medicine, MESH : Adolescent, medicine, Humans, MESH : Ventricular Premature Complexes, MESH: Adolescent, MESH: Humans, Stress test, business.industry, MESH : Heart Rate, MESH : Humans, MESH: Adult, MESH: Death, Sudden, Cardiac, medicine.disease, MESH: Male, MESH: Electrocardiography, MESH: Ventricular Premature Complexes, MESH : Exercise Test, Death, Sudden, Cardiac, Bigeminy, MESH: Syncope, Mutation, Exercise Test, Tachycardia, Ventricular, MESH: Tachycardia, Ventricular, business, MESH: Exercise Test, MESH: Female, MESH : Death, Sudden, Cardiac
Abstract: International audience; AIMS: Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmic disorder with a highly malignant clinical course. Exercise-stress test is the first-line approach to diagnose suspected individuals. We sought to elucidate the value of exercise-stress test for predicting mutations and future cardiac events in CPVT-family relatives. METHODS AND RESULTS: The present study included 67 asymptomatic relatives (24 ± 15 years) of 17 genetically positive CPVT probands, who underwent exercise-stress test without any medication and genetic testing. Exercise-stress test, which was considered positive with the induction of ventricular tachycardia or premature ventricular contractions consisting of bigeminy or couplets, was positive in 17 relatives (25%). Genetic analysis disclosed mutations in 16 of these 17 relatives (94%) and in 16 of the 50 relatives (32%) with negative exercise-stress test; the sensitivity and specificity for a positive genotype were 50 and 97%, respectively (P< 0.001). Among 32 mutation carriers, cardiac events occurred in 7 of the 16 relatives with positive and 2 of the 16 relatives with negative exercise-stress test during the follow-up period of 9.6 ± 3.8 years, and four with positive and two with negative stress test were not on regular beta-blocker treatment at these events. In the 16 relatives with positive stress test, those on beta-blocker treatment demonstrated a trend of lower cardiac event rate (Log-rank P= 0.054). CONCLUSION: In asymptomatic relatives of CPVT probands, exercise-stress test can be used as a simple diagnostic tool. Nevertheless, because of the low sensitivity for predicting mutations and future cardiac events in those with negative stress test, genetic analysis should be performed to improve patient management.
Published: 2012

46. Trends in perinatal health in France from 1995 to 2010. Results from the French National Perinatal Surveys

Author: Blondel, Béatrice, Lelong, Nathalie, Kermarrec, Morgane, Goffinet, François, Recherche Epidémiologique en Santé Périnatale et Santé des Femmes et des Enfants (UMR_S 953), Université Paris-Sud - Paris 11 (UP11)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), National Coordination Group of the National Perinatal Surveys, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5)-Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris-Sud - Paris 11 (UP11), Recherche Epidémiologique en Santé Périnatale et Santé des Femmes et des Enfants ( UMR_S 953 ), and Université Paris-Sud - Paris 11 ( UP11 ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: MESH: Health, perinatal health, MESH : Health, MESH : Young Adult, MESH: Professional Practice, MESH: Pregnancy, antenatal care, MESH : Adolescent, MESH : Maternal-Child Health Centers, MESH : Female, MESH: Data Collection, MESH : France, MESH: Maternal-Child Health Centers, MESH : Obstetrics, MESH: Adolescent, MESH: Humans, MESH : Humans, MESH: Time Factors, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Adult, MESH : Adult, MESH : Maternal Age, MESH: Mothers, MESH: France, MESH : Pregnancy, MESH : Professional Practice, MESH: Young Adult, MESH : Mothers, maternal characteristics, MESH: Perinatal Care, MESH: Maternal Age, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Perinatal Care, MESH : Data Collection, delivery, MESH: Female, MESH : Time Factors, MESH: Obstetrics
Abstract: International audience; OBJECTIVE: To study trends in the main indicators of health, medical practices and risk factors in France. POPULATION AND METHOD: We collected data from samples of all births in France during one week in 1995 (n=13318), 1998 (n=13718), 2003 (n=14737) and 2010 (n=14903) and have compared them. RESULTS: Between 1995 and 2010, maternal age and body mass index increased steadily, but tobacco use decreased. In 2010, 39.4% of pregnant women had a visit with a midwife in a maternity unit, versus 26.6% in 2003. Deliveries occurred in large public hospitals more and more frequently. The increase in caesarean sections was no longer significant between 2003 and 2010. In general, medical decisions during pregnancy and delivery were closer to professional recommendations in 2010 than in earlier years. Live births before 37 weeks increased steadily from 5.4% in 1995 to 6.6% in 2010, but the proportion of birth weights below 2500g or the 10th percentile stopped increasing after 2003. CONCLUSION: Routine national perinatal surveys highlight major trends in maternal characteristics, obstetric practices, organisation of services, and perinatal health.
Published: 2012

47. Infectious complications in adult acute myeloid leukemia: analysis of the Acute Leukemia French Association-9802 prospective multicenter clinical trial

Author: Mauricette Michallet, Claude Gardin, Pierre Fenaux, Xavier Thomas, Emmanuel Raffoux, Mohamed Elhamri, Giovanna Cannas, Sylvie Castaigne, Cécile Pautas, Thierry de Revel, Oumedaly Reman, Stéphane de Botton, Hervé Dombret, Nicolas Boissel, Bruno Quesnel, Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon ( HCL ), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), hopital saint louis, Département d' Hématologie, Centre de recherche Jean-Pierre Aubert-Neurosciences et Cancer, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Lille, Droit et Santé, hopital des armées percy, hopital georges clémenceau, Service d'hématologie clinique [Avicenne], Université Paris 13 ( UP13 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Avicenne, Service d'hématologie [Hôpital Edouard Herriot - HCL], Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hopital andré mignot, Département d'hématologie, Lymphocyte et cancer, IFR105-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre de Recherche en Cancérologie de Lyon ( CRCL ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Centre Léon Bérard [Lyon]-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon (HCL), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U1172 Inserm - U837 (JPArc), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Lille Nord de France (COMUE)-Université de Lille, Université Paris 13 (UP13)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Avicenne [AP-HP], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre Hospitalier de Versailles André Mignot (CHV), IFR105-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Cancérologie de Lyon (UNICANCER/CRCL), Centre Léon Bérard [Lyon]-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Lille Nord de France (COMUE)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille, Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), and Centre de Recherche Jean-Pierre AUBERT Neurosciences et Cancer - U837 (JPArc)
Subjects: Male, Cancer Research, Myeloid, MESH : Prospective Studies, MESH : Induction Chemotherapy, Salvage therapy, MESH: Consolidation Chemotherapy, Medical Oncology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Medicine, MESH : Female, Prospective Studies, 030212 general & internal medicine, Societies, Medical, MESH: Medical Oncology, Acute leukemia, MESH: Middle Aged, Myeloid leukemia, Induction Chemotherapy, Hematology, Middle Aged, MESH : Adult, MESH: Induction Chemotherapy, 3. Good health, MESH: Salvage Therapy, Leukemia, Myeloid, Acute, Leukemia, MESH : Infection, medicine.anatomical_structure, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, France, MESH: Leukemia, Myeloid, Acute, MESH: Infection, Adult, medicine.medical_specialty, Adolescent, MESH : Male, MESH: Societies, Medical, MESH : Leukemia, Myeloid, Acute, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, Infections, MESH : Consolidation Chemotherapy, Young Adult, 03 medical and health sciences, MESH : Medical Oncology, Internal medicine, MESH : Adolescent, Humans, MESH : Societies, Medical, MESH : Middle Aged, MESH : France, Salvage Therapy, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Induction chemotherapy, Adult Acute Myeloid Leukemia, MESH: Adult, medicine.disease, MESH: Prospective Studies, MESH: Male, Surgery, Consolidation Chemotherapy, Clinical trial, MESH: France, MESH : Salvage Therapy, business, MESH: Female
Abstract: International audience; Infections are a major complication in patients with acute myeloid leukemia undergoing intensive chemotherapy. They remain a major cause of therapy-associated morbidity and mortality, and represent a frequent cause of treatment withdrawal. An analysis of the medical charts of 459 younger adults included in the multicenter Acute Leukemia French Association (ALFA)-9802 trial showed that 1369 febrile episodes occurred among the 459 registered patients, including fever without identifiable source (23%) and clinically or microbiologically documented infections (77%). Bloodstream infections occurred in 314 episodes, including 129 documented episodes with Gram-positive and 96 with Gram-negative pathogens. Pulmonary infection was diagnosed in 144/1054 documented infectious episodes (14%). Invasive fungal infection was probable or proven in 116 patients. In all, 15 patients died of infection-associated complications, of whom seven died during early induction therapy, one during salvage therapy and seven during consolidation therapy. Better supportive care strategies may improve overall survival in patients undergoing chemotherapy for acute myeloid leukemia.
Published: 2012

48. Association of environmental insecticide exposure and fetal growth with a Bayesian model including multiple exposure sources: the PELAGIE mother-child cohort

Author: François Coquet, Claire Petit, Marta Blangiardo, Sylvaine Cordier, Cécile Chevrier, Sylvia Richardson, Institut de recherche, santé, environnement et travail ( Irset ), Université d'Angers ( UA ) -Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -École des Hautes Études en Santé Publique [EHESP] ( EHESP ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ) -Université des Antilles ( UA ), Department of Epidemiology and Public Health, Imperial College Norfolk Place, Institut de Recherche Mathématique de Rennes ( IRMAR ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -AGROCAMPUS OUEST-École normale supérieure - Rennes ( ENS Rennes ) -Institut National de Recherche en Informatique et en Automatique ( Inria ) -Institut National des Sciences Appliquées ( INSA ) -Université de Rennes 2 ( UR2 ), Université de Rennes ( UNIV-RENNES ) -Centre National de la Recherche Scientifique ( CNRS ), Ecole Nationale de la Statistique et de l'Analyse de l'Information ( ENSAI ), Ensai, Ecole Nationale de la Statistique et de l'Analyse de l'Information, the National Institute for Public Health Surveillance, the Ministry of Labor, the Regional Health Department of the Brittany region, a fellowship from GlaxoSmithKline., Institut de recherche en santé, environnement et travail (Irset), Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )-Institut National de la Santé et de la Recherche Médicale (INSERM)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université d'Angers (UA), Institut de Recherche Mathématique de Rennes (IRMAR), AGROCAMPUS OUEST, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Ecole Nationale de la Statistique et de l'Analyse de l'Information [Bruz] (ENSAI), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-École normale supérieure - Rennes (ENS Rennes)-Université de Rennes 2 (UR2), Université de Rennes (UNIV-RENNES)-Centre National de la Recherche Scientifique (CNRS)-INSTITUT AGRO Agrocampus Ouest, Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro)-Institut national d'enseignement supérieur pour l'agriculture, l'alimentation et l'environnement (Institut Agro), Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), and Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-École normale supérieure - Rennes (ENS Rennes)-Université de Rennes 2 (UR2)-Centre National de la Recherche Scientifique (CNRS)-INSTITUT AGRO Agrocampus Ouest
Subjects: multiple sources, MESH : Insecticides, Insecticides, Epidemiology, agricultural activities, 010501 environmental sciences, MESH : Agriculture, 01 natural sciences, Cohort Studies, Fetal Development, Toxicology, 0302 clinical medicine, MESH: Pregnancy, Pregnancy, Surveys and Questionnaires, Credible interval, Fetal growth, MESH : Female, 030212 general & internal medicine, MESH: Maternal Exposure, MESH: Cohort Studies, 2. Zero hunger, MESH : Head, MESH: Infant, Newborn, MESH : Models, Statistical, MESH: Diet Surveys, MESH : Questionnaires, Agriculture, MESH : Maternal Exposure, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Follow-Up Studies, MESH : Adult, insecticide exposure, household use, Maternal Exposure, MESH: Young Adult, Cohort, head circumference, MESH: Head, Female, France, MESH: Agriculture, MESH: Fetal Development, Adult, Multiple exposure, Adolescent, Birth weight, MESH: Bayes Theorem, MESH : Young Adult, MESH : Cohort Studies, Biology, MESH : Infant, Newborn, Diet Surveys, Young Adult, 03 medical and health sciences, MESH : Bayes Theorem, Environmental health, MESH : Adolescent, Humans, MESH: Birth Weight, Latent variable model, MESH : France, 0105 earth and related environmental sciences, MESH: Adolescent, Models, Statistical, MESH: Humans, business.industry, MESH: Questionnaires, MESH : Humans, Infant, Newborn, birth weight, Bayes Theorem, MESH: Adult, MESH : Birth Weight, MESH : Follow-Up Studies, Bayesian modeling, MESH: Insecticides, MESH: France, MESH : Pregnancy, MESH : Fetal Development, Residence, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, diet, MESH : Diet Surveys, Head, MESH: Female, MESH: Models, Statistical, Follow-Up Studies
Abstract: International audience; It has been suggested that prenatal exposure to insecticides adversely affects fetal growth, but the overall results have been inconsistent, partly because of the different exposure sources and exposure assessments used. In the French PELAGIE (Perturbateurs Endocriniens: Étude Longitudinale sur les Anomalies de la Grossesse, l'Infertilité et l'Enfance) mother and child cohort (2002-2006), the authors investigated the association between fetal growth and insecticide exposure (n = 1,213) using an integrated Bayesian latent variable model to include multiple exposure sources: agricultural activities, nonorganic diet, household insecticide use on plants, and household insecticide use against insects. They used a questionnaire to collect information on household use and organic diet, and a national agricultural census provided data on agricultural activities in the women's municipalities of residence. A 0.10-cm decrease in head circumference at birth (95% credibility interval: -0.22, 0.01) was associated with fetal insecticide exposure from agricultural activities in the municipality of residence. Decreases in average birth weight (-27 g; 95% credibility interval: -59, 6) and head circumference (-0.12 cm; 95% credibility interval: -0.26, 0.01) were associated with household insecticide use to treat plants. The present results suggest an inverse association between fetal growth and prenatal insecticide exposure from nearby agricultural activity or household use. Bayesian modeling via latent variables is a natural framework for including multiple sources of exposure to environmental pollutants.
Published: 2012

49. Preeminence of Staphylococcus aureus in infective endocarditis: a 1-year population-based survey

Author: Christine Selton-Suty, Claire POYART, Tristan Ferry, Albert HAGEGE, Bernard Iung, Cellier Christophe, Francois Vandenesch, Anne TRISTAN, Francois Philippart, BRUNO MOURVILLIER, Vincent Le Moing, François Alla, Céline Plainvert, Patrick Assayag, Nataf Patrick, Catherine Sportouch, Albert Sotto, Recherches Translationnelles sur le VIH et les maladies infectieuses (TransVIHMI), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Recherche pour le Développement (IRD)-Université Montpellier 1 (UM1)-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Universtié Yaoundé 1 [Cameroun]-Université de Montpellier (UM), services de maladies infectieuses, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon), Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service de cardiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), CHU Pontchaillou [Rennes], Centre National de référence des Staphylocoques, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Hospices Civils de Lyon (HCL), Centre d'Epidémiologie Clinique (CIC-EC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), CIC - CHU Bichat, Institut National de la Santé et de la Recherche Médicale (INSERM), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, AEPEI Study Group, Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques et émergentes (TransVIHMI), Université Montpellier 1 (UM1)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Laboratoire Chrono-environnement (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Centre d'investigation clinique - Epidémiologie clinique [Nancy] (CIC-EC), Centre d'investigation clinique [Nancy] (CIC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Recherches Translationnelles sur le VIH et les maladies infectieuses ( TransVIHMI ), Université de Montpellier ( UM ) -Universtié Yaoundé 1 [Cameroun]-Université Cheikh Anta Diop ( UCAD ) -Université Montpellier 1 ( UM1 ) -Institut de Recherche pour le Développement ( IRD ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire Chrono-environnement - UFC (UMR 6249) ( LCE ), Université Bourgogne Franche-Comté [COMUE] ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ), Centre d'Epidémiologie Clinique ( CIC-EC ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Maladies chroniques, santé perçue, et processus d'adaptation ( APEMAC ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Université Montpellier 1 ( UM1 ) -Université Cheikh Anta Diop ( UCAD ) -Universtié Yaoundé 1 (Cameroun)-Université de Montpellier ( UM ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Recherches Translationnelles sur le VIH et les maladies infectieuses endémiques er émergentes (TransVIHMI), Université Cheikh Anta Diop [Dakar, Sénégal] (UCAD)-Institut de Recherche pour le Développement (IRD)-Université de Yaoundé I-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Université Montpellier 1 (UM1), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7)
Subjects: Male, Staphylococcus, [SDV]Life Sciences [q-bio], MESH : Aged, 030204 cardiovascular system & hematology, 0302 clinical medicine, MESH: Aged, 80 and over, Risk Factors, MESH: Risk Factors, MESH : Population Surveillance, MESH: Staphylococcus aureus, MESH : Female, 030212 general & internal medicine, MESH: Incidence, Young adult, MESH : Endocarditis, Bacterial, Aged, 80 and over, MESH: Aged, education.field_of_study, Cross Infection, MESH : Prognosis, MESH: Middle Aged, Incidence (epidemiology), Incidence, MESH : Staphylococcus aureus, Hazard ratio, MESH: Staphylococcus, Middle Aged, Staphylococcal Infections, MESH : Adult, Prognosis, MESH: Hospitals, MESH : Risk Factors, Hospitals, MESH : Incidence, 3. Good health, Community-Acquired Infections, MESH : Hospitals, Infectious Diseases, MESH: Community-Acquired Infections, MESH: Young Adult, Infective endocarditis, Population Surveillance, Female, France, MESH : Cross Infection, Microbiology (medical), Adult, MESH : Community-Acquired Infections, medicine.medical_specialty, Staphylococcus aureus, Adolescent, MESH : Male, Population, MESH : Young Adult, MESH: Staphylococcal Infections, [SDU.STU.PE]Sciences of the Universe [physics]/Earth Sciences/Petrography, MESH: Prognosis, MESH: Population Surveillance, 03 medical and health sciences, Young Adult, Internal medicine, MESH : Adolescent, medicine, Endocarditis, Humans, MESH : Middle Aged, MESH: Endocarditis, Bacterial, education, MESH : Aged, 80 and over, MESH : France, Aged, MESH : Staphylococcus, [ SDU.STU.PE ] Sciences of the Universe [physics]/Earth Sciences/Petrography, MESH: Adolescent, MESH: Humans, [ SDV ] Life Sciences [q-bio], business.industry, Proportional hazards model, MESH : Humans, MESH: Cross Infection, MESH: Adult, Endocarditis, Bacterial, medicine.disease, Confidence interval, MESH: Male, Surgery, MESH: France, MESH : Staphylococcal Infections, business, MESH: Female
Abstract: International audience; BACKGROUND: Observational studies showed that the profile of infective endocarditis (IE) significantly changed over the past decades. However, most studies involved referral centers. We conducted a population-based study to control for this referral bias. The objective was to update the description of characteristics of IE in France and to compare the profile of community-acquired versus healthcare-associated IE. METHODS: A prospective population-based observational study conducted in all medical facilities from 7 French regions (32% of French individuals aged ≥18 years) identified 497 adults with Duke-Li-definite IE who were first admitted to the hospital in 2008. Main measures included age-standardized and sex-standardized incidence of IE and multivariate Cox regression analysis for risk factors of in-hospital death. RESULTS: The age-standardized and sex-standardized annual incidence of IE was 33.8 (95% confidence interval [CI], 30.8-36.9) cases per million inhabitants. The incidence was highest in men aged 75-79 years. A majority of patients had no previously known heart disease. Staphylococci were the most common causal agents, accounting for 36.2% of cases (Staphylococcus aureus, 26.6%; coagulase-negative staphylococci, 9.7%). Healthcare-associated IE represented 26.7% of all cases and exhibited a clinical pattern significantly different from that of community-acquired IE. S. aureus as the causal agent of IE was the most important factor associated with in-hospital death in community-acquired IE (hazard ratio [HR], 2.82 [95% CI, 1.72-4.61]) and the single factor in healthcare-associated IE (HR, 2.54 [95% CI, 1.33-4.85]). CONCLUSIONS: S. aureus became both the leading cause and the most important prognostic factor of IE, and healthcare-associated IE appeared as a major subgroup of the disease.
Published: 2012

50. Impact of a region wide antimicrobial stewardship guideline on urinary tract infection prescription patterns

Author: Danièle Sekri, Xavier Bertrand, C. Slekovec, Nathalie Vernaz-Hegi, Bruno Hoen, Daniel Talon, J. Leroy, Jean-Pierre Faller, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Hôpital Jean Minjoz, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques
Subjects: Health Knowledge, Attitudes, Practice, Antibiotics, MESH : Drug Prescriptions, MESH: Health Knowledge, Attitudes, Practice, MESH : Aged, MESH: Urinary Tract Infections, Toxicology, MESH: Regression Analysis, MESH : General Practitioners, MESH : Guideline Adherence, 0302 clinical medicine, MESH : Physician's Practice Patterns, Anti-Infective Agents, MESH : Regression Analysis, Medicine, Pharmacology (medical), MESH : Urinary Tract Infections, Practice Patterns, Physicians', MESH: Drug Utilization, 0303 health sciences, MESH: Program Evaluation, MESH : Education, Medical, Continuing, MESH: Middle Aged, 3. Good health, MESH : Practice Guidelines as Topic, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Young Adult, MESH: Guideline Adherence, MESH : Anti-Infective Agents, Regression Analysis, Education, Medical, Continuing, Guideline Adherence, medicine.medical_specialty, MESH : Fosfomycin, Attitude of Health Personnel, Urinary system, MESH: Attitude of Health Personnel, MESH : Young Adult, Pharmacy, Drug Prescriptions, 03 medical and health sciences, MESH : Adolescent, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Humans, MESH : Middle Aged, MESH : Norfloxacin, MESH: Physician's Practice Patterns, Norfloxacin, Aged, Pharmacology, MESH: Adolescent, MESH: Humans, 030306 microbiology, MESH : Humans, MESH: Adult, Guideline, MESH: Education, Medical, Continuing, Nitrofurantoin, MESH: Female, MESH : Attitude of Health Personnel, Pediatrics, Time Factors, MESH : Health Knowledge, Attitudes, Practice, Pharmaceutical Science, MESH : Drug Utilization, MESH: Fosfomycin, MESH: Practice Guidelines as Topic, MESH: Drug Prescriptions, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, Antimicrobial stewardship, MESH : Female, 030212 general & internal medicine, MESH: Aged, MESH : Adult, Middle Aged, MESH: General Practitioners, MESH : Program Evaluation, Practice Guidelines as Topic, Urinary Tract Infections, MESH: Nitrofurantoin, Female, France, medicine.drug, MESH : Time Factors, Adult, MESH: Norfloxacin, Adolescent, medicine.drug_class, MESH: Anti-Infective Agents, Young Adult, Fosfomycin, General Practitioners, Internal medicine, MESH : Nitrofurantoin, Medical prescription, MESH : France, business.industry, MESH: Time Factors, Drug Utilization, MESH: France, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Program Evaluation
Abstract: International audience; BACKGROUND: Fluoroquinolones are frequently prescribed for non complicated urinary tract infection treatments and have a negative ecological impact. We aimed to substitute them by antibiotics with narrower activity spectrum in order to preserve fluoroquinolone activity in complicated hospital infections. OBJECTIVE: To assess the impact of a multi-modal approach that combines the dispatching of antibiotic prescription guidelines and voluntary attendance at educational sessions on general practitioners' (GP) antibiotic prescription habits. SETTING: This study was led in Franche-Comté, a French eastern region, where GPs were given a guideline recommending a restricted use of fluoroquinolones for urinary tract infections. METHOD: Segmented regression analysis of interrupted time series was used to assess changes in antibiotic prescription. MAIN OUTCOME MEASURE: The antibiotic prescription data of nitrofurantoin, fosfomycin-trometamol and fluoroquinolones for women aged 15-65 years were obtained from the regional agency of health insurance. RESULTS: Twenty months after intervention, the number of nitrofurantoin and fosfomycintrometamol prescriptions increased by 36.8% (95% CI: 30.6-42.2) and 28.5% (95% CI: 22.9-35.4), respectively, while that of norfloxacin decreased by 9.1% (95% CI: -15.3 to -3.5). CONCLUSION: This study suggests that the dispatch of the guideline on urinary tract infection had a moderate impact on antibiotic prescriptions.
Published: 2012

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

199 results on '"MESH : Adolescent"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources